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Abstract  
Background: Recent developments in our understanding of the biology of cancer has 
provided the opportunity to develop targeted agents with more specific pharmacological 
activity against cancer cells. Despite this shift toward targeted drug discovery, the much 
hoped-for paradigm shift in cancer treatment has not been realised. Tumour heterogeneity, 
plasticity and genomic instability are issues that contribute to this problem. One approach to 
circumvent these issues is to adopt a phenotypic based approach to drug evaluation where 
compounds with multiple mechanisms of action leading to a desirable phenotypic effect can 
be identified. The challenge with such an approach is to retain selectivity toward cancer cells 
as opposed to non-cancer cells.   
Aims: The aim of this study is to apply a phenotype based drug evaluation program that 
incorporates a measure of selectivity to the preclinical evaluation of a series of novel 
organometallic complexes. 
Methods: In this study, a series of novel inorganic complexes were evaluated against 
cancer and non-cancer cell lines. The primary evaluation procedures involved chemosensitivity 
testing with compounds being selected for further studies based upon (i) potency (ii) an in 
vitro selectivity index (SI) defined as the IC50 for non-cancer cells divided by the IC50 for cancer 
cells and (iii) comparable or improved properties than cisplatin, oxaliplatin and carboplatin 
with respect to potency and selectivity. Those compounds that met the selection criteria were 
evaluated further with the initial aim of characterising key pharmacological events such as cell 
cycle effects and induction of apoptosis. 
Results and Discussion: Initial studies focused on the clinically approved platinum based 
with cisplatin and oxaliplatin being significantly more potent than carboplatin. Selectivity for 
cancer over non-cancer cells was observed with selectivity index (SI) values typically in the 
range of 0.85-9.71, 0.36-3.35 and 2.18-7.44 for cisplatin, oxaliplatin and carboplatin 
respectively. A total of 210 test compounds were evaluated in this thesis and of these, a total 
of 91 compounds exhibited potency values equal to or better than the platinates. In contrast 
however, only 64 compounds had superior SI values compared to platinates. Of these, the 
most promising compounds were a series of large molecular weight metallohelicates that 
exhibited potency (in the nM range) and SI values up to a maximum of 93 (nearly 28 times 
higher than the best performing platinum drug). Analysis of these compounds demonstrated 
that they do not induce apoptosis, but preliminary data suggests that they induce an 
autophagic death response.  
Conclusions: The results of this study have demonstrated that a phenotypic based drug 
evaluation process based upon potency and selectivity in vitro is capable of identifying novel 
chemical entities with promising properties. This screen has more discriminatory power than 
potency alone and the concept of an 'in vitro selectivity index' has proved valuable in 
identifying a series of novel metallohelicate compounds as potential anti-cancer drugs. 
Significant further work is required to identify their mechanism(s) of action and 
pharmacological properties but their potential ability to induce autophagic cell death over 
apoptosis is of interest.  
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Chapter 1 - Introduction 
1.1 What is Cancer?  
Cancer is fundamentally defined as the abnormal, uncontrolled growth of 
previously normal cells resulting from the accumulation of DNA alterations (genetic 
and epigentic) and defective cellular function. The primary characteristic of cancer is 
its ability to replicate uncontrollably, to defy normal restraints on cell division and an 
inability to undergo programmed cell death. This results in an overall increase in the 
number of cells and the formation of solid masses. Its second major property is its 
ability to invade and colonise nearby and distant tissues forming secondary tumours in 
territories often reserved for other cells. This property distinguishes benign from 
malignant tumours and the more widely a cancer spreads, the more difficult it is to 
eradicate (Alberts, 2002). As normal cells transform into cancer cells, they acquire a 
number of characteristics or 'hallmarks'.  
In 2000 Hanahan and Weinberg described these hallmarks of cancer, which 
comprise of six biological capabilities acquired during the multistep development of 
human tumours (illustrated in figure 1.1A). Together these hallmarks constitute an 
organising principle that provides a logical framework for understanding the 
remarkably diverse and complex tumour microenvironment. The six initial hallmarks 
identified were; 1) sustaining proliferative signalling, 2) evading growth suppressors, 3) 
resisting cell death, 4) inducing angiogenesis, 5) enabling replicative immortality and 6) 
activating invasion and metastasis (Hanahan & Weinberg, 2000). In 2011, the same 
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authors described four additional distinct characteristics (illustrated in figure 1.1B) of 
the tumour cell and its environment consisting of two emerging hallmarks and two 
enabling hallmarks. The two emerging hallmarks outlined are believed to be important 
in the pathogenesis of some if not all cancers. The first is the ability of cancers to 
deregulate cellular energetics resulting in support for neoplastic proliferation. The 
second allows cancer cells to evade immunological destruction and like the first, is 
classed as an emerging hallmark. Additionally two enabling characteristics were 
identified genomic instability and tumour promoting inflammation (Hanahan & 
Weinberg, 2011). The importance of these articles is that they summarise the key 
molecular and biological events that lead to cancers and this understanding is 
fundamentally important in the development of new therapies for treating cancer as 
will be described later.  
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Figure 1.1: The A) Six original hallmark capabilities as proposed by Hanahan and Weinberg in 2000 
(panel A), along with the emerging hallmarks and enabling characteristics as proposed in 2011 (panel B). 
Both articles (Hanahan & Weinberg, 2000; Hanahan & Weinberg, 2011) represent seminal overviews of 
tumour biology that directly impact upon drug discovery.  
 
B) 
A) 
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1.2 - The Cancer Problem 
Despite recent advances in early detection, treatment, genetic testing and 
understanding of the molecular basis of cancer biology, cancer remains one of the 
leading causes of death worldwide. It is estimated to be responsible for one in every 
eight deaths (Garcia et al., 2007; Lucas et al., 2012). Globally, cancer is a massive 
burden both financially and socially with an estimated 1,685,210 new cases predicted 
for 2016 in the United States alone. Of these estimated cases, it is predicted that 
595,690 people would succumb to the disease (WHO, 2015). The four most prevalent 
cancers in the UK and the US are breast, lung, prostate and colorectal (ACS, 2016) with 
pancreatic cancer being the most lethal malignancy; only 7.7% of reported cases 
survive 5 years (NCI, 2016). These alarming statistics for pancreatic cancer have not 
improved over 40 years, largely due to its typically late diagnosis, its aggressive 
behaviour and resistance to both chemotherapy and radiotherapy (Sclafani, 
Cunningham, Okines, Ratnayake, & Chau, 2017) . Therefore, improved development 
and design of new strategies for (i) early detection of the disease (ii) prevention via 
avoidance of known risk factors and (iii) better treatments including surgery, 
radiotherapy and chemotherapy are needed. Within the field of chemotherapy, the 
search for new anticancer agents has been and remains an important area of research 
where the ultimate aim is to increase treatment efficacy, prolong survival and improve 
quality of life for patients, particularly for those with advanced metastatic disease. 
Along with the emergence of resistant tumours and the severe side effects associated 
with chemotherapeutic agents, the field is observing reduced clinical efficiency of a 
   
 
Page | 37  
 
 
 
 
large variety of anticancer agents that are currently in practice (Ali et al., 2012). The 
aim of drug development for novel chemotherapeutic agents is therefore focused on 
the identification of agents which exert an adequate therapeutic index reflecting the 
treatments’ specific effects on target cells, whilst exhibiting a lack of clinically 
significant effects on the hosts “healthy” cells (Sellers & Fisher, 1999). Potency and 
selectivity are therefore the ultimate therapeutic goal to maximise clinical outcome. 
1.3 - Chemotherapy 
The origins of cancer chemotherapy can be traced back to the use of mustard gas 
in World War One where physicians noted a drop in white cell counts in soldiers 
exposed to mustard gas (Nobel & Farmacológico). It was not until the pioneering work 
of Gilman and Goodman in the 1940s that the first chemotherapy agent was 
developed and used in humans. These drugs were derivative of sulphur mustard 
(nitrogen mustards called methyl-bis (β-chloroethyl) amine hydrochloride and tris (β-
chloroethyl) amine hydrochloride) and significant effects on previously untreatable 
cancers such as Hodgkins lymphoma, lymphosarcoma and leukaemias were reported  
(Goodman et al., 1946). These compounds are alkylating agents that induce cell death 
by binding to DNA (cross linking). Since their discovery, a number of chemotherapy 
agents have been discovered, all of which typically target the process of cell replication 
at various stages (figure 1.2). Traditional anticancer drug development concentrated 
on the malignant characteristic that tumour cells replicate more rapidly than normal 
cells and that DNA replication is the main biochemical feature driving the cancer 
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process. As a result the majority of drugs routinely used in clinical practice result in 
DNA damage, interruption of  cell division and subsequently cell death (Bailón-
Moscoso, Romero-Benavides, & Ostrosky-Wegman, 2014). Most chemotherapy drugs 
cause damage to DNA or prevent chromosomal replication leading to programmed cell 
death (apoptosis)(Al-Dimassi, Abou-Antoun, & El-Sibai, 2014). These drugs can be 
classified into five groups and can be summarised by the stage at which they are most 
active in the cell cycle (figure 1.2). 
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Figure 1.2: Summary of mechanistic and cell cycle dependency of the classical cytotoxic agents. G1, S, 
M, G2 and G0 refer to the stages of the cell cycle and the action of the 5 key groups of cytotoxic drugs 
on cells at different stages of the cell cycle is illustrated. This figure has been adapted from reference 
sources (Airley, 2009; Bhosle & Hall, 2009). 
 
 
 
M 
G2 
S 
G1 
G0 
Alkylating agents: 
Cell cycle phase independent   
agents attack both dividing and non-
dividing cells include platinums 
(cisplatin, carboplatin), nitrogen 
mustard derivatives (chlorambucil) 
and oxazophosphorines 
(cyclophosphamide, ifosfamide). 
Mitotic inhibitors: 
Prevent formation of 
mitotic spindle by 
binding to tubulin 
subunits therefore 
acting on cells 
undergoing mitosis, 
include taxanes   
(paclitaxel) and vinca  
alkaloids (vincristine). 
Cytotoxic 
antibiotics: 
Cell cycle non-
specific, therefore tend 
be of use in slow 
growing tumours that 
have a low growth 
fraction. Include 
anthracyclines 
(doxorubicin, 
epirubicin), bleomycin, 
mitoxantrone 
Antimetabolites: 
Analogues of nucleic 
acid bases, which are 
converted to 
nucleotides and 
incorporated into DNA , 
thus acting on cells 
undergoing DNA 
synthesis, these 
include methotrexate, 
5-fluorouracil, 
capecitabine and 6-
mercaptopurine. 
Topoisomerase 
inhibitors: 
Active during S-phase 
as they interfere with 
the activity of enzymes 
functioning during 
DNA replication. 
These include 
Topoisomerase-I 
inhibitors (irinotecan, 
topotecan), 
topoisomerase-II 
inhibitors (etopside). 
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Although the use of classical cytotoxic agents has achieved significant success, the 
biochemical selectivity of these conventional cytotoxic agents is poor. Side effects are 
common and can be life threatening leading to dose limiting toxicity. It is well-
documented that dose limiting toxicity not only reduces patient compliance, but it can 
also be the cause or a contributing factor towards a patient’s decline in health or their 
mortality. Due to the agents ubiquitous targeting of DNA, selectivity between normal 
and cancer cells is poor as the drugs cannot distinguish between a replicating cancer 
cell and a replicating normal cell. Side effects of chemotherapeutic agents include 
nausea and vomiting, hair loss, mucositis, leukopaenia and pancytopaenia, mainly due 
to their non-specific targeting of proliferating cells. More severe toxicities caused by 
chemotherapeutic agents include cardiotoxicity, renal toxicity, neurotoxicity, 
extravasations and nephrotoxicity which is most commonly observed with the 
platinum compounds (Plenderleith, 1990). 
In addition to toxicity, the emergence of a drug resistant phenotype is a further 
major challenge to successful chemotherapy. Over time, on-going genetic instability 
generates a plethora of alterations and diversity within a cancer, which can lead to the 
promotion of growth and survival advantages and treatment resistance (Turner & Reis-
Filho, 2012).  Resistance is a major limiting factor of chemotherapy treatment in solid 
tumours contributing to lack of response and consequently failure to adequately treat 
the tumour. Tumours can be either intrinsically resistant prior to treatment or can 
acquire resistance during treatment towards agents they were once susceptible 
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towards (Kerbel, Kobayashi, & Graham, 1994). The principle mechanisms of resistance 
to cytotoxic chemotherapy include well documented mechanisms of altered 
membrane transport resulting in the acceleration of drug efflux. The most studied 
example of this is the enhanced expression of ATP binding cassette (ABC) transporter 
proteins, such as P-glycoprotein (Pgp) (Gottesman, Fojo, & Bates, 2002). This increased 
efflux of the drug from the intracellular space leads to “multi-drug resistance” due to 
its ability to affect a number of chemotherapeutic agents (Wilson, Longley, & Johnston, 
2006). Other mechanisms may include the alteration of target proteins such as 
mutated topoisomerase II, decreased drug activation and increased drug degradation 
due to alteration of enzyme expression related to drug metabolism. Other mechanisms 
of drug resistance include drug inactivation, subcellular re-distribution, drug 
interactions, enhanced DNA repair and failure to undergo apoptosis as a result of 
mutated cell cycle proteins (Luqmani, 2005). 
 The emerging hallmarks highlighted in figure 1.1 provide the survival mechanisms to 
withstand environmental stresses such as the ones induced by chemotherapy with 
hypoxia being a pivotal driving force of malignant progression (Al-Dimassi et al., 2014). 
Due to the rapid proliferation tumour cells rapidly outgrow their blood supply, leading 
to areas of necrosis bordered by hypoxic tissue. These adaptive molecular changes are 
transcriptionally regulated via hypoxia inducible factors (HIFs), which up regulate 
hypoxia inducible genes regulating angiogenesis, anaerobic glycolysis and cell survival 
genes, whilst suppressing genes associated with cell death (Semenza, 2003). For this 
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reason tumour hypoxia and its effects have become attractive targets for targeted 
anticancer agents due to their strong correlation with increased malignancy, likelihood 
of metastasis and treatment failure (Airley, 2009). 
As indicated above recent developments in molecular biology and our greater 
understanding of the biology of cancer have provided researchers with the opportunity 
to develop novel agents that are targeted at the hallmark characteristics of the 
disease. As these agents target cancer biology, the hope was that these drugs would 
have greater pharmacological activity against cancer cells and be more selective than 
cytotoxic drugs. Agents in this class are designed to inhibit and/or modify a selected 
molecular target deemed important in cancer progression, growth and/or metastasis 
(Narang & Desai, 2009). These agents are designed to target specific aspects of tumour 
biology which although are expressed in variable degrees from patient to patient are 
characteristic properties with the same type of cancer. Examples of these agents are 
illustrated below (Figure 1.3) 
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Figure 1.3: Novel drugs that target the Hallmarks of Cancer. The hallmarks of cancer as defined by 
Hanahan and Weinberg (2011) are presented in the inner components of the 'the wheel' and the major 
groups of therapeutic agents targeting these hallmarks are described on the outer part of the wheel. 
These agents reflect the fact that understanding the biology of the disease can provide a number of 
therapeutic opportunities. 
 
These ten capabilities distinguish tumour cells from normal cells and have guided 
the development of novel targeted agents. Further understanding of the complex 
systems and molecular changes underlying cancer development have facilitated the 
research and development of agents that specifically target these malfunctioning 
genes and pathways. Targeting the ‘oncogenic drivers’ that lead to cancer has now 
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lead to the development of more effective and rationally designed cancer therapy 
(Sawyers, 2004). 
These include Imatinib (Gleevec) which is small molecule inhibitor of the BCR-ABL 
tyrosine kinase, which was initially approved for use by the FDA in 2001 for the 
treatment of chronic myelogenous leukaemia (CML) and has since been approved in 
the use of a number of gastrointestinal cancers (Pray, 2008). Others in include 
bortezomib (Velcade) a small molecule proteasome inhibitor, rituximab (Rituxin) and 
trastuzumab (herceptin) which are both monoclonal antibodies, which induce cancer 
cell death by evoking an immune response. Sawyers (2004) discusses the mechanistic 
detail of such targeted therapies in much more in depth and reviews their clinical 
relevance in modern cancer therapy.   
With the development of drugs that target specific biochemical features of cancer, 
it was hoped that there would be a paradigm shift in the treatment of cancer leading 
to reduced mortality and reduced side effects. It was also hoped that the problem of 
drug resistance which is a common feature of classical cytotoxic drugs would not be a 
problem. Whilst the discovery and development of new targeted therapies has 
generated effective and novel cancer therapies, significant concerns remain, and it is 
now apparent that the much hoped-for paradigm shift in cancer treatment has not 
occurred.  The reasons for this apparent lack of success are gradually being unravelled 
but the key issues are the emergence of new resistance mechanisms (via mutation of 
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the pharmacological target for example), tumour heterogeneity and tumour plasticity, 
details of which are described elsewhere (Meacham & Morrison, 2013).  
With regards to the emergence of drug resistance, the presence within a single 
tumour of multiple clones of cells with different genomic backgrounds and 
characteristics can lead to the positive selection of a drug resistant clone (Greaves & 
Maley, 2012) Furthermore, evidence has emerged demonstrating that cancer cells 
have the ability to switch between different phenotypical cellular states allowing them 
to circumvent the blockade of a specific pathway by switching to another (Aparicio et 
al., 2015; Meacham & Morrison, 2013). This phenomenon is referred to as plasticity 
and it allows cells to differentiate into other cell types that may be functionally, very 
far away from the original cell. This new paradigm of cellular differentiation, once 
viewed as a unidirectional process allows the cancer cells to create adaptive mutations 
in an almost Darwinian environment with the “fittest” surviving the selective pressure 
of the drug growing and forming a resistant state (Gravitz, 2014). This selective 
pressure of targeted therapy is causing cells to rewire their circuitry during treatment 
and may be driving tumours to become more heterogeneous (Bourzac, 2014). In some 
cases therefore, it could be considered that some targeted therapies are "too 
targeted" making the “magic bullet” theory becoming harder to achieve (ElShamy & 
Duhé, 2013).  
In addition to resistance, selective therapy poses difficulties chemically, as it is 
very difficult to chemically achieve single target specificity. This is because compounds 
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are found to interact with multiple targets with most drug molecules interacting with 
an estimated six known molecular targets on average (Mestres, Gregori-Puigjané, 
Valverde, & Solé, 2009). This gives further support to the shift from the concept of 
“one drug, one target” which is the cornerstone of target based drug development 
(Lee & Bogyo, 2013). Furthermore it is now becoming evident that many of the most 
effective drugs in cancer therapy such as Gleevec act on multiple rather than single 
targets (Paolini, Shapland, van Hoorn, Mason, & Hopkins, 2006). This phenomenon 
whereby compounds hit multiple targets is known as poly-pharmacology and 
represents a novel avenue for novel drug discovery. Designing drugs with a specific yet 
multi-target profile or designing a rational combination of such is complex but it could 
tackle the two major causes for attrition in drug development – poor efficacy and 
toxicity (Hopkins, 2008).  
1.4 - Phenotypic Approach to Drug Discovery and Target Deconvolution 
In view of the evidence emerging demonstrating that therapeutic agents targeted 
at specific pathways may be ineffective in the long term, there has been a resurgence 
in interest in a phenotypic based approach to drug discovery. Very much along the 
lines of the random screening program run by the National Cancer Institute in the 
United States (the NCI60 screen), this approach assumes that there are compounds in 
existing archives that are capable of targeting multiple pathways leading to a 
phenotypically desirable effect (reduced angiogenesis, reduced invasion for example). 
The selection of the specific endpoint that identifies a desirable phenotypic effect can 
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be varied and this distinguishes this approach from the NCI60 screen. Once a 
promising compound has been identified, then the process of understanding its 
mechanism(s) of action can begin in a process known as target deconvolution (Lee & 
Bogyo, 2013). As with all drug development approaches, there are significant 
advantages and challenges. With regards to advantages, this approach has the 
potential to identify compounds capable of inducing a useful therapeutic effect via 
multiple mechanisms of action. This has the potential to reduce the problem of tumour 
heterogeneity by being able to target multiple clones and thereby reducing the 
emergence of resistant clones. Furthermore, there are significant opportunities to 
identify molecules that have novel chemical structures. In the years between 1998-
2008 259 therapeutic agents have been approved by the FDA (Food and Drug 
Administration) 50 of which were small molecule first in class drugs, 28 were 
discovered by a phenotypic approach and 17 by target based drug discovery (Swinney 
& Anthony, 2011). Many drugs in use today have been discovered via phenotypic drug 
discovery including ezetimibe (cholesterol lowering drug) and linezolid (antimicrobial). 
The utility of phenotypic drug discovery allows for the investigation of drugs by 
phenotypic response allowing for the discovery of compounds which exert novel and 
unexpected mechanisms of action. This is particularly useful for diseases which do not 
have established and/or validated therapeutic targets allowing drug discovery in rarer 
and lesser understood conditions (Zheng, Thorne, & McKew, 2013). 
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The major challenge this approach faces however is the issue of selectivity for 
cancer cells over non-cancer cells. By identifying compounds with multiple 
mechanisms of action, it becomes challenging to identify compounds that selectively 
target cancer cell biology. 
Despite the challenges of this approach to drug discovery there are significant 
potential advantages to a phenotypic based approach that make it an attractive 
alternative to targeted drug discovery pathways (Gujral, Peshkin, & Kirschner, 2014).  
The concept is relatively straight forward, and it relies on the identification of hit 
compounds with desirable properties followed by target deconvolution to identify 
mechanism(s) of action. It determines the mechanisms of action, identifies effective 
pathways, determines suitable combinations of drug targets or drugs whilst addressing 
any target specific or off target toxicity early in the discovery of the drug (Boran & 
Iyengar, 2010; Drews, 2000; Lee & Bogyo, 2013). Within this context, this thesis 
focuses on the evaluation of a series of novel organometallic compounds as poly-
targeted anti-cancer agents using a phenotypic and target deconvolution based 
approach. Within this context, this thesis focuses on the evaluation of a series of novel 
organometallic compounds as poly-targeted anti-cancer agents using a phenotypic and 
target deconvolution based approach. Details of the rationale and aims of the project 
are described in more detail in the following sections. 
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1.5 - Rationale and Aims of Thesis 
In recent years organometallic complexes have undergone a resurgence in interest 
largely because they have been shown to exert their effects via mechanisms that do 
not involve DNA alkylation (Gasser, Ott, & Metzler-Nolte, 2010). Current research is 
therefore shifting away from the cisplatin paradigm where DNA is the established 
target with a number of new and alternative metal complexes often showing 
innovative mechanisms of action including targeting of multiple biologically important 
pathways (Bruijnincx & Sadler, 2008). Their diverse chemical structures and chemical 
properties make this class of compounds good candidates for a phenotypic based 
approach to drug discovery and this thesis focuses on evaluating a series of novel 
organometallic complexes from a variety of collaborative laboratories.  
With regards to the phenotypic evaluation strategy, the approach employed is 
chemosensitivity testing against cancer cell lines in vitro which is similar to the strategy 
employed by the NCI (although nowhere near as comprehensive). The steps that make 
this approach distinct from the NCI is the inclusion of non-cancer cell lines in the panel 
with the aim of establishing an in vitro 'selectivity index' as a key decision-making tool 
for selecting interesting compounds for further development. This addresses the key 
potential limitation of phenotype based drug discovery programs which is the issue of 
selectivity and how will this be achieved by compounds with multiple mechanisms of 
action. In addition, the in vitro selectivity index can be determined for the clinically 
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approved platinum based drugs and this information can be used as a further decision-
making point. In summary therefore, the aims of this thesis are: 
1. To evaluate the cytotoxic activity of platinum based anti-cancer drugs with 
a view to establishing a baseline selectivity index defined as the ratio of IC50 
values in non-cancer cells to cancer cells.  
2. To determine the potency and in vitro selectivity of a series of novel 
organometallic complexes and select compounds for further evaluation 
based upon (i) better selectivity than the platinates in vitro and (ii) 
equivalent or better potency than platinates in vitro.  
3. For those compounds that meet the selection criteria defined above, their 
pharmacological properties and potential mechanism(s) of action will be 
explored.  
4. In some cases where the chemical structures suggest that the compounds 
may have preferential activity in the tumour microenvironment, the ability 
of these compounds to selectivity kill hypoxic cells will be determined.  
5. To critically appraise whether this approach to drug development is capable 
of leading to the selection of compounds that have anti-tumour activity in 
vivo.  All in vivo studies were conducted by collaborators at the University 
of Bradford and acknowledgement to their involvement in the project is 
provided at the appropriate place in this thesis.  
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Chapter 2 – General Methods 
2.1 - Materials 
Unless otherwise stated, all reagents were obtained from Sigma Aldrich (Poole, 
Dorset) and all cell lines were obtained from either the American Tissue Culture 
Collection (ATCC) or European Collection of Cell Cultures (ECACC). A list of the cell lines 
used are presented below in table 2.1 and 2.2: 
2.2 - Cell lines and Media  
2.2.1 - Non-Cancerous Cell Lines 
Cell line Description Media Supplementation 
ARPE-19 Retinal pigmented 
epithelium 
DMEM F:12 1mM sodium pyruvate, 2mM L-glutamine, 
10% FBS. 
WI-38 Normal lung fibroblasts EMEM 1mM sodium pyruvate, 2mM L-glutamine, 
10% FBS. 
 
Table 2.1: Summary of non-cancerous cell lines used throughout this investigation along with their 
culture media and additives, note media purchased is both L-glutamine and sodium pyruvate free. 
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2.2.2 - Cancerous Cell Lines 
Cell line Description Media Supplementation 
BE Colon carcinoma DMEM 1mM sodium pyruvate, 2mM L-glutamine, 10% 
FBS. 
HCT116 
p53+/+ 
P53 wild type colonic 
adenocarcinomas 
DMEM 1mM sodium pyruvate, 2mM L-glutamine, 10% 
FBS. 
HCT116 
p53
-/-
 
P53 knock down colonic 
adenocarcinomas 
DMEM 1mM sodium pyruvate, 2mM L-glutamine, 10% 
FBS. 
HT29 Human colorectal 
adenocarcinoma 
DMEM 1mM sodium pyruvate, 2mM L-glutamine, 10% 
FBS. 
MIA-
PaCa2 
Pancreatic carcinoma DMEM 1mM sodium pyruvate, 2mM L-glutamine, 10% 
FBS. 
Panc 
10.05 
Pancreatic 
adenocarcinoma 
RPMI 
1640 
1mM sodium pyruvate, 2mM L-glutamine, 
10mg/litre human insulin, 15% FBS. 
PSN – 1 Epithelial like pancreatic 
adenocarcinoma 
RPMI 
1640 
1mM sodium pyruvate, 2mM L-glutamine, 10% 
FBS heat inactivated heat inactivated FBS 
supplied by Fisher Life Technologies. 
MDA-
MB-231 
Mammary gland 
adenocarcinoma 
L-15 1mM sodium pyruvate, 2mM L-glutamine, 10% 
FBS. 
 
Table 2.2: Summary of cancerous cell lines used throughout this investigation along with their culture 
media and additives. Note media purchased is both L-glutamine and sodium pyruvate free. 
 
All cells were routinely maintained in antibiotic free culture media as monolayer 
cultures and incubated at 37°C in a humidified, CO2 enriched (5%) atmosphere. Cancer 
cell lines were passaged for up to 10 passages, after which they were then discarded to 
reduce the risk of genetic drift affecting the reproducibility of results. Once cultures 
had reached passage 10, new cultures were resuscitated from stock cultures stored in 
the liquid nitrogen bank.  Non-cancerous cells lines were maintained in culture until 
they showed signs of deterioration (slow growth rates and senescence) and new 
cultures were then established from the liquid nitrogen bank.  
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2.3 - Cell Culture Methods 
All general cell culture was undertaken in laminar flow hoods using sterile 
techniques with sterile reagents ensuring sterility of cultured cells. Cells were checked 
daily to ensure expected growth as per specification and to avoid cells overgrowing. 
Prior to use all reagents are warmed in a water bath at 37°C for at least 30 minutes to 
prevent shock to the cells. 
2.3.1 - Resuscitation of Cells from Cryo-Preservation  
When cells were removed from liquid nitrogen efficiency is key to ensure the cells 
are removed from the freezing medium as soon as possible. Once cells are taken from 
the liquid nitrogen they were defrosted rapidly in a water bath at 37°C, then 
immediately added to at least 20ml of culture medium, ensuring the DMSO in the 
freezing medium is thoroughly diluted. The resulting suspension was centrifuged at 
1000-1500 rpm (depending on cell line) for 3 minutes producing a cell pellet from 
which the media solution was carefully removed. The resulting pellet was then re-
suspended in culture media and an adequate volume of cell suspension added to the 
desired cell culture flask. 
2.3.2 - Counting Cells in a Haemocytometer 
The haemocytometer was cleaned with 70% alcohol before and after use and 
thoroughly dried. Once dried the coverslip were fixed in place (pressed down until 
newton rings are visible), 10µl of cell suspension (treated with trypan blue to help 
distinguish viable from non-viable cells) was carefully added to the haemocytometer 
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being careful not to overfill the chamber. The haemocytometer was then placed on an 
inverted microscope using 10 x objective lens and unstained, viable cells counted in 
each of the four corner squares (made up of 16 smaller squares), counting only cells 
set within the squares and on the right and lower boundaries (see figure 2.1). The 
resulting cell number was divided by 4 to give an average, multiplied by the dilution of 
the contrast media, then further multiplied by 104 which gives the number of viable 
cells within 1ml of the cell suspension.  
 
 
Figure 2.1: General haemocytometer gridlines with one of the four “counting squares” highlighted. 
 
2.3.3 - Sub-Culturing by Trypsinisation of Monolayer Cultures 
Sub-culturing was undertaken either to prepare cells for specific experiments or to 
maintain cell cultures in exponential growth for future use. Media was removed from 
the flasks in which the cells are attached, the cells were then washed twice with PBS 
removing residual FBS, which inactivates the trypsin solution. The PBS was then 
     
Count  
     Don’t Count  
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removed and replaced with a sufficient volume (depending on flask size) of trypsin 1x 
solution and the flask gently rolled to ensure sufficient coverage. The flasks are 
incubated at 37°C for between 1 to 5 minutes depending on the cell line and their 
confluency. Once detached, cells were immediately re-suspended in growth medium 
to inhibit the action of trypsin. Cells were added to a fresh, labelled flask as per 
recommended split ratio and the required volume of culture media is added. The cells 
are then incubated overnight to reattach and settle following which the media is 
changed to remove any residual trypsin. Each time a cell line is sub-cultured the 
passage number is recorded on the flask. 
2.3.4 - Cryo-Preservation  
Following trypsinisation as described above, cells were re-suspended in culture 
media containing 20% FBS and 10% DMSO and 1ml of this cell suspension placed in a 
pre-labelled cryo-vial. The cryo-vials were then frozen by gradient freezing using a 
Nalgene “Mr Frosty” system loaded with isopropyl. Once the cryo-vials are inserted 
into the “Mr Frosty” at room temperature, this was placed in a -80°C freezer overnight 
prior to transferring the cryo-vials into the liquid nitrogen storage facility. The exact 
location, number of vials, date and cell line details were then entered into the liquid 
nitrogen storage logging system. 
2.4 - Validation of the Clonogenic Assay 
To validate the clonogenic assay for use in chemo-sensitivity testing, the 
relationship between the number of cells seeded and the number of colonies formed 
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was determined. Each cell line was seeded into six well plates at seeding densities 
ranging from 500 cells to 3500 cells per well. Each of the seeding densities were 
replicated three times and cells were incubated at 37°C in a humidified, CO2 enriched 
(5%) atmosphere. The plates were visually monitored (to determine when distinct 
colonies of >50 cells had formed) on days 2,3,4,8 and 9 with media changes made on 
days 4 and 8. The plates were quartered with each quadrant monitored for colony 
formation and overlapping colonies. If cell colonies in a single quadrant started to 
exceed 25 colonies or overlapping occurred, it was documented as these factors 
suggest overcrowding and this affects the ability to count the colonies accurately. Once 
colonies had formed (usually after 10 days incubation) viable colonies were stained (as 
described in 2.4.1 below) and counted using an Oxford Optronix Gel Count (Colony 
Counter). The software accurately counts all viable colonies along with providing mean 
colony diameter readings. 
2.4.1 - Viable Colony Staining Protocol 
Medium was removed, and cells were washed twice with PBS. After removal of 
PBS, 2-3 ml per well of fixation solution (acetic acid: methanol 1:7) was added and left 
at room temperature (RT) for 5 min. After 5 minutes, the fixative solution was 
removed and plates were dried at RT for 15 minutes. Once dried, 0.5% crystal violet 
solution was added to each well and incubated at 37°C for 2 hours. After removal of 
the crystal violet, the dishes/plates were carefully immersed in tap water to rinse off 
the crystal violet taking care not to remove any colonies. The dishes/plates were then 
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air-dried at RT for two days after which they were then processed by the Optronix Gel 
Count (Colony Counter), which uses high resolution imaging to accurately count and 
size colonies and spheroids.  
2.5 - The MTT Assay 
2.5.1 - Validation of the MTT Assay 
A single cell suspension was prepared at 5 x104 cells per ml. A 96 well plate was 
then seeded with varying volumes of cell suspension (ranging from 200 µl to 0 µl, 
decreasing in 20 µl aliquots) and medium added to make the final volume in each well 
up to 200 µl. The first lane contained 200 µl of media only to serve as a blank for the 
spectrophotometric readings and each condition was repeated 8 times (i.e. rows A-H 
on the 96 well plate). Immediately after plating the cells, 20µl of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5mg/ml) was added to 
each well and cells were incubated at 37°C for 4 hours. Following incubation, the 
media/MTT solution was removed from each well taking care not to remove any of the 
formazan crystals. After removal of the media, 150µl of dimethyl sulfoxide (DMSO) was 
added to each well and mixed with a micro spatula to ensure the formazan crystals 
have fully dissolved. The plates were then immediately read by a Tecan microplate 
photometer set at 540nm. The mean true absorbance was calculated (mean 
absorbance of wells containing cells minus the mean of the blank) for each lane and 
plotted against cell number. 
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2.5.2 - Determination of Optimum Seeding Densities for Use in the MTT Assay 
Previous studies in the laboratory had established the optimum seeding density 
for most cell lines used in this thesis except for PSN-1 and Panc-10.05 cell lines. To 
ensure that cells remain in exponential growth at the end of the chemosensitivity 
assay, PSN-1 and Panc-10.05 cells were seeded into 96 well plates at increasing cell 
densities per row ranging from 100-2000 cells per well then incubated at 37° for five 
days to mimic the total time cells are cultured in chemosensitivity assays). After five 
days, the medium was removed from each well and 200µl of fresh medium added 
along with 20µl of MTT (5 mg/ml). The MTT assay was conducted as described above 
and cell number plated against absorbance determined. The cell seeding density that 
gave results within the linear portion of the results obtained was selected for use in 
chemosensitivity studies.   
2.5.3 - Chemosensitivity Studies Under Aerobic Conditions 
Culture plates (96 well) were seeded as per the optimum initial seeding density 
established above and left overnight in the incubator at 37°C in a CO2 enriched 
atmosphere (5%) for cells to adhere to the plates. Test compounds were dissolved in 
either water based solutions i.e. medium or DMSO (details provided in each 
subsequent chapter) and a range of drug concentrations prepared by serial dilution. 
For compound’s not soluble in water/media the final concentration of DMSO was 0.1% 
(v/v) which is not known to be toxic to cells. Within each 96 well plate, blanks, controls 
and five compounds at eight different concentrations repeated twice were evaluated 
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on each plate as illustrated in figure 2.2. For each compound, an initial run was 
completed with a wide concentration range from 0.00128µM-100µM. Cells were 
exposed to compounds for 96 hours before cell survival was determined using the MTT 
assay as described above.  
2.5.4 - Determination of the IC50 Value  
The IC50 (inhibitory concentration at 50%) values were calculated by firstly 
subtracting the average absorbance of the blank column from all the average 
absorbance values to obtain the true absorbance. The percentage cell survival was 
then calculated using the true absorbance value as 100% cell survival. The IC50 value 
was calculated by plotting the percentage cell survival on a scatter graph, performing 
linear regression analysis and then using the equation Y=MX+C where Y=50 (50%) and 
M and C are calculated from the line plotted on the scatter graph X (the 
concentration). Once an approximate IC50 was established, experiments were then 
repeated using a much narrower concentration range to determine an accurate IC50. 
All experiments were performed in triplicate on separate days to achieve a mean IC50. 
In addition to the novel organometallics, a platinum panel was also run as a 
benchmark for the novel compounds (see chapter 3). 
 
 
 
   
 
Page | 60  
 
 
 
 
 A  B  C  D  E  F  G  H  I  J  K  L  
1   B l a n k   C o n t r o l  D r u g  1  D r u g  2  D r u g  3  D r u g  4  D r u g  5  
2  B l a n k  C o n t r o l       
3  B l a n k  C o n t r o l       
4  B l a n k  C o n t r o l       
5  B l a n k  C o n t r o l       
6  B l a n k  C o n t r o l       
7  B l a n k  C o n t r o l       
8  B l a n k  C o n t r o l       
 
Figure 2.2: Typical MTT plate setup used to test allowing 5 compounds to be tested per 96 well plate. 
 
2.5.5 - Chemosensitivity Studies Under Hypoxic Conditions  
Culture plates (96 well) were seeded using the optimum density determined 
above and left overnight in the incubator at 37°C for cells to adhere to the plates.  The 
plates were then transferred to the Don Whitley H35 hypoxia workstation set at 0.1% 
O2, 94% N2, 5% CO2 and 37°C. Along with the corresponding medium for the specific 
cell type, the plate(s) and the medium are then left for a further 24 hours in order for 
the oxygen to be purged and cells to adapt to hypoxic conditions. Cells were then 
exposed to drugs as described above in the hypoxia cabinet for a further for 96 hours. 
After 96 hours the medium was removed from each well and 20µl of MTT (5 mg/ml) 
was added to each well. The plates were then incubated in the hypoxia cabinet for 4 
hours. After 4 hours, the media/MTT solution was then carefully removed from each 
well taking care not to remove any of the formazan crystals. After removal of the 
medium, 150µl of dimethyl sulfoxide (DMSO) was added to each well and mixed with a 
micro-spatula to ensure the formazan crystals have fully dissolved. The plates were 
then immediately read by a Tecan reader set at 540nm. IC50 values were calculated as 
Increasing drug concentration 
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described above. As per previous protocols, all experiments were performed in 
triplicate to achieve a mean IC50 ± standard deviation. 
2.5.6 - Pseudo-Hypoxic Conditions  
Culture plates (96 well) were seeded at the optimum cell density as described 
above and left overnight in the incubator at 37°C for cells to adhere to the plates. After 
24 hours, the medium on all plates in all wells was then replaced with medium 
containing cobalt (II) chloride hexahydrate at a concentration of 150µM for an 
additional 24 hours. After 24 hours the cobalt medium is removed, washed with PBS 
and replaced with fresh cobalt chloride (150 µM) supplemented medium containing 
drug solutions covering a range of concentration. Following a 96-hour drug exposure 
under aerobic conditions, cell survival was determined using the MTT assay as 
described above.  Each experiment was repeated in triplicate and the results 
presented are the mean ± standard deviation.  
2.6 - Analysis of Drug Induced Cell Cycle Arrest and Apoptosis Induction 
Using the NucleoCounter (NC-3000) Cytometer 
The NucleoCounter 3000 or NC3000 is an advanced cytometer which uses 
fluorescence imaging to characterise cell properties. Compounds which were selected 
as being lead compounds based on their potency and/or selectivity index relative to 
that of the platinum standards were assessed for cell cycle arrest and apoptosis 
induction. 
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2.6 1 - 96-Hour Investigations  
For each of the compounds selected for further analysis, three T-25 flasks with 
1.66 x105 cells and left overnight in the incubator at 37°C to allow the cells to adhere 
to the flasks. A further flask was also seeded at the same cell density to serve as a 
control. The seeding density reflects the seeding density used for the MTT assays 
multiplied by the ratio of the area of a T25 flask to that of a single 96 well (i.e. the 
number of cells per cm2 is the same in both cases). Cells were exposed to 
corresponding IC50 values of compounds and in cases where organic solvents such as 
DMSO were used to dissolve compounds, a final concentration of 0.1% v/v DMSO was 
maintained in both treated and control flasks. As per previous MTT protocols the flasks 
were then incubated at 37°C for 96 hours. After drug exposure, images were taken 
(Evos XL digital microscope) of each flask for visual comparison prior to trypsinisation 
to obtain a cell suspension.  Cells were then analysed using the NC3000 and the 
following tests were performed: (i) a viability assay (ii) measurement of apoptosis 
induction and (iii) cell cycle analysis. For all these assays, the original medium was 
always kept and re-added prior to centrifugation to create a cell suspension with all 
living, apoptotic and necrotic populations present.  
2.6.2 - Varied Time Point Investigations 
For some compounds, timed drug exposures were employed and in these cases, a 
higher seeding density (7x105 cells/T25) was used. Cells were exposed to test 
compounds (at the IC50 concentration) for time points ranging from 1 to 72 hours, 
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following which cells were washed twice with PBS and trypsinised to generate a single 
cell suspension as described above.  
2.6.3 - Viability Assay 
Following the preparation of a single cell suspension, cells were drawn into the 
Via1-cassette by inserting the tip of the cassette into the cell suspension and pressing 
the piston. The Via1-cassettes are pre-loaded with Acridine orange, which stains the 
entire population and DAPI which stains the non-viable cells only. The cassettes were 
then immediately placed into the NC-3000 for analysing. The cell suspension should be 
in the range of 5x104 cells/ml to 5x106 cells/ml to assure reliable results in the viability 
assay and ensuring manageable cell densities for subsequent assays. The viability assay 
not only determines the viability of a cell suspension but provides and accurate cell 
count which facilitates the use of consistent cell numbers throughout subsequent 
assays.  
2.6.4 - Mitochondrial Potential Assay 
To determine whether compounds induced apoptosis, a mitochondrial membrane 
potential assay was performed. A suspension of 1x106 cells/ml was prepared in PBS to 
12.5µl of 200µg/ml JC-1 was added. The resulting suspension was then incubated for 
10 minutes at 37°C before being centrifuged at 400g for 5 minutes. The supernatant 
was then removed via careful pipetting to avoid disturbing the pellet. The pellet was 
then washed twice with PBS to remove JC-1 dye and prevent unspecific binding then 
vortexed to reduce the occurrence of aggregates.  The supernatant was then carefully 
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removed and the pellet re-suspended in 250µl of1µg/ml DAPI in PBS then analysed 
immediately on an A8 or A2 slide (Chemometec) depending on the number of samples. 
These are plain glass slides with no impregnated stains or dyes and the number 
corresponds to the number of samples that can be analysed on them. The rationale 
behind the assay is that it automates detection of cells with collapsed mitochondrial 
membrane potential (de-polarised), which is known to precede apoptosis. The cells are 
dyed with JC-1 which in negatively charged, healthy cells stain fluorescent red as it 
accumulates and aggregates in the mitochondrial matrix. In apoptotic cells the 
mitochondrial potential collapses and the JC-1 localises in the cytosol in its fluorescent 
green form. Late apoptotic and necrotic cells are stained blue by DAPI. Non-
viable/necrotic cells with a high DAPI signal were discounted from the results to 
reduce the inclusion of naturally occurring cell death. The degree of apoptosis is 
measured using a scatter plot of JC-1 red fluorescence vs JC-1 green fluorescence, 
therefore apoptotic cells present with a reduction in red/green fluorescence ratio. 
2.6.5 - Annexin V Assay 
As no single assay is exclusively selective for apoptosis induction, an additional 
apoptotic assay (the Annexin V assay) was also performed. From the viability assay a 
cell suspension at 2-4x105 cells/ml was prepared in PBS. The cells were washed twice 
in PBS before re-suspending the cell pellet in 100µl of Annexin V binding buffer (BD 
Biosciences).  Annexin V-CF488A conjugate (2µl) (Santa Cruz Biotechnology) and 
Hoechst 33342 (final concentration 10µg/ml) (Thermo-Scientific) was then added and 
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the resulting suspension mixed thoroughly and incubated at 37°C for 15 minutes. After 
incubation, the suspension was centrifuged for 5 minutes at 400g and the cell pellet 
was re-suspended in 300µl of Annexin V binding buffer and mixed thoroughly. The 
suspension was again centrifuged, the supernatant removed, and the resulting pellet 
re-suspended in 100µl of Annexin V binding buffer and 10µg/ml Propidium Iodide (PI). 
This cell suspension was analysed immediately by adding 30µl to an A2 slide. The 
whole cell population will be stained by Hoechst 33342 emitting violet light with 
Annexin V-CF488A conjugate staining apoptotic cells a fluorescent green light. Non-
viable/late apoptotic cells will be stained with both Hoechst and PI emitting violet and 
red light respectively, with late apoptotic population also emitting green fluorescence 
(Annexin V CF488A). The fluorescence intensity of Annexin V-CF488A vs the 
fluorescence intensity of PI is displayed in a scatter plot with only cells with nuclei 
(Hoechst 33342 stained) being displayed on the scatter plot. This assay therefore 
quantifies healthy, early apoptotic, late apoptotic and non-viable cells.  
2.6.6 - Cell Cycle Assay 
To determine whether, or not, selected compounds induced cell cycle arrest, a cell 
suspension at 1 x 106 cells/ml was prepared. Cells were washed twice in PBS prior to 
the addition of 250µl of Solution 10 (lysis buffer, Chemometec) supplemented with 
10µg/ml DAPI. The cell suspension was then incubated for 5 minutes at 37°C followed 
by the addition of 250µl of solution 11 (stabilisation buffer, Chemometec). The 
resulting sample was then immediately analysed again using A2 or A8 slides dependent 
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on the number of samples. The principle of the assay is that DNA content of cells is 
quantified based on DNA staining with DAPI. In a single population, cells are 
distributed among three major phases; G1/G0 with one set of paired chromosomes per 
cell, S phase where DNA is synthesised thus resulting in variable DNA content, and 
G2/M phase where there are two sets of paired chromosomes per cell. Sub G1 
populations are classed as apoptotic with populations with higher fluorescent 
intensities than G2/M phase being classed as polyploid. DAPI intensity vs cell 
population is plotted on a histogram which is used to quantify the percentage of the 
cell population in the various cell cycle stages based on DAPI intensity which directly 
relates to DNA content.  
2.6.7 Statistical analysis 
In order to determine if variances in two populations i.e. activity of specific 
compounds in non-cancerous opposed to cancerous cell lines are statistically 
significant paired t-test were completed. This statistical analysis of two means tests the 
hypothesis  that the use of different cell lines, isogenic clones or alterations in oxygen 
tension results in significant differences in the activity of both our platinum standards 
and novel compounds. This statistical formula results in a P-value or probability value 
which when below 0.05 established statistical significance between two populations. 
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Chapter 3 - Response of Human Tumour Cells and 
Non-Cancer Cells to Clinically Approved Platinum 
Based Anti-Cancer Drugs 
3.1 - Introduction 
This chapter concentrates on the validation and optimisation of chemosensitivity 
assays methodologies and the characterisation of cellular response to clinically 
approved platinum based anti-cancer drugs. The purpose of this is to establish a 
‘baseline’ or ‘yardstick’ against which the relative merits of novel organometallic 
compounds can be measured with regards to (i) potency and (ii) selectivity for cancer 
as opposed to non-cancer cell lines. In effect, compounds will be selected for further 
evaluation if they demonstrate superior activity profiles compared to established 
metal containing anti-cancer drugs. The following information reviews the current 
literature with regards to platinum based anti-cancer drugs with respect to their 
pharmacology.  
As described earlier in this thesis, cisplatin remains one of the leading drugs in cancer 
therapy and is used for the treatment of a variety of cancers including ovarian, 
testicular, lung and bladder cancers. Cisplatin is present in 32 of 78 treatment 
regimens listed in the Martindale (Press, 2017) and is utilised not only as a mono-
therapeutic agent but also its use in combination therapy (Sweetman, 2009). Cis-
diamminedichloroplatinum (II) better known as cisplatin is a metal co-ordination 
compound which was approved for clinical use in testicular cancer in 1978 (Loehrer & 
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Einhorn, 1984) and remains one of the most potent anti-tumour agents known. It’s 
clinically considered one of the most effective chemotherapeutic agent and is used to 
treat 50% of all cancers including testicular, ovarian, head and neck, colorectal, bladder 
and lung cancer (Galanski, Jakupec, & Keppler, 2005). Its anti-tumour effect remains a 
benchmark for novel metal-based anti-cancer agents. It is thought cisplatin enters the 
cell by three modes of action passive diffusion, copper transporter proteins and/ or 
organic cation transporters (Puckett, Ernst, & Barton, 2010). Cisplatin exerts its 
anticancer effects by multiple modes of action, yet most prominently via the formation 
of DNA lesions via covalent bonding to Guanine and to a lesser extent adenine, 
resulting in intra and inter-strand adducts (demonstrated in figure 3a). These adducts 
cause bending and unwinding of the DNA culminating in the induction of mitochondrial 
dysfunction (Galluzzi et al., 2012). This mitochondrial dysfunction has been shown to 
precede apoptosis and the loss of mitochondrial membrane potential is thought to 
take a central role in apoptosis causing the release of apoptogenic factors and the loss 
of oxidative phosphorylation (Ly, Grubb, & Lawen, 2003).  
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Figure 3a: Main DNA lesions formed upon cisplatin binding to DNA, adapted from (Cepeda et al., 2007; 
Conconi, 2013). 
In the 40 years since its discovery, the success of cisplatin has motivated the 
synthesis of several hundred platinum derivatives. Yet of the vast number of novel 
platinate compounds synthesised, only 23 other platinum based drug have entered 
clinical trial and of these, only two have gained international marketing approval 
(Wheate, Walker, Craig, & Oun, 2010). This lack of success is due largely to limitations 
associated with dose limiting toxicity and ever-increasing resistance towards platinum 
therapy.  
Resistance towards cisplatin treatment has been studied extensively and as 
previously discussed has been attributed to two broad mechanisms. The first 
mechanism involves the reduction of DNA damage induction either by reduced drug 
uptake or drug inactivation by thiol containing species (Kelland, 2000, 2007). The 
second mechanism involves a failure to achieve cell death after platinum DNA adduct 
formation, mainly because of upregulation of DNA repair (Al-Dimassi et al., 2014). Of 
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the five recognised DNA repair pathways that repair DNA following damage 
(nucleotide excision repair, mismatch repair, double strand break repair, base excision 
repair and direct repair (Giaccone, 2000), two have been identified as the mechanism 
behind increased tolerance to platinum induced DNA damage. These two pathways are 
upregulation of nucleotide excision repair and loss of function of the mismatch repair 
pathway which ordinarily triggers an apoptotic response (Galluzzi et al., 2012). 
In addition to direct resistance to DNA damage, platinum resistance may also be 
mediated through alterations to downstream proteins involved in apoptosis such as 
P53 and the BCL2 family (Kelland, 2000).  As previously discussed, cisplatin therapy is 
known to bind with DNA resulting in distortion in the DNA including unwinding and 
bending. These DNA adducts can impede key cellular processes such as DNA 
replication and transcription leading to a cellular stress response and commonly the 
induction of apoptotic cell death. The phenotypic effects of these adducts can also 
include prolonged G2 cell cycle arrest, altered growth via signal transduction 
pathways, or differentiation (Kelland, 2007) Tumours can acquire resistance to 
apoptosis by the  increased expression of anti-apoptotic proteins or by the 
downregulation or mutation of pro-apoptotic proteins (Igney & Krammer, 2002). 
Resistance caused by mutations in P53 and the DNA repair pathways are a major 
limitation to platinum therapy and therefore, novel approaches are needed to 
circumvent this major therapeutic problem.  
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Carboplatin was the first of the two novel platinum agents to gain global approval 
and it is now the drug of choice for treatment of ovarian cancer (Ai, Lu, Qiu, & Fan, 
2016; Piccart, Lamb, & Vermorken, 2001). Carboplatin is often referred to as a cisplatin 
pro-drug as it requires conversion to its reactive species and the rate of conversion is 
much slower than that of cisplatin. This reduction in conversion rates significantly 
diminishes the nephrotoxic effects seen with cisplatin (Kostova, 2006). This is a result 
of replacing dichloride ligands with 1,1-cyclobutanedicarboxylate (see table 1 for 
compound structures) which aquates much slower. Platinum toxicity is directly related 
to the ease at which these leaving groups are aquated (i.e. how easily they are 
displaced by water). Therefore, by manipulating these leaving groups, carboplatin is 
converted to its reactive species much slower which significantly reduces the dose 
limiting nephrotoxic effects observed with cisplatin (Wheate et al., 2010). 
Unfortunately, carboplatin does carry its own side effects including myelosuppression 
and thrombocytopenia, which can be managed with adjuvant treatments such as the 
granulocyte-stimulating growth factors, filgrastim and pegfilgrastim alongside regular 
monitoring of bloods. These side effects, although dose limiting, can be managed 
unlike the potentially life-threatening nephrotoxicity observed with cisplatin. This 
therefore enables the administration of higher doses and much more prolonged 
administration of carboplatin to patients compared to cisplatin.  Despite its altered 
toxicity profile, carboplatin’s mechanism of action mirrors that of cisplatin forming the 
same adducts as cisplatin resulting in cross resistance. This therefore reduces the 
clinical application of carboplatin especially in colorectal and pancreatic tumours to 
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which cisplatin resistance is already well established (Weiss & Christian, 1993)(Weiss & 
Christian, 1993). 
The limitations of cisplatin and carboplatin ultimately led to the development and 
subsequent approval of the second platinum agent, oxaliplatin. This compound 
showed both a reduced toxicity profile and the ability to overcome cisplatin resistance 
(Misset, Bleiberg, Sutherland, Bekradda, & Cvitkovic, 2000). Oxaliplatin as a single 
agent and as part of combinational therapy shows little cross-resistance with cisplatin 
or carboplatin.  
Although oxaliplatin targets the same DNA site as cisplatin and carboplatin, the 
resulting DNA adducts formed differ in structure. The two amine ligands presented on 
cisplatin are substituted for single bidentate ligands with 1,2-diaminocyclohexane 
(DACH) carrier ligands. These DACH ligands form much bulkier, hydrophobic adducts 
which point into the DNA major groove preventing the binding of DNA repair proteins 
(Misset, Bleiberg, Sutherland, Bekradda, & Cvitkovic, 2000; Raymond, Chaney, 
Taamma, & Cvitkovic, 1998). It is also these oxalate ligands, which reduce the toxicity 
profile of oxaliplatin. Its potential was initially overlooked for a decade due to dose 
limiting neuropathy although this was subsequently found to be avoidable with the 
addition of calcium and magnesium solutions (Cersosimo, 2005). As a single agent, 
oxaliplatin has limited but consistent activity but as a combinational therapy, it holds 
much promise. It shows remarkable synergistic activity with fluoropyrimidines such as 
5-fluorouracil/folic acid for which it is clinically licensed as a combinational therapy for 
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metastatic colorectal cancer (FOLFOX regimen) and locally advanced and metastasised 
pancreatic cancer (FOLFORINOX regimen) (Conroy et al., 2011; Raymond, Chaney, 
Taamma, & Cvitkovic, 1998). Its synergistic potential as a combinational therapy has 
more recently been investigated in platinum resistant ovarian cancers as both an 
active regimen with topotecan (topoisomerase-I inhibitor) and as a moderately 
effective multi-drug regimen with gemcitabine (Elshebeiny & Almorsy, 2016; Stein et 
al., 2013). 
As stated earlier, this thesis is designed to evaluate a series of chemically diverse 
organometallic complexes in the hope of identifying lead compounds that can be 
evaluated further. To select these novel compounds for further evaluation, the 
potency and selectivity of platinum based complexes under aerobic and hypoxic 
conditions will be determined as this serves as a benchmark against which the relative 
merits of novel compounds can be judged. In essence, if novel compounds perform as 
well as or better than platinum based compounds in initial experimental 
chemosensitivity studies, they will be selected as potential ‘hit’ compounds for further 
evaluation. The purpose of this chapter therefore is to characterise the response of cell 
lines to cisplatin, carboplatin and oxaliplatin under various experimental conditions.   
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3.2 - Methods 
3.2.1 - Chemosensitivity Studies 
All compounds were obtained from Sigma Aldrich (Dorset, UK) and stock solutions 
were prepared as described in table 3. All stock solutions of drugs were aliquoted into 
2µl batches and stored at -20°C until required for chemosensitivity studies. Stock 
solutions were not subjected to repeated freeze thaw conditions and all stocks were 
disposed of 3 months after preparation. All results represent the mean ± standard 
deviation of three independent experiments. The selectivity index is defined as the 
mean IC50 of non-cancer cells divided by the IC50 for tumour cells; values >1 indicate 
selectivity for tumour cells in vitro. 
Compound MW Diluent  Solubility 
Molar concentration 
(𝐦𝐌) 
Compound structure 
 
Carboplatin 
 
371.25 
 
PBS 
 
10mg/ml 
 
20mM  
 
 
Cisplatin 
 
300.05 
 
PBS 
 
2.5mg/ml 
 
1mM 
 
 
Oxaliplatin 
 
397.29 
 
PBS 
 
5mg/ml 
 
10mM 
 
 
 
Table 3.1: Preparation of stock solutions for platinum compounds. 
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3.2.2 - NucleoCounter 3000 Studies  
Cisplatin is known to induce apoptosis and G2/M cell cycle arrest and it is therefore 
an ideal positive control to compare with the novel compounds tested. The NC3000 
studies were completed as per sections 2.6.2, 2.6.3, 2.6.4, 2.6.5 and 2.6.6 with all 
compounds sourced and prepared as per section 2.2.1. In all cases, cisplatin was used 
at a concentration of 30µM which is known to induce apoptosis and cell cycle arrest 
(Berndtsson et al., 2007; Zaffaroni et al., 1998). 
3.3 - Results 
3.3.1 - Validation of the Clonogenic Assay as an Endpoint for 
Chemosensitivity Testing 
The clonogenic assay was performed as described in section 2.3 where the initial 
objective was to determine the relationship between the number of cells plated and 
the number of colonies formed. Initial studies were conducted using the pancreatic 
cancer cell line Panc 10.05 and significant problems were encountered. These are 
illustrated in figure 2.1 where large ‘super colonies’ formed in the centre of each 6 well 
plate, particularly at initial seeding densities of 1000 cells per well or greater. This 
result was reproducible and despite several attempts to improve the situation, it was 
not possible to determine the relationship between cell number and number of 
colonies formed in this cell line. 
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Figure 3.1: Validation of the clonogenic assay using Panc10.05 cells. These experiments were conducted 
in 6 well plates using a range of initial seeding densities (as indicated on the left-hand side of each 
plate). Cells were cultured for up to 10 days to allow colonies to form and colonies were stained with 
methylene blue. The results demonstrate that the majority of colonies formed in the centre of each well 
making it impossible to assess colony formation accurately. 
 
To reduce the possible clustering of cells at the time of seeding, a number of 
dispersion and agitation techniques were used. Firstly, when the cell suspension was 
added to each well whilst seeding, it was added at four points North, East, South and 
West. Then every 20 minutes for 1 hour the plates were agitated by again moving the 
plates North, East, South and West as Panc10.05 cells start to adhere after 10-15 
minutes with around 40% of the cells being attached after 30 minutes. The results 
displayed in figure 2.2 demonstrate that better colony dispersion occurred although 
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clustering in the centre of the well was still apparent. Furthermore, cells also formed 
colonies at the edge of each well. Even with careful agitation, it was not possible to 
determine the relationship between cells number and colony formation in the 
Panc10.05 cell line. 
 
 
Figure 3.2: Colony formation by Panc10.05 cells following agitation. Ranges of cell numbers were seeded 
across the 6 well plates and whilst greater colony dispersion occurred, a strong rim of colonies formed 
at the edge of each well. 
 
To determine whether the results obtained above were unique to Panc10.05 cells, 
further clonogenic assays were also performed using an additional cell line. MDA-MB -
231 the mammary gland breast adenocarcinoma was used but as illustrated in figure 
2.3, the same issues with central clumping and overlapping was observed. Because of 
these technical issues encountered, the clonogenic assay was not used as the endpoint 
for chemosensitivity testing in this thesis. 
2500 
2000 
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.  
Figure 3.3: Colony formation of MDA-MB-231 cells plated at 100 and 500 cells per well. Central 
clumping was still apparent regardless of change in cell line. 
 
3.3.2 - Validation of the MTT Assay for use as an Endpoint for 
Chemosensitivity Testing 
Validation assays designed to determine the relationship between cell number 
and absorbance at 540nm were performed as described in section 2.4.1. The results 
for MIA-PaCa2 and ARPE-19 cells are presented in figures 2.4 and 2.5 respectively.  The 
results demonstrate that a linear relationship between cell number and absorbance 
was obtained in both tumour (MIA-PaCa2) and non-cancer (ARPE-19) cells. The MTT 
assay was therefore considered a valid endpoint for chemosensitivity testing. 
500 
100 
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Figure 3.4: Relationship between cell number (MIA-PaCa2) and absorbance generated using the MTT 
assay. The results are for one experiment only (n=1 with 8 replicates) and R2 represents the regression 
coefficient obtained following linear regression analysis (the solid line). 
 
 
Figure 3.5: Relationship between cell number (ARPE-19) and absorbance generated using the MTT 
assay. The results are for one experiment only (n=1 with 8 replicates) and R2 represents the regression 
coefficient obtained following linear regression analysis (the solid line). 
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3.3.3 - Determination of the Optimum Seeding Density for the MTT Assay 
In all assays such as the MTT assay it is essential that the controls (untreated) 
remain in exponential growth at the end of the 96-hour drug exposure period 
otherwise erroneous results can be obtained. This is clearly a function of how many 
cells you add to each well and the duration of the culture period. To establish the 
initial seeding density, a range of cell numbers were plated into 96 well plates and 
cultured for 96 hours before conducting the MTT assay. The results are presented in 
figures 3.6 and 3.7.  The results for Panc10.05 cells (figure 3.6) demonstrate that as the 
initial cell seeding density increases, the absorbance values post incubation increase 
linearly up to a maximum of 1.08. Initial seeding densities between 1000 and 1500 
gave good results in terms of the absorbance generated and viability at the end of the 
96-hour exposure period. In contrast, similar studies using the non-cancer PSN-1 cell 
line demonstrated significantly different results (figure 3.7). In this case, initial cell 
seeding densities above 1500 cells generated reduced absorbance values suggesting 
that cultures were entering the ‘death’ phase of the growth curve after 96-hour 
incubation.  A seeding density of 1000 cells per well was chosen in this case. Similar 
studies were conducted for all the cell lines employed in this thesis and the results are 
summarised in table 3.2. 
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Figure 3.6: Relationship between cell number and absorbance generated using the MTT assay. This 
experiment was run once (n=1 with 8 replicates) to obtain an optimal seeding density for the Panc10.05 
cell line. 
 
 
 
Figure 3.7:  Relationship between cell number and absorbance generated using the MTT assay. This 
experiment was run once(n=1 with 8 replicates) to obtain an optimal seeding density for the PSN-1 cell 
line. 
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Cell line Description Optimal seeding density 
ARPE-19 Retinal pigmented epithelium 2000 
W1-38 Normal lung fibroblasts 3000 
BE Colon carcinoma 2000 
HCT116 p53+/+ P53 up-regulated colonic adenocarcinomas 2000 
HCT116 p53-/- P53 knock down colonic adenocarcinomas 2000 
HT29 Human colorectal adenocarcinoma 2000 
MIA-PaCa2 Pancreatic carcinoma 2000 
Panc 10.05 Pancreatic adenocarcinoma 2000 
PSN – 1 Epithelial like pancreatic adenocarcinoma 1000 
 
Table 3.2: Summary of optimal seeding densities for the different cell lines used in chemosensitivity 
testing.  
3.3.4 - Response of Cancer and Non-Cancer Cell Lines to Cisplatin, 
Carboplatin and Oxaliplatin 
3.3.4.1 - Aerobic Conditions  
The response of a panel of cancer and non-cancer cell lines to 96 hours of 
continuous exposure to cisplatin, carboplatin or oxaliplatin under aerobic conditions is 
presented in figure 3.8 (dose response for HCT116 cancer cells) with IC50 values for all 
cell lines presented in figure 3.9. In general terms, carboplatin was the least active 
compound against all cell lines tested with IC50 values ranging from 10.45 ± 3.15 to 
77.73 ± 10.52µM (Figure 3.9).  Cisplatin and oxaliplatin were significantly more active 
in vitro with some cell lines being very sensitive (sub µM IC50) to cisplatin (BE and HT-
29) and oxaliplatin (HCT116 p53+/+). 
   
 
Page | 83  
 
 
 
 
 
 
Figure 3.8 Percentage cell survival of HCT116 p53+/+ cell line in response to increasing doses of the three 
platinate standards cisplatin, carboplatin and oxaliplatin. Data are from three independent MTT assays 
n=3 (each individual experiment replicated twice ) and are represented by the mean ± SE. The 
percentage cell survival values are expressed as a percentage of viable cells compared with untreated 
controls. 
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Figure 3.9: Response of a panel of cell lines to oxaliplatin, cisplatin and carboplatin. The results 
presented are the mean IC50 values ± SD for three independent experiments n=3 (each individual 
experiment replicated twice ). 
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3.3.4.2 - Selectivity Indices In Vitro  
The relative activity of cisplatin, oxaliplatin and carboplatin against tumour and 
non-cancer cells (ARPE-19) is presented and illustrated graphically in figure 3.10. The 
selectivity index (SI) is defined as the IC50 for non-cancer cells divided by the IC50 for 
cancer cells with values greater than 1 indicating selectivity for cancer as opposed to 
non-cancer cells. In the case of ARPE19 cells, carboplatin was selectively toxic to all 
cancer cells with SI values ranging from 2.18 to 7.44 resulting in statistically significant 
(p-value = less than 0.05) reductions in potency toward the none cancerous cell line 
investigated. Similarly, with cisplatin, SI values ranged from 1.77 to 9.71 in all cancer 
cells except for HCT116 p53-/- cells where an SI of 0.85 was obtained (p-value 0.32). 
Oxaliplatin on the other hand was generally less toxic towards the cancer cells 
resulting in statistically significant (p-value = less than 0.05) decreases in potency 
towards 3 out of the 5 cancer cell lines investigated.  
 
 
   
 
Page | 86  
 
 
 
 
 
Figure 3.10: Selectivity index of three platinum compounds on a range of cancerous cell lines. The 
selectivity index is defined as the ratio of the mean IC50 in non-cancerous cells to the mean IC50 in 
cancerous cells. As mean values are used to calculate the SI, no error bars are present in this data set. 
Statistical analysis was performed using a student’s t-test where values <0.05 indicates a statistically 
significant difference between IC50 values in cancerous and none cancerous cell lines. 
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Compound BE MIA-PaCa2 HCT116 p53
+/+ HCT116 p53-/- PANC10.05 
 SI p-value SI p-value SI p-value SI p-value SI p-value 
Cisplatin 9.71 0.0043 1.77 0.10 1.97 0.033 0.85 0.32 3.75 0.025 
Carboplatin 2.38 0.029 2.18 0.031 2.40 0.023 2.18 0.014 7.44 0.0089 
Oxaliplatin 0.36 0.0064 0.48 0.020 3.35 0.010 0.85 0.65 0.41 0.047 
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3.3.4.3 - Response of HCT116 Cells to Cisplatin, Carboplatin and Oxaliplatin: 
P53 Dependency 
The HCT116 p53+/+ and HCT116 p53-/- cells are isogenic colorectal carcinoma cells 
that differ only with regards to their p53 status. The relationship between p53 status 
and the response of cells to platinum based anti-cancer drugs is presented in figure 
3.11. Whilst no significant difference exists in the response of HCT116 p53+/+ and 
HCT116 p53-/- cells to carboplatin (p=0.2461) and oxaliplatin (p=0.0862) the p53 null 
cell line HCT116 p53-/- was significantly more resistant to cisplatin (p = 0.0035). In the 
search for novel anti-cancer drugs with activity against p53 null tumours, this baseline 
information will also be used to characterise the activity of novel compounds tested in 
this thesis. 
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 Average IC50 ± standard deviation (µM) 
 Cisplatin Carboplatin Oxaliplatin 
HCT116 p53
+/+
 3.26±0.38 32.37±11.14 0.93±0.11 
HCT116 p53-/- 7.52±0.65 35.7±9.06 6.44±1.05 
p-value 0.0035 0.2461 0.0862 
 
Figure 3.11: Comparison of IC50 values ± SD of platinum compounds towards HCT116 p53
+/+ and p53−/− 
isogenic clones. Data generated by triplicated MTT assays completed on consecutive days n=3 (each 
individual experiment replicated twice ). Statistical analysis was performed using a student’s t-test 
where values <0.05 indicates a statistically significant difference between IC50 values HCT116 p53
+/+ and 
HCT116 p53-/-cell lines. 
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3.3.4.4 - Response of Cancer Cells Following Continuous Exposure to 
Cisplatin, Carboplatin and Oxaliplatin Under Hypoxic Conditions 
A comparison of the dose response of HCT116 p53+/+ and MIA-PaCa2 cells to 
platinum based anti-cancer drugs under aerobic and hypoxic conditions (0.1% O2) is 
presented in figures 3.12 to 3.14 (IC50 values summarised in table 3.3). The results 
demonstrate that hypoxia (0.1% O2) significantly reduces the activity of cisplatin, 
carboplatin and oxaliplatin (all supported by p-values <0.05).  Oxaliplatin was the most 
active of the platinates against the MiaPac2 pancreatic cancer cell line under hypoxia 
IC50 87.72 ± 7.29µM), As with aerobic investigations carboplatin appeared the least 
active under hypoxic conditions with an IC50 value unattainable in both cell lines with 
drug concentrations up to 100µM.  
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3.3.4.4.1 - Cisplatin 
 
 
 
Figure 3.12: Dose response curves of cisplatin towards A) MIA-PaCa2 and B) HCT116 p53
+/+ cell lines in 
both hypoxic and aerobic conditions. Data from three independent MTT assays n=3 (each individual 
experiment replicated twice ) and are represented by the mean ± SE. The percentage cell survival values 
are expressed as a percentage of viable cells compared with untreated controls. 
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B) 
3.3.4.4.2 - Carboplatin  
 
 
 
Figure 3.13: Dose response curves of carboplatin towards A) MIA-PaCa2 and B) HCT116 p53
+/+ cell lines 
in both hypoxic and aerobic conditions. Data from three independent MTT assays n=3 (each individual 
experiment replicated twice ) and are represented by the mean ± SE. The percentage cell survival values 
are expressed as a percentage of viable cells compared with untreated controls. 
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3.3.4.4.3 - Oxaliplatin 
 
 
 
Figure 3.14: Dose response curves of oxaliplatin towards A) MIA-PaCa2 and B) HCT116 p53
+/+ cell lines in 
both hypoxic and aerobic conditions. Data from three independent MTT assays n=3 (each individual 
experiment replicated twice ) and are represented by the mean ± SE. The percentage cell survival values 
are expressed as a percentage of viable cells compared with untreated controls. 
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Table 3.3: Summary of IC50 values of three platinum compounds towards  HCT116 p53
+/+ and MIA-PaCa2 
cell lines under hypoxic and aerobic conditions. Data from three independent MTT assays n=3 (each 
individual experiment replicated twice) and are represented by the mean ± SD. Statistical analysis was 
performed using a student’s t-test where values <0.05 indicates a statistically significant difference 
between IC50 values in hypoxic and aerobic conditions in two cancerous cell lines. 
3.3.4.5 - Response of HCT116 p53+/+ and MIA PaCa2 Cells to Platinates Under 
Pseudo-Hypoxic Conditions 
The response of HCT116 p53+/+ and MIA-PaCa2 cells to platinum based anti-cancer 
drugs under aerobic and pseudo-hypoxic conditions is presented in figures 3.15 to 3.17 
and summarised in table 3.4. The results demonstrate that under pseudo-hypoxic 
conditions, all cells are more resistant to platinum-based drugs compared to aerobic 
conditions with cisplatin and carboplatin displaying significantly reduced potency (p-
values <0.05). The magnitude of the change in sensitivity varies but is typically a 2 to 3-
fold increase in resistance.  
 Average IC50 ± standard deviation (µM) 
 Cisplatin  Carboplatin  Oxaliplatin  
 Aerobic Hypoxic p-value  Aerobic Hypoxic p-value  Aerobic Hypoxic p-value 
HCT116 
p53
+/+
 
3.26±0.38 95.49±3.9
2 
0.00071 32.37±11.
14 
>100 0.0089 0.93±0.11 >100 0.0000004
1 
MIA-
PaCa2 
3.62±0.74 >100 0.00002 35.59±7.9
1 
>100 0.0050 6.44±1.05 87.72± 
7.29 
0.0021 
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3.3.4.5.1 - Cisplatin 
 
 
 
Figure 3.15: Dose response curves of cisplatin towards A) MIA-PaCa2 and B) HCT116 p53
+/+ cell lines in 
both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays n=3 (each 
individual experiment replicated twice ) and are represented by the mean ± SE. The percentage cell 
survival values are expressed as a percentage of viable cells compared with untreated controls. 
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3.3.4.5.2 - Carboplatin 
 
 
 
Figure 3.16: Dose response curves of carboplatin towards A) MIA-PaCa2 and B) HCT116+/+ cell lines in 
both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays n=3 (each 
individual experiment replicated twice ) and are represented by the mean ± SE. The percentage cell 
survival values are expressed as a percentage of viable cells compared with untreated controls. 
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3.3.4.5.3 - Oxaliplatin 
 
 
 
Figure 3.17: Dose response curves of oxaliplatin towards A) MIA-PaCa2 and B) HCT116 p53
+/+ cell lines in 
both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays n=3 (each 
individual experiment replicated twice ) and are represented by the mean ± SE. The percentage cell 
survival values are expressed as a percentage of viable cells compared with untreated controls. 
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Table 3.4: Summary of IC50 values of three platinum compounds towards both colorectal and pancreatic 
cancerous cell lines HCT116 p53+/+ and MIA-PaCa2 in pseudo-hypoxic and aerobic conditions. Data from 
three independent MTT assays n=3 (each individual experiment replicated twice) and are represented 
by the mean ± SD. Statistical analysis was performed using a student’s t-test where values <0.05 
indicates a statistically significant difference between IC50 values in pseudo-hypoxic and aerobic 
conditions in two cancerous cell lines. 
3.3.5 - Analysis of Cisplatin Induced Apoptosis and Cell Cycle Arrest 
To create a baseline set of parameters by which the activity of novel test 
compounds can be compared, the ability of cisplatin to induce cell cycle arrest and 
apoptosis was determined. The assays were conducted on both HCT116+/+ and ARPE-
19 cell lines to establish any differences between the response of cancerous and non-
cancerous cell lines, which will be of particular interest with our novel “hit” 
compounds. The time points at which the assays were completed were 2, 8, 24, 48 and 
72 hours, with an untreated control sample for each time point.  
3.3.5.1 - Viability Assay 
The results of viability assays completed on both untreated and treated (cisplatin 
30µM) samples over a 72-hour period are summarised in tables 3.5 and 3.6 and 
Average IC50 ± standard deviation (µM) 
 Cisplatin Carboplatin Oxaliplatin 
 Aerobic Pseudo-
Hypoxic 
p-value Aerobic Pseudo-
Hypoxic 
p-value Aerobic Pseudo-
Hypoxic 
p-value 
HCT116 
p53+/+ 
3.26±0.38 6.83±2.12 0.095 32.37± 
11.14 
>100 0.0089 0.93±0.11 1.53±0.52 0.14 
MIA-PaCa2 3.62±0.74 8.78±0.89 0.0017 35.59± 
7.91 
>100 0.0050 6.44±1.05 12.09±4.8
4 
0.24 
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displayed in figures 24 and 25.  In the case of HCT 116 p53+/+ cells, whilst control 
cultures grew consistently over the 96 hour period, cultures treated with cisplatin 
remained at a constant cell number. In contrast, a significant decrease in viable cell 
number was observed in ARPE-19 cells treated with cisplatin. 
 
2 hours 8 hours 24 hours 
Control Cisplatin  Control Cisplatin  Control Cisplatin  
Viability (%) 96.5 96.3 96.5 97.1 95.4 82.4 
Cell count 1.22 x 106 1.26 x 106 1.22 x 106 1.23 x 106 3.02 x 106 1.52 x 106 
       
 48 hours 72 hours   
 Control Cisplatin  Control Cisplatin    
Viability (%) 93.9 85.1 95.6 91.6   
Cell count 5.35 x 10
6
 1.40 x 10
6
 5.57 x 10
6
 1.26 x 10
6
   
 
Figure 3.18: Viability assay data of both cisplatin (30µM) and untreated controls on human colorectal 
adenocarcinoma HCT116 p53+/+ cells at various time points over a 72-hour exposure. The viability is 
presented as a percentage and an accurate cell count calculated based on the entire population which is 
stained with Acridine Orange and non-viable cells stained by 4',6-diamidino-2-phenylindole (DAPI) (n=1). 
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2 hours 8 hours 24 hours 
Control Cisplatin  Control Cisplatin  Control Cisplatin  
Viability (%) 96.9 92.9 92.4 92.9 93.7 81.8 
Cell count  8.41 x 105 8.08 x 105 8.31 x 105 8.08 x 105 1.57 x 106 1.19 x 105 
       
 48 hours 72 hours   
 Control Cisplatin  Control Cisplatin    
Viability (%) 96.1 64.3 96.9 66.0   
Cell count  1.74 x 106 1.35 x 105 1.82 x 106 1.13 x 105   
 
Figure 3.19: Viability assay data of both cisplatin (30µM) and untreated controls on non-cancerous 
retinal epithelial ARPE-19 cells at various time points over a 72-hour exposure. The viability is presented 
as a percentage and an accurate cell count calculated based on the entire population which is stained 
with Acridine Orange and non-viable cells stained by 4',6-diamidino-2-phenylindole (DAPI) (n=1). 
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3.3.5.2 - Annexin V Assay  
The annexin V assay as illustrated in figure 3.20 detects both early and late phase 
apoptosis/ or necrosis with an increase in annexin V staining being representative of 
early apoptosis and an increase in propidium iodide staining being representative of 
late apoptosis. For both the cancerous HCT116+/+ and non-cancerous ARPE-19 cell lines 
there is a definitive increase in induction of apoptosis with increasing exposure time to 
cisplatin (tables 3.5 to 3.6).  The induction of apoptosis is more profound in the non-
cancerous ARPE-19 cells (observed after 2 hours exposure as opposed to 24 hours in 
HCT116+/+). 
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Figure 3.20: Representative example of data generated by the Annexin V assay. Annexin V assay after 2-
hour cisplatin (30µM) exposure on colorectal adenocarcinoma HCT116+/+ cells. The quadrant on scatter 
plot A is determined by firstly gating the entire population expressing Propidium Iodide (PI) in histogram 
C this sets the parameter for the upper quadrants (Q3ur) late apoptotic –necrotic and none viable (Q3ul) 
portions of the cell population. The maximum intensity peak (histogram B - annexin V intensity) is then 
gated, this determines the apoptotic portion of the cell population (right side of the quadrant late  Q3ur 
and early Q3lr). Any cells therefore gated in the lower left quadrant within the plot (Hoechst 33342 
positive, PI negative and little to no annexin V expression) are healthy (n=1). 
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Table 3.5: Summary of annexin V data on colorectal adenocarcinoma HCT116 p53+/+ cells after exposure 
to cisplatin (30µM) at varying time points. Data displayed as percentage values of total cell population 
(n=1). 
  
2 hours 8 hours 24 hours 
Control Cisplatin  Control Cisplatin  Control Cisplatin  
Healthy  89 85 83 75 80 62 
Apoptotic 2 7 4 5 6 16 
Late apoptotic/ 
necrotic 
8 8 11 17 13 19 
None viable  1 0 2 3 1 3 
       
 48 hours 72 hours   
 Control Cisplatin  Control Cisplatin    
Healthy  88 64 85 55 
  
Apoptotic 3 11 4 36 
  
Late apoptotic/ 
necrotic 
7 22 10 9 
  
None viable  4 3 1 0 
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Table 3.6: Summary of annexin V data on non-cancerous retinal epithelial cells after exposure to 
cisplatin (30µM) at varying time points. Data displayed as percentage values of total cell population 
(n=1). 
 
2 hours 8 hours 24 hours 
Control Cisplatin  Control Cisplatin  Control Cisplatin  
Healthy 75 46 75 43 82 49 
Apoptotic 14 43 10 32 14 27 
Late apoptotic/ necrotic 11 11 15 19 10 23 
None viable  0 0 0 6 1 1 
       
 48 hours 72 hours   
 Control Cisplatin  Control Cisplatin    
Healthy 95 15 84 10 
  
Apoptotic 1 7 5 24 
  
Late apoptotic/ necrotic 3 67 10 58 
  
None viable  1 11 1 8 
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Figure 3.21: Summary of annexin V data on A) untreated and B) cisplatin (30µM) treated colorectal 
adenocarcinoma HCT116+/+ cells over 72 hours (n=1). 
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Figure 3.22: Summary of annexin V data on A) untreated and B) cisplatin (30µM) treated non-cancerous 
retinal epithelial ARPE-19 cells over 72 hours  (n=1). 
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3.3.5.3 - Mitochondrial Potential Assay  
The analysis of the mitochondrial potential assay on both treated (cisplatin 30µM) 
and untreated samples over a 72-hour period is explained in figure 3.23 with the 
processed data summarised in tables 3.7 and 3.8. The processed data is also further 
illustrated in figures 3.24 and 3.25 with both cancerous and non-cancerous cells 
demonstrating increased induction of apoptosis with increased exposure time. 
Increased induction of apoptosis can be observed after just 2 hours exposure with the 
ARPE-19 cells and after 8 hours with the HCT116+/+ cells. 
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Figure 3.23: Mitochondrial potential assay after 2-hour cisplatin (30µM) exposure on colorectal 
adenocarcinoma HCT116+/+ cells. The quadrant on scatter plot A is determined by firstly gating the high 
intensity DAPI peak (histogram D) and excluding them from scatter plot A as these are necrotic cells. The 
high intensity red JC-1 peak (histogram C) and the entire population excluding the high intensity JC-1 
green peak (histogram B) are used to define the healthy population and thus plot the boundaries on 
scatter plot A, populations above the boundary are deemed healthy and anything below are apoptotic, 
the high intensity DAPI stained population is the necrotic portion. 
Untreated control 
A) B) C) D) 
Cisplatin treated 
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Table 3.7: Summary of mitochondrial potential data on colorectal adenocarcinoma HCT116 p53
+/+
 cells 
after exposure to cisplatin (30µM) at varying time points. Data displayed as percentage values of total 
cell population (n=1). 
 
Table 3.8: Summary of mitochondrial potential data on non-cancerous retinal epithelial cells after 
exposure to cisplatin (30µM) at varying time points. Data displayed as percentage values of total cell 
population (n=1). 
 
2 hours 8 hours 24 hours 
Control Cisplatin Control Cisplatin Control Cisplatin 
Healthy  80 74 78 63 80 51 
Apoptotic 2 4 6 19 5 38 
Necrotic  18 22 16 18 15 11 
       
 48 hours 72 hours   
 Control Cisplatin Control Cisplatin   
Healthy  74 37 68 33   
Apoptotic 13 56 23 62   
Necrotic  13 7 9 5   
2 hours 8 hours 24 hours 
Control Cisplatin Control Cisplatin Control Cisplatin 
Healthy 82 65 74 66 82 65 
Apoptotic 11 30 14 28 8 33 
Necrotic 7 5 12 6 10 2 
       
 48 hours 72 hours   
 Control Cisplatin Control Cisplatin   
Healthy 87 29 79 48   
Apoptotic 8 67 12 42   
Necrotic 5 4 9 9   
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Figure 3.24: Summary of mitochondrial potential assay on A) untreated and B) cisplatin (30µM) treated 
colorectal adenocarcinoma HCT116 p53
+/+
 cells over 72 hours (n=1). 
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Figure 3.25: Summary of mitochondrial potential assay on A) untreated and B) cisplatin (30µM) treated 
non-cancerous retinal epithelial ARPE-19 cells over 72 hours (n=1). 
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3.3.5.4 - Cell Cycle Assay 
Figure 3.26 demonstrates the process by which the cell cycle data is processed 
with tables 3.9 and 3.10 displaying the processed data of untreated and treated 
(cisplatin 30µM) samples for both the cancerous and non-cancerous cell lines over a 
72-hour period. In both the cancerous and non-cancerous cell lines, the untreated 
samples display increased cell populations within the G0/G1 phase with increased 
exposure time. The treated samples begin to display notable cell cycle disruption after 
24 hours exposure in HCT116 P53+/+ cells with a significant increase of cells in the 
G2/M phase. In ARPE-19 cells however, there was a significant increase in cells in the 
sub G0 phase which were deemed apoptotic. 
 
Figure 3.26: Cell cycle assay after 2-hour cisplatin (30µM) exposure on colorectal adenocarcinoma 
HCT116 p53+/+ cells. The intensity of signal dictates the cell cycle stage as explained in section 1.6.6. The 
M2 gate represents G0/G1 phase, M3 represents S phase and M4 represents G2/M phase. Sub G0 phase 
represented by the M1 gate are deemed the apoptotic population of cells and cells with an intensity 
higher than G2/M phase are either binucleated or aggregated cells. 
Untreated control Cisplatin treated 
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Table 3.9: Summary of cell cycle data on colorectal adenocarcinoma HCT116 p53+/+ cells after exposure 
to cisplatin (30µM) at varying time points. Data displayed as percentage values of total cell population 
(n=1). 
 
Table 3.10: Summary of mitochondrial potential data on non-cancerous retinal epithelial cells after 
exposure to cisplatin (30µM) at varying time points. Data displayed as percentage values of total cell 
population (n=1). 
 
2 hours 8 hours 24 hours 
Control Cisplatin  Control Cisplatin  Control Cisplatin  
Sub G0 /apoptotic 4 4 2 2 2 6 
G0/G1 51 50 55 57 63 26 
S phase 18 22 23 23 16 30 
G2/M 26 23 19 17 16 35 
       
 48 hours 72 hours   
 Control Cisplatin  Control Cisplatin    
Sub G0 /apoptotic 2 6 2 4   
G0/G1 69 27 87 25   
S phase 14 9 4 7   
G2/M 12 55 6 61   
2 hours 8 hours 24 hours 
Control Cisplatin  Control Cisplatin  Control Cisplatin  
Sub G0 /apoptotic 2 2 3 3 3 12 
G0/G1 57 57 58 58 82 48 
S phase 19 20 19 19 4 22 
G2/M 17 17 16 17 10 15 
       
 48 hours 72 hours   
 Control Cisplatin  Control Cisplatin    
Sub G0 /apoptotic 3 41 3 50   
G0/G1 81 28 80 20   
S phase 5 17 5 19   
G2/M 11 12 12 8   
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Figure 3.27: Summary of cell cycle assay on A) untreated and B) cisplatin (30µM) treated colorectal 
adenocarcinoma HCT116 p53+/+ cells over 72 hours (n=1). 
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Figure 3.28: Summary of cell cycle assay on A) untreated and B) cisplatin (30µM) treated non-cancerous 
retinal epithelial ARPE-19 cells over 72 hours  (n=1). 
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3.4 - Discussion 
3.4.1 - Clonogenic Assays and Validation of the MTT Assay 
The clonogenic assay is an established endpoint for measuring chemosensitivity 
and this method was initially explored for use in this project. As demonstrated in the 
results section, initial validation studies designed to assess the relationship between 
the number of colonies formed and the cell number seeded proved challenging due to 
the ‘clumping’ and merging of colonies in the centre of each well. This phenomenon 
occurred at various cell-seeding densities and was not significantly improved by 
making sure cells were well dispersed at the time of seeding. This effect was observed 
in two cell lines and at this stage, the clonogenic assay was abandoned and it was 
decided that the MTT assay endpoint would be used as the primary endpoint for 
assessing chemo sensitivity.  
The reasons why the clonogenic assay did not generate usable results are not 
clear, especially as this is an established methodology. Cancer cells are highly mobile, 
and it is likely that the clumping/merging of colonies is due to cell migration over the 
course of the assay. One way of solving this is to use semi-solid matrices (such as soft 
agarose) as these restrict the movement of cells. This however adds to the complexity 
of the assay procedures and is not applicable to testing potentially large numbers of 
compounds. The MTT assay however proved reliable and a good correlation between 
cell number and absorbance was obtained. This assay is suitable for moderate to large-
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scale screening and therefore it was adopted as the assay of choice in the first phase of 
the project. To avoid potential problems caused by test compounds interfering with 
the metabolic conversion of MTT to formazan, all plates were visualised prior to the 
addition of MTT to determine approximately where the IC50 resides. If results different 
significantly from the observed range of IC50 values, then further studies would be 
required using a different assay endpoint.  
3.4.2 - Chemosensitivity Investigations of Platinum Compounds 
For chemosensitivity studies to work, the drug or test compound must be soluble 
in biologically compatible solvents. Frequently DMSO is used to dissolve compounds 
but in the case of cisplatin, this is can cause significant problems. An investigation into 
the effects of DMSO as a solvent for platinum compounds by Hall et al. (2014) 
determined that platinum cytotoxicity was greatly diminished compared to cisplatin 
dissolved in aqueous media. The study also demonstrated using mass spectrometry 
that solvation in DMSO results in ligand displacement and dramatic alterations to the 
structure of the platinum compounds. All the platinum based drugs used in this 
chapter and throughout the thesis were therefore dissolved in PBS to avoid this 
potential source of error. 
Cisplatin displays the greatest cytotoxicity throughout the cancerous cell line panel 
with the exception of the HCT116 cell lines. Oxaliplatin as previously discussed is the 
most widely used chemotherapy agent for the treatment of advanced stages of 
colorectal cancers in the clinic, with these tumours showing much greater resistance to 
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cisplatin than oxaliplatin (Park, 2014). This shift in potency could be attributed to the 
differing mechanism of the dach-platinum complex formed by oxaliplatin compared to 
that of cis-diammine platinum complexes generated by cisplatin and carboplatin. 
Although not fully defined, in humans at least six MMR proteins are required for 
mismatch recognition, these proteins form a number of heterodimer combinations, it 
is these complexes which then recognise  mispaired bases or insertions/deletions in 
DNA and coordinate communication between mismatch recognition complexes and 
additional proteins required for MMR  (Peltomäki, 2001). The aforementioned study by 
Vaisman et al. (1998)  identified HCT116 cell lines lack the protein MLH1 which results 
in the loss of mismatch repair activity due to the subsequent defects in the hMutLα 
mismatch recognition complex. Where cisplatin and carboplatin rely on mismatch 
recognition to exert their action and are greatly affected by this bypass of platinum 
adducts, the bulkier dach adducts formed by oxaliplatin are not recognised by the 
mismatch recognition complexes thus not dependent on mismatch repair systems 
(Drummond, Anthoney, Brown, & Modrich, 1996). Tumours with defects in mismatch 
repair will therefore respond better to oxaliplatin opposed to cisplatin and carboplatin, 
which is reflected by the chemosensitivity data. These results are further validated by 
the chemosensitivity data collected by Vaisman et al. (1998) whom found oxaliplatin to 
be more potent in a number of isogenic clones of the HCT116 cell line compared to 
cisplatin.  
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In addition to increased sensitivity of HCT116 cell lines toward carboplatin it is 
pertinent to discuss the difference between sensitivity toward platinum compounds 
and p53 expression. Across the three platinum compounds chemo-sensitivity is 
reduced by a lack in p53 expression. p53 an established clinical barrier for conventional 
cancer therapy with the tumour suppressor gene is the most frequently mutated gene 
in human cancers and thought to be involved in the maintenance of the genome 
integrity (Hollstein et al., 1999). It has been extensively documented that cisplatin and 
its’ recognised platinum derivatives induce apoptosis in cells with functional p53 with 
recent studies in HCT116 cell lines establishing p53 deficient cells are much less 
sensitive to apoptosis by cisplatin (Bragado, Armesilla, Silva, & Porras, 2007). It is 
therefore expected the HCT116 p53-/- cell line will be more resistant to platinum 
therapy as displayed by the data in figure 13. 
A central cornerstone of the hypothesis being tested in this thesis is that 
determination of the selectivity index in vitro could help identify compounds for 
further evaluation in the context of phenotypic based drug discovery programs. In this 
context, the platinum based compounds were evaluated against non-cancer cell lines 
thereby enabling a selectivity index in vitro to be created. This was defined as the IC50 
in non-cancer cells divided by the IC50 in cancer cells and all values above 1 indicate 
selectivity towards cancerous cells over non-cancerous cells. From clinical experience it 
is well established the platinum agents carry debilitating side effects with cisplatin 
presenting as the least selective with resulting side effects that are irreversible and 
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often chronic. Figure 3.10 displays the relative selectivity’s of the cell line panel used in 
this investigation compared to ARPE-19 cell line. Overall, oxaliplatin displays the 
poorest selectivity with only one cell line displaying a selectivity index over one 
(HCT116 p53+/+). This is due to its potency towards the ARPE-19 (IC50 = 3.12 ± 0.28µM, 
figure 3.9) making it the most potent platinum agent in this particular non-cancerous 
cell line. Carboplatin on the other hand is not very active against the ARPE-19 cell line 
(IC50 = 77.73 ± 10.52µM, figure 3.9) which results in the highest selectivity overall; 
selectivity indices were all at two or above (figure 3.10). This reflects the rationale 
behind the synthesis of carboplatin and its mores stable leaving group, which lowers 
its toxicity profile. Although more selective, this poor activity on the non-cancerous cell 
line is also reflected in its lack of potency on the cancerous cell lines, which as 
discussed above is estimated to be 20-40 times lower than that of cisplatin. Cisplatin 
although fairly potent towards the non-cancerous cell line (IC50 = 6.41 ± 0.95µM, figure 
3.9) does display one of the highest selectivity indexes within this panel on the 
colorectal BE cell line. Overall only one cell line (HCT116 p53+/+) has a selectivity index 
lower than one therefore suggesting cisplatin is the most desirable compound of the 
three platinum compounds investigated displaying both selectivity and potency.  
Hypoxia is a significant barrier to effective chemotherapy with hypoxic cells being 
more resistant to a wide range of anti-cancer therapy (Teicher, 1994) , which will be 
discussed in more detail in chapter 6. It is well-documented that platinum 
chemotherapy agents are much more resistant to cells with hypoxic profiles and the 
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results presented in this study (figures 3.12-3.14) are consistent with these findings. In 
this study, all the compounds had significantly increased IC50 and in many cases IC50 
values could not be determined (above the highest drug concentration tested). To 
investigate the potential effects of HIF-1 on the cytotoxic properties of platinum based 
drugs, a pseudo-hypoxic state was induced by conditioning the cells with cobalt 
chloride, a known HIF-1 inducer (Pourpirali et al., 2015). From the results presented in 
figures 3.15-3.17, the addition of cobalt chloride reduces the potency of platinum 
based chemotherapy drugs suggesting a role for HIF1 in resistance of cells to platinum 
based drugs.  Although enhanced, the chemoresistance observed is much less than 
that seen in true hypoxic conditions suggesting that even in a mono-layered cell 
culture environment, hypoxia may contribute to resistance via additional mechanisms 
other than HIF-1 induction alone.  
3.4.3 - Cisplatin Induced Apoptosis and Cell Cycle Disruption 
Both annexin V assays and mitochondrial potential assays were completed to 
detect cisplatin induced apoptosis (figures 3.21-3.22 and 3.24-3.25). These assays were 
compared on both the cancerous HCT116 p53+/+ cell line and non-cancerous ARPE-19 
cell line for exposure times up to 72 hours. Both the apoptotic assays showed an 
increase in apoptotic induction with increasing exposure time with apoptosis being 
induced as early as 2-hour exposures in the ARPE-19 cell line.  
Cisplatin known to induce G2/M phase arrest was used as a positive control to help 
define an appropriate exposure time for novel compounds with unknown mechanism. 
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As with the apoptotic assays a time dependent dose response was observed with G2/M 
phase arrest observed after 24 hours.  
3.5 - Conclusion 
The aim of this chapter was to define parameters by which the relative merits of novel 
compounds can be measured as part of a strategy to identify “hit” compounds which 
possess improved properties in terms of (i) selectivity in vitro (ii) potency (iii) activity 
against p53 null and (iv) hypoxic cells. Quantitative data has been collected in the form 
of chemosensitivity data which acts as a direct comparative parameter for our novel 
compounds. Another aim of the chapter was to aid the mechanistic profiling of our 
novel compounds in terms of establishing exposure time parameters for the analysis of 
apoptotic induction and cell cycle disruption. These studies demonstrated that 
induction of apoptosis and cell cycle disruption can be detected after exposure times 
of 24 hours and above. The parameters established in this chapter therefore provide a 
'yardstick' for potency, selectivity for cancer cells in vitro, the effect of hypoxia (and 
pseudo-hypoxia) on cellular response, induction of apoptosis and effects on cell cycle 
kinetics against which the relative merits of test compounds can be measured.   
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Chapter 4 - Cobalt Complexes as Anti-Cancer 
Agents 
4.1 - Introduction 
The evolution of resistance and the toxic side effects associated with classical 
platinum-based anti-cancer drugs has stimulated the search for novel organometallic 
complexes with improved anti-cancer properties. Initial studies were predominantly 
focused on platinum based compounds but over recent years, studies have 
demonstrated that other metal containing compounds have anti-cancer effects that 
are not caused by inducing DNA damage (Gasser et al., 2010). Due to the biological 
importance of metals in many metabolic processes, metals such as cobalt have been 
extensively studied over the past three decades for their anti-microbial, anti-viral and 
anti-cancer properties (Munteanu & Suntharalingam, 2015).  
Cobalt is a trace element naturally occurring in all animals, predominantly in the 
form of cobalamin (Vitamin B12). Cobalt plays a crucial role in several biological 
processes such as red blood cell formation and DNA synthesis and it possesses an array 
of properties which can be manipulated to yield promising drug candidates (Sigel, 
Sigel, & Sigel, 2013). Given its prominent biological role, the body already possesses 
the ability to naturally overcome cobalt overload thereby offering the potential for 
reduced toxicity profiles unlike many non-essential metals (Elvers, Hawkins, & Schultz, 
1992). Cobalt is a trace element naturally occurring in all animals, predominantly in the 
form of cobalamin (Vitamin B12). Cobalt plays a crucial role in several biological 
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processes such as red blood cell formation and DNA synthesis and it possesses an array 
of properties which can be manipulated to yield promising drug candidates (Sigel et al., 
2013). Given its prominent biological role, the body already possesses the ability to 
naturally overcome cobalt overload thereby offering the potential for reduced toxicity 
profiles unlike many non-essential metals (Elvers et al., 1992). A variety of cobalt based 
complexes have been synthesised and evaluated as potential anti-cancer agents with 
their novel and varied mechanisms of action contributing to their appeal. These 
mechanisms have been extensively reviewed elsewhere (Munteanu & Suntharalingam, 
2015)  and they include the ability to target hypoxic cells. Hypoxia in tumours is caused 
by a poor and inefficient vascular supply to tumours and is widely regarded as a major 
contributing factor to drug resistance, resistance to radiotherapy and the evolution of 
an aggressive phenotype (Unruh et al., 2000). There has been considerable interest in 
the development of hypoxia activated prodrugs (Phillips, 2016) and this includes cobalt 
based compounds.  
Their ability to serve as potential hypoxia activated prodrugs stems from their 
redox properties with the reduction of Co(III) to Co(II) being favoured under hypoxic 
conditions  (Baran & Konopleva, 2017; de Souza et al., 2016). Various mechanisms 
have been described including the release of ligands such as EGFR inhibitors following 
reduction of Co(III) to Co(II) (Karnthaler‐Benbakka et al., 2014). Although its 
mechanism is widely unknown, bioactive cobalt complexes exert their mode of action 
in three proposed classes complexes reactive to ligand exchange and the 
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aforementioned complexes with bioactive ligands and bio-reductively activated cobalt 
complexes all of which are summarised in figure 4a. 
 
 
 
 
 
 
 
 
 
Figure 4a: Summary of the modes of action of bioactive cobalt complexes. Adapted from (Heffern, 
Yamamoto, Holbrook, Eckermann, & Meade, 2013) 
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 In a collaboration with Professor Patrick McGowan at the University of Leeds, a 
series of cobalt compounds conjugated to various ligands including the biologically 
active ligand picolinamide. Picolinamide is known to inhibit poly(ADP-ribose) 
polymerases (PARP) (Piskunova, Iurova, Zabezhinskiĭ, & Anisimov, 2007; Yamamoto & 
Okamoto, 1980) and it is widely regarded as attractive target in cancer therapy. It has 
an established role in the DNA repair process and its inhibition has been explored as a 
mechanism of (i) sensitising cancer cells to DNA damaging agents and (ii) directly 
inducing cell death via the process of synthetic lethality (Bryant et al., 2005; Farmer et 
al., 2005). Synthetic lethality is based on the hypothesis that a combination of 
deficiencies in the expression two or more genes results in increased cell death where 
either deficiency alone does not (Iglehart & Silver, 2009) . PARP and BRCA genes are 
involved in cellular DNA repair therefore the mutation of either one still allows for DNA 
repair by the alternative pathway. The exploitation of synthetic lethality is based on 
the treatment of BRCA mutated cancers with PARP inhibitors resulting in increased 
sensitivity and ultimately increased cell death, summarised in figure 4b (Lord, Tutt, & 
Ashworth, 2015). 
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Figure 4b: Mechanism of cell death by exploitation of synthetic lethality with the use of PARP-1 
inhibitors in BRCA mutated malignancies. Taken from Inglehart and Silver (2009).  
A series of compounds were provided in either the active cobalt (II) form or as a 
prodrug in the form of cobalt (III). The aim of the research presented in this chapter 
was to evaluate the potency and selectivity of these compounds under aerobic 
conditions together with the evaluation of Co(III) derivatives conducted under both  
aerobic and hypoxic conditions.  
4.2 - Methods 
A series of compounds were obtained from Professor McGowan’s research group 
and these were organised into Classes (1 to 3) with class 1 compounds split into 2 sets 
based on structural criteria. The chemical structures and preparation of stock solutions 
are presented below. 
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4.2.1 - Chemical Structures and Preparation of Drug Stock Solution 
 
Red form Brown form 
Class 1 
Set 1 
 
 
Table 4.1: Class 1, set 1 cobalt (III) tris-picolinamide complexes structure and stock solution preparation. 
  
Compound MW 
Weight 
(mg) 
Diluent 
Diluent 
volume 
(µ𝐥) 
Molar 
concentration 
(𝐦𝐌) 
R 
substituent 
Cobalt (III) tris-picolinamide red form 
LG097-2 650.57 0.65 DMSO 9.99 100 H 
LG156 704.54 1.98 DMSO 28.1 100 2-F 
LG155 704.54 3.70 DMSO 52.6 100 3-F 
LG154 704.54 3.40 DMSO 48.3 100 4-F 
LG157 758.51 1.96 DMSO 25.8 100 2,4-diF 
LG158 758.51 3.52 DMSO 46.4 100 2,5-diF 
LG164 753.91 1.87 DMSO 24.8 100 3-Cl 
LG163 753.91 3.83 DMSO 50.8 100 4-Cl 
LG169 887.26 2.18 DMSO 24.6 100 3-Br 
LG167 887.26 3.11 DMSO 42.9 100 4-Br 
LG103-2 854.57 1.33 DMSO 15.6 100 3-CF3 
LG104-2 854.57 1.66 DMSO 19.4 100 4-CF3 
LG101-2 1058.56 3.63 DMSO 34.3 100 3,5-diCF3 
LG153 692.65 1.48 DMSO 21.4 100 3-Me 
LG145 692.65 1.78 DMSO 25.7 100 4-Me 
LG121 734.73 12.12 DMSO 165 100 3,5-diMe 
Cobalt (III) tris-picolinamide brown form 
LG097-1 650.57 1.43 DMSO 22 100 H 
LG152-1 692.65 1.31 DMSO 18.9 100 3-Me 
LG144-1 692.65 1.32 DMSO 19.1 100 4-Me 
LG100A 734.73 2.21 DMSO 30.1 100 3,5-diMe 
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Red form Brown form 
Class 1 
Set 2 
 
 
Table 4.2: Class 1, set 2 cobalt (III) tris-picolinamide complexes structure and stock solution preparation. 
  
Compound MW 
Weight 
(mg) 
Diluent 
Diluent 
volume 
(µ𝐥) 
Molar 
concentration 
(𝐦𝐌) 
R 
substituent 
Cobalt (III) tris-picolinamide red form 
LG290-2 830.73 3.07 DMSO 36.96 100 3,5-diOMe 
LG293-2 740.65 2.45 DMSO 33.08 100 4-OMe 
Cobalt (III) tris-picolinamide brown form 
LG290-1 830.73 3.29 DMSO 39.60 100 3,5-diOMe 
LG293-1 740.65 3.00 DMSO 40.50 100 4-OMe 
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SCN Cl H2O (I
- counterion) 
Class 2   
 
Table 4.3: Class 2 cobalt (II) bis-picolinamide complexes structure and stock solution preparation 
  
Compound MW 
Weight 
(mg) 
Diluent 
Diluent 
volume 
(µ𝐥) 
Molar 
concentration 
(𝐦𝐌) 
R 
substituent 
Cobalt (II) bis-picolinamide-SCN 
LG116 571.54 4.87 DMSO 85.21 100 H 
LG175 599.59 2.16 DMSO 36.02 100 2-Me 
LG174 599.59 2.73 DMSO 45.53 100 3-Me 
LG173 599.59 2.04 DMSO 34.02 100 4-Me 
LG176 627.65 5.07 DMSO 80.78 100 2,3-diMe 
LG137 627.65 5.28 DMSO 84.12 100 3,5-diMe 
LG297 631.59 2.13 DMSO 33.72 100 4-OMe 
LG298 691.64 3.34 DMSO 48.29 100 3,5-diOMe 
Cobalt (II) bis-picolinamide-Cl 
LG107 526.28 2.38 DMSO 45.22 100 H 
Cobalt (II) bis-picolinamide-H2O (I
- counterion) 
LG113 745.21 7.52 DMSO 100.91 100 H 
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Simple acac Ferrocene acac 
Class 3  
 
Table 4.4: Class 3 cobalt (II) bis-picolinamide complexes with acetylacetone (acac) ligands, structure and 
stock solution preparation. 
  
Compound MW 
Weight 
(mg) 
Diluent 
Diluent 
volume 
(µ𝐥) 
Molar 
concentration 
(𝐦𝐌) 
R 
substituent 
Cobalt (II) bis-picolinamide2(acac) with simple acac 
LG300 824.46 2.22 DMSO 26.92 100 CH3 
LG275 886.53 2.64 DMSO 29.78 100 Ph 
LG268 948.60 2.02 DMSO 21.29 100 Ph & Ph 
LG276 904.52 2.46 DMSO 27.19 100 3-F Ph 
LG277 904.52 3.64 DMSO 40.24 100 4-F Ph 
LG278 900.55 2.11 DMSO 23.43 100 3-Me Ph 
LG279 900.55 4.15 DMSO 46.08 100 4-Me Ph 
LG280 916.55 3.85 DMSO 42.00 100 4-OMe Ph 
LG296 954.53 5.15 DMSO 53.95 100 4-CF3 Ph 
Cobalt (II) bis-picolinamide2(acac) with ferrocene acac 
LG263 994.45 1.90 DMSO 19.10 100 CH3 
LG264 1048.42 2.44 DMSO 23.27 100 CF3 
LG274 1030.43 4.22 DMSO 40.95 100 CF2 
LG266 1056.52 3.30 DMSO 31.23 100 Ph 
LG271 1074.51 2.33 DMSO 21.58 100 3-F Ph 
LG269 1074.51 4.50 DMSO 41.88 100 4-F Ph 
LG272 1092.50 1.54 DMSO 14.09 100 3,5-diF Ph 
LG289 1070.54 7.71 DMSO 72.02 100 3-Me Ph 
LG265 1070.54 2.83 DMSO 26.43 100 4-Me Ph 
LG273 1084.57 7.54 DMSO 69.52 100 3,5-diMe 
Ph 
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Compounds LG300/265/273 (highlighted) were not fully soluble therefore were 
withdrawn. 
All drug stock solutions were stored at -20°C in individual 2µl aliquots to prevent 
any potential degradation of the compounds caused by repeat freeze thawing cycles. 
All stock solutions were discarded after 3 months of storage. 
4.2.2 - Chemo-Sensitivity Testing, Analysis of Cell Viability and Cell Cycle 
Inhibition 
The response of cell lines following continuous 96-hour exposures to test 
compounds under aerobic and hypoxic conditions was determined using the MTT 
assay, details of which have been described elsewhere in this thesis (see 1.5). Analysis 
of cell viability and cell cycle parameters was determined using the NC3000 cytometer, 
details of which have been described elsewhere (see 1.6). For these experiments, drug 
exposure concentrations ranged from 5µM to 20µM; duration of drug exposures was 
set at 96 hours to replicate the conditions used in the MTT assays.  
4.3 - Results 
4.3.1 - Chemosensitivity Studies in Aerobic Conditions  
The response of cell lines to various test LG compounds are presented in table 3.1. 
A significant number of compounds were inactive against all cell lines with IC50 values 
greater than the highest dose tested which was typically 100µM. Some compounds 
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showed only modest activity against one or two cell lines (e.g. LG169) but of the 
compounds tested, only LG101-2 and LG100A showed significant activity in vitro.  
4.3.1.1 - Response of MIA-PaCa2, BE and ARPE-19 Cells to Test Compounds 
Under Aerobic Conditions 
IC50 value ± standard deviation 
Compound MIA-PaCa2 BE ARPE-19 
LG097-2 >100 >100 >100 
LG156 >100 >100 >100 
LG155 >100 >100 >100 
LG154 >100 >100 >100 
LG157 >100 >100 >100 
LG158 >97.46 >100 >100 
LG164 >86.38 >100 >65.5 
LG163 >100 >93.21 >100 
LG169 68.46±13.51 >100 >100 
LG167 37.40±18.89 >74.87 >65.42 
LG103-2 >62.33 >100 >100 
LG104-2 >100 >100 >100 
LG101-2 37.43±8.69 3.77±1.98 7.57±3.92 
LG153 >100 >100 >100 
LG145 >100 >100 >100 
LG121 >98.06 >100 >100 
LG097-1 >66.99 >100 >82.42 
LG152-1 45.54±2.80 52.61±6.99 37.89±18.12 
LG144-1 55.82±1.63 37.45±13.04 30.20±5.23 
LG100A 7.38±2.17 19.31±1.38 9.63±6.88 
LG290-2 >100 - >100 
LG293-2 >100 - >100 
LG290-1 >100 - >100 
LG293-1 >100 - >100 
LG116 >100 - >100 
Table 4.5: Response of pancreatic carcinoma cell line MIA-PaCa2, colorectal carcinoma cell line BE and 
the non-cancerous retinal epithelial cell line ARPE-19 following continuous 96-hour exposure to LG 
cobalt based compounds. The results presented are the mean IC50 values ± standard deviations for three 
independent experiments n=3 (each individual experiment replicated twice). The most promising results 
in terms of potency are highlighted in red.  The “>” symbol represents the highest dose tested in vitro.  
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IC50 value ± standard deviation 
Compound MIA-PaCa2 BE ARPE-19 
    
LG175 >100 - >100 
LG174 >100 - >100 
LG173 >100 - 93.44 
LG176 >100 - 82.5 
LG137 >100 - >100 
LG297 >100 - >100 
LG298 >100 - >100 
LG107 >100 - >100 
LG113 >100 - >100 
LG275 >100 - >100 
LG268 >100 - >100 
LG276 >100 - >100 
LG277 >100 - >100 
LG278 >100 - >100 
LG279 >100 - >100 
LG280 >100 - >100 
LG296 92.04±13.79 - >100 
LG263 >100 - >100 
LG264 >100 - >100 
LG274 32.85±6.82 - >100 
LG266 >100 - >100 
LG271 >100 - >100 
LG269 >100 - >100 
LG272 >100 - >100 
LG289 >100 - >100 
Cisplatin 3.62 ±  0.74 0.66 ±  0.33 6.41 ±  0.95 
Carboplatin 35.59 ±  7.91 32.72 ±  4.64 77.73 ±  10.52 
Oxaliplatin 6.44 ±  1.05 8.56 ±  0.48 3.12 ±  0.28 
 
Table 4.5 (continued): Response of pancreatic carcinoma cell line MIA-PaCa2, colorectal carcinoma cell 
line BE and the non-cancerous retinal epithelial cell line ARPE-19 following continuous 96-hour exposure 
to LG cobalt based compounds. The results presented are the mean IC50 values ± standard deviations for 
three independent experiments n=3 (each individual experiment replicated twice ). The most promising 
results in terms of potency are highlighted in red.  The “>” symbol represents the highest dose tested in 
vitro. Platinum standards included as a reference of activity. 
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4.3.2 - Comparison of LG101-2 and LG100A with Platinum Based Anti-Cancer 
Drugs 
The performance of LG101-2 and LG100A in terms of (i) potency and (ii) selectivity 
compared to platinum based anti-cancer drugs is presented in figures 4.6 and 4.7 
respectively. With regards to potency against the two cancer cell lines tested, both 
LG101-2 and LG100A were less active than cisplatin and oxaliplatin. Compared to 
carboplatin, LG100A was significantly more potent against MIA-PaCa2 cells but only 
marginally more active against BE cells. LG101-2 was approximately 8-fold more active 
than carboplatin against BE cells (IC50 of 3.77uM versus 32.72uM) but the response of 
MIA-PaCa2 cells was comparable to carboplatin. Both LG compounds were more active 
against the ARPE-19 non-cancer cell line than carboplatin. In contrast, LG100A was less 
active against ARPE-19 cells than oxaliplatin and cisplatin.    
With regards to selectivity for cancer as opposed to non-cancer cells (figure 4.7), 
both LG compounds had lower selectivity indices compared to cisplatin and 
carboplatin. Compared to oxaliplatin there was some evidence of improved selectivity 
in MIA-PaCa2 (LG100A only) and BE (LG101-2 only) cells but overall, there was no 
significant improvement in selectivity. None of the compounds display statistically 
significant reductions in activity toward none cancerous cell opposed to cancerous cell 
lines. 
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Compound MIA-PaCa2  BE ARPE-19 
LG100A 7.38 ±  2.17 19.31 ±  1.38 9.63 ±  6.88 
LG101-2 37.43 ±  8.69 3.77 ±  1.98 7.57 ±  3.92 
Cisplatin  3.62 ±  0.74 0.66 ±  0.33 6.41 ±  0.95 
Carboplatin 35.59 ±  7.91 32.72 ±  4.64 77.73 ±  10.52 
Oxaliplatin 6.44 ±  1.05 8.56 ±  0.48 3.12 ±  0.28 
 
Figure 4.1: Comparison of the potency of LG101-2 and LG100A to cisplatin, oxaliplatin and carboplatin 
on MIA-PaCa2, BE and ARPE-19 cells. The values presented are the mean IC50 values ± standard deviation 
of three independent experiments n=3 (each individual experiment replicated twice ). 
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Compound MIA-PaCa2  p-value BE p-value 
LG100A 1.3 0.71 0.5 0.18 
LG101-2 0.2 0.054 2 0.35 
Cisplatin  1.77 0.10 9.71 0.0043 
Carboplatin 2.18 0.031 2.38 0.029 
Oxaliplatin 0.48 0.020 0.36 0.0064 
 
Figure 4.2: Comparison of the selectivity index of LG101-2 and LG100A to cisplatin, oxaliplatin and 
carboplatin.  The selectivity index is defined as the mean IC50 for non-cancerous cells divided by the IC50 
of cancerous cells. Values greater than 1 indicate that compounds have selectivity for cancer cells as 
opposed to non-cancer cells. As the mean IC50 values are used to calculate selectivity indices, no error 
bars are included on the graphs. Statistical analysis was performed using a student’s t-test where values 
<0.05 indicates a statistically significant difference between IC50 values in cancerous and none cancerous 
cell lines. 
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4.3.3 - Chemosensitivity Investigations in Hypoxic Conditions 
The response of cell lines to various test LG compounds in hypoxic conditions are 
presented in table 4.6. These compounds (Class 1, set 1; table 4.1) were selected as 
the cobalt in these compounds exists as Co(III) which has the potential to be reduced 
in a hypoxic environment to Co(II). All of the compounds tested showed either reduced 
activity under hypoxic conditions or the IC50 remained >100uM as under aerobic 
conditions (Table 4.6). Only two compounds (LG100A and LG152-1) have an IC50 value 
less than the highest dose tested (100µM). 
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4.3.3.1 - Response of MIA-PaCa2 Cells to Co(III) Compounds Under Aerobic 
and Hypoxic Conditions 
Compound MIA-PaCa2 aerobic MIA-PaCa2 hypoxia 
LG097-2 >100 >100 
LG156 >100 >100 
LG155 >100 >100 
LG154 >100 >100 
LG157 >100 >100 
LG158 >97.46 >100 
LG164 >86.38 >100 
LG163 >100 >100 
LG169 68.46±13.51 >100 
LG167 37.40±18.89 >100 
LG103-2 >62.33 >100 
LG104-2 >100 >100 
LG101-2 37.43±8.69 >100 
LG153 >100 >100 
LG145 >100 >100 
LG121 >98.06 >100 
LG097-1 >66.99 >100 
LG152-1 45.54±2.80 74.25±3.68 
LG144-1 55.82±1.63 >100 
LG100 7.38±2.17 29.68±2.18 
 
Table 4.6: Response of MIA-PaCa2 and Panc10.05 cell lines following continuous 96-hour exposure to set 
1 class 1 LG cobalt compounds in hypoxic conditions. The results presented are the mean IC50 values ± 
standard deviations for three independent experiments n=3 (each individual experiment replicated 
twice) .The most promising compounds in terms of potency LG100A and LG152-1 are highlighted in red.  
The “>” symbol represents the highest dose tested in vitro. For comparative purposes the response of 
the same cell line in aerobic conditions is presented within the data set. 
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4.3.4 - Comparison of LG100A and LG152-1 With Platinum Based Anti-Cancer 
Drugs 
The performance of LG100A and LG152-1 in terms of potency under hypoxic 
conditions compared to platinum based anti-cancer drugs is presented in table 4.7. 
With regards to potency against cancer cell lines in hypoxia, both LG100A and LG152-1 
are more active than all three platinum compounds. The hypoxic cytotoxicity ratios 
were all below 1 indicating resistance under hypoxia compared to aerobic conditions. 
In comparison to the platinates however, the level of resistance under hypoxia is 
significantly less with LG152-1 being only marginally more resistant under hypoxic 
conditions (HCR = 0.61).  
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Compound 
MIA-PaCa2 
aerobic 
MIA-PaCa2 
hypoxia 
p-value Hypoxic 
Cytotoxicity Ratio 
LG152-1 45.54±2.80 74.25±3.68 0.00027 0.61 
LG100A 7.38±2.17 29.68±2.18 0.0011 0.25 
Cisplatin  3.62±0.74 >100 0.00002 >0.036 
Carboplatin 35.59±7.91 >100 0.0050 >0.35 
Oxaliplatin 6.44±1.05 87.72±7.29 0.0021 0.073 
 
Table 4.7: Response of MIA-PaCa2 cells following continuous 96-hour exposure to LG cobalt compounds 
and platinate standards in hypoxic and aerobic conditions. The results presented are the mean IC50 
values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice ). The hypoxic cytotoxicity ratio (HCR) is defined as the ratio of IC50 values under aerobic 
divided by the IC50 under hypoxic conditions. Values > 1 demonstrates that the compound has selective 
activity against hypoxic cells. The “>” symbol represents the highest dose tested in vitro. Statistical 
analysis was performed using a student’s t-test where values <0.05 indicates a statistically significant 
difference between IC50 values in hypoxic and aerobic conditions. 
4.3.5 - Analysis of Cell Viability and Cell Cycle Parameters of LG101-2 and 
LG100A 
As the most promising of the cobalt complexes in terms of potency, selectivity and 
activity under hypoxia, LG101-2 and LG100A were selected for further investigation. 
MIA-PaCa2 cells were exposed to these two “hit” compounds for 96h under conditions 
paralleling those used for the MTT studies and analysed for any effects on cell viability 
and/or the cell cycle. Although LG100A was~6-fold more active than LG101-2 against 
MIA-PaCa2 cells in the MTT chemosensitivity assays, both compounds caused a similar 
dose-dependent reduction in total cell number in these 96 hours experiments (Figure 
4.8, Figure 4.11). The percentage cell viability for both LG101-2 and LG100A on the 
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other hand remained stable over the range of concentrations tested (figures 4.8 and 
4.11 respectively) suggesting although cell number is reduced, the remaining cells are 
viable. Figures 4.10 and 4.13 demonstrate the effects of these “hit” compounds on the 
percentage of the cell population at specific stages of the cell cycle. For both 
compounds the proportion of sub-G1 cells remained stable with increasing drug 
concentration whilst the proportion of cells within the G2/M and S phase increased 
slightly with no profound difference between the two compounds.  
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4.3.5.1 - LG101-2 
 
 
 
Figure 4.3: Effect of increasing doses of LG101-2 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 5µM, 
10µM and 20µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1).  
 
Figure 4.4: Microscope images of pancreatic adenocarcinoma cell line MIA-PaCa2 exposed to increasing 
doses of LG101-2 over a 96- hour exposure time.  
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Figure 4.5: Cell cycle response of pancreatic adenocarcinoma cell line MIA-PaCa2 to increasing doses of 
LG101-2 after 96-hour exposure time. “0” denotes the control sample and the percentage of the cell 
population within each cycle stage is determined by the cell’s DNA content with nuclear stain DAPI 
(n=1). 
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4.3.5.2 - LG100A 
 
 
 
Figure 4.6: Effect of increasing doses of LG100A on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 5µM, 
10µM and 20µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
Figure 4.7: Microscope images of pancreatic adenocarcinoma cell line MIA-PaCa2 exposed to increasing 
doses of LG100A over a 96- hour exposure time. 
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Figure 4.8: Cell cycle response of pancreatic adenocarcinoma cell line MIA-PaCa2 to increasing doses of 
LG100A after 96-hour exposure time. “0” denotes the control sample and the percentage of the cell 
population within each cycle stage is determined by the cell’s DNA content with nuclear stain DAPI 
(n=1). 
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4.4 - Discussion  
From the IC50 values, two compounds from class 1 showed promising potency 
towards the three cancer cell lines tested. Although displaying poorer activity than the 
platinate gold standard cisplatin, these novel cobalt based compounds do display 
comparable and in some cases superior potency to that of carboplatin with LG101-2 
also demonstrating superior potency towards the colonic adenocarcinoma cell line BE 
than oxaliplatin (IC50 = 3.7 ± 1.98µM and 8.56 ± 0.48µM respectively, table 4.5). 
Although potency data is initially promising the selectivity of these agents is much less 
impressive with none of the compounds displaying selectivity that is superior to the 
established platinate standards (figure 4.7).  
As a number of these novel cobalt compounds exist in the form of Cobalt (III), their 
cytotoxic activity was also investigated in hypoxic conditions.  As described in chapter 
2, hypoxia significantly reduces the chemosensitivity of cells to platinum agents and 
hypoxic cytotoxicity ratios (HCR) are significantly below 1 in all cases. The results of 
HCR studies are presented in table 4.7 and these demonstrate that the novel cobalt 
(III) compounds are not selectively toxic to hypoxic MIA-PaCa2 cells (table 4.6). 
Although these compounds display reduced activity in hypoxic conditions, their use in 
such environments should not be disregarded as LG152-1 is not as adversely affected 
by hypoxia (HCR = 0.61) as cisplatin (HCR = 0.036), oxaliplatin (HCR < 0.073) and 
carboplatin (HCR < 0.35) (table 4.6). It could therefore be argued that this improved 
activity in hypoxic conditions compared to the platinum standards (albeit poor in 
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comparison to other hypoxia activated prodrugs) is a platform on which the 
compounds can be developed with a view to enhancing activity under hypoxia.  
Additional issues that need to be considered if these compounds are to be 
developed further is their solubility and stability. The compounds tested are not 
soluble in water/aqueous buffers and in some cases, a noticeable precipitate formed 
following the addition of compounds to cell culture media. This could account for the 
lack of activity observed in many of the compounds investigated in this study. 
Furthermore, initial studies demonstrated that reproducible data was difficult to 
obtain with some compounds suggesting that stability issues during storage maybe 
problematical.   
Although the compounds possess many unfavourable properties two, of the 
compounds do possess a degree of cytotoxic activity that is comparable to platinates. 
With the mechanism of action of these cobalt complexes being unknown, preliminary 
mechanistic investigations were completed in the form of their effects on cell cycle 
kinetics and viability assays after a 96-hour exposure. The results of this study 
demonstrate that for both LG101-2 and LG100-A, there is a slight increase (just over 
2%) in the population of cells within the S phase. The biggest effect on the cell cycle 
after exposure to the cobalt complexes is the percentage of cells in the G2/M phase, 
which has more than doubled from the control to the highest concentration.  This 
could therefore suggest the cobalt compounds initiate a level of M phase arrest; this is 
also reflected by the reduction of cells in the G0/G1 phase. The M phase or mitosis 
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phase is when molecular motors draw chromosomes apart and the cell divides. Many 
drugs such as Taxol and (as seen in chapter 2) cisplatin target this cell cycle phase 
freezing the process thus reducing the number of cells entering the G1 phase resulting 
in reduced cell synthesis (Hartwell & Kastan, 1994). As the margins are small it is hard 
to fully determine if this is the case and further investigations at higher concentrations 
could be more informative. On reflection, the choice of a 96-hour exposure to 
compounds before assessing cell cycle parameters could mask any larger shifts in cell 
cycle kinetics that occurred before cell death. In addition to the cell cycle assay a 
viability assay was performed not only to help maintain a consistent cell number for 
the cell cycle assay but also show the effects of the drug toward cell viability and cell 
number. For both compounds the viability of the cells remains consistent between 70-
80% yet it can be observed the cell number dramatically reduces at 20µM (figures 4.8 
and 4.11) further suggesting that the compounds initiate some form of cell cycle arrest 
reducing cell replication thus reducing cell number without effecting viability.  This 
could also be a manifestation of the long exposure times used in these experiments as 
described above. Furthermore, the preliminary mechanistic studies whilst indicating 
possible effects on the cell cycle does not reveal the basis of the differential activity of 
the two hit compounds in the chemosensitivity screens indicating the need for further 
investigations of this. 
In conclusion, the majority of compounds evaluated here were largely inactive in 
vitro with the exception of LG101-2 and LG100-A. Both compounds showed a level of 
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potency that was comparable to the platinates (particularly carboplatin) but failed to 
show any significant improvement in the in vitro selectivity index compared to the 
platinates. In the context of drug evaluation procedures, the screen has identified 
compounds that are as potent as the platinates in vitro but fail to show any significant 
improvement in selectivity for cancer as opposed to non-cancer cells. On this basis, 
they are not promising compounds for future development. In addition to studies 
conducted under aerobic conditions, several Co(III) based compounds were also 
examined under hypoxic conditions. These studies demonstrated that whilst they do 
not selectively kill hypoxic cells in vitro, the level of resistance under hypoxia is less 
than that observed with the platinates. Whilst this could be viewed as an interesting 
result, the reality is that it does not improve the in vitro selectivity index and therefore 
these compounds are not good candidates for future development. 
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Chapter 5 - Ruthenium and Iridium β-Ketoiminate 
Compounds as Anti-Cancer Agents 
5.1 - Introduction 
5.1.1 - Ruthenium Compounds 
Ruthenium complexes have become one of the most popular metals in drug 
discovery due in part to their similarities in ligand exchange kinetics to cisplatin 
complexes. Furthermore, their unique characteristics such as easily accessible 
oxidation states and its ability to mimic iron in binding to certain biological molecules 
make them good 'platforms' for drug development (Allardyce & Dyson, 2001). Another 
benefit of ruthenium complexes is that they have a tendency to adopt octahedral 
coordination geometries as opposed to the square planar geometries of platinum 
(figure 5.1). This is believed to favour the formation of inter-strand cross-links between 
DNA strands and this differs from the intra-strand cross link formation favoured by 
cisplatin. As a consequence, cell lines that have developed resistance to cisplatin via 
accelerated repair of the intra-strand crosslinks are still susceptible to ruthenium 
(Frühauf & Zeller, 1991). 
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Figure 5.1: A) General chemical structure of ruthenium (II) arene “piano stool” complexes B) cisplatin’s 
square planar geometry. Adapted from Sadler and Peacock (2008). 
 
This co-ordination environment also plays an important role in the stabilisation of 
the complexes in varying oxidation states, thus dictating the redox properties of the 
central metal ion (Antonarakis & Emadi, 2010; Baitalik & Adhikary, 1997; Chakravarty 
& Bhattacharya, 1996). An additional advantage to this differing ligand geometry is the 
ability to fine tune ligand affinities, substitution rates and redox potential (Amin & 
Buratovich, 2009). This increases the specificity of the agents towards cancerous cells 
as the majority of the drug will be deposited in the cancer cells, which, in turn 
increases the therapeutic activity of the drug.  These properties are summarised in 
figure 5.2.  
 
B)  A) 
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Figure 5.2: Oxidation states of ruthenium, adapted from (Allardyce & Dyson, 2001). A unique property 
of ruthenium is its easily accessible oxidation states existing as its inert state Ru(III), and biologically 
active state Ru(II). Ru(III) can therefore be administered as a pro-drug which is converted to its  active 
state in reducing environment improving selectivity and bioavailability of the drug (Antonarakis & 
Emadi, 2010).  
 
Ruthenium compounds have an array of clinical applications including use as 
immunosuppressant’s and antimicrobials, and now Novel Anti-Tumour Metastasis 
Inhibitor A (NAMI-A) is the first representation of a ruthenium complex (III) complex to 
undergo clinical trials. NAMI-A has entered phase II clinical trials as an anti-metastatic 
agent and is demonstrating potential importance to the treatment of cancer (Büchel et 
al., 2017). The proposed mechanism(s) of action of NAMI-A include its direct effect on 
tumour cell DNA via coordination binding to nucleic acids, transient cell cycle arrest of 
tumour cells in the pre-mitotic G2/M phase and the inhibition of matrix 
metalloproteinases which play a critical role in angiogenesis and the invasion and 
metastatic process (Antonarakis & Emadi, 2010; A Bergamo et al., 1999; Pluim, van 
Waardenburg, Beijnen, & Schellens, 2004; Vacca et al., 2002; Zorzet et al., 2000). These 
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anti-angiogenic and anti-invasive properties allow NAMI-A to specifically target tumour 
metastases, preventing both the formation of metastases but also their growth once 
established (Leijen et al., 2015). Not only has NAMI-A showed selectivity to solid 
tumours as a mono-therapy chemotherapeutic agent but has recently completed a 
phase I/II study in combination with gemcitabine as a second line treatment for non-
small cell lung cancer ( Alberta Bergamo, Riedel, Dyson, & Sava, 2015).  
5.1.2 - Iridium Compounds 
In contrast to ruthenium complexes, Iridium complexes have received much less 
attention as potential anti-cancer agents. This previous lack of interest is due to them 
being considered unlikely candidates owing to the kinetic inertness of iridium as a 
transitional metal centre (Geldmacher, Oleszak, & Sheldrick, 2012). Although known 
for being inert, iridium with the addition of pentamethylcyclopentadienyl (CP) forming 
the half sandwich fragment CP*IrIII has exhibited cytotoxic activity towards the A2780 
human ovarian cell line. The investigation by Liu et al (2011) summarised that the 
chemical reactivity and cytotoxic activity of CP*Ir III complexes can be controlled by 
variation of the chelating ligands. Therefore, the optimisation of the ligands 
surrounding these iridium complexes is of importance in producing chemotherapeutic 
iridium complexes. 
Investigations by Lord et al (2015) concluded that iridium complexes with a β-
ketoiminato ligand generated promising IC50 values. In addition, it was observed that 
almost all the β-ketoiminato complexes were slightly more active than cisplatin with 
   
 
Page | 154  
 
 
 
 
activity against cisplatin resistant A2780cis cells. The same β-ketoiminato complexes 
were also more active under hypoxic conditions suggesting they are hypoxia sensitive 
and as described in the previous chapter, this characteristic property is of particular 
interest in the field of anti-cancer drug development. This data is therefore very 
encouraging as it could suggest iridium complexes target both aerobic and hypoxic 
cells in solid tumours with a higher affinity for cancer specific hypoxic environments.  
5.1.3 - Aims and Objectives 
In a collaboration with Dr Rianne Lord and Professor Patrick McGowan at the 
University of Leeds, a series of ruthenium and iridium complexes bearing β-
ketoiminate ligands were synthesised and previous studies conducted by Dr Lord 
evaluated their activity against a panel of cell lines in vitro. These were all cancer cell 
lines and the results showed that a number of these compounds have potent cytotoxic  
profiles (comparable to platinates) and are not adversely affected by hypoxic 
conditions (R. M. Lord et al., 2015). In the context of this thesis, the purpose of this 
chapter was to determine the activity of these complexes against the non-cancerous 
ARPE-19 cell line with the aim of establishing the in vitro selectivity index and exploring 
its value as a decision-making tool compared to just potency alone.  
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5.2 - Methods 
5.2.1 - Preparation of Drug Stock Solution  
A series of iridium and ruthenium based compounds were obtained from Professor 
McGowan’s research group, their chemical structures and the preparation of stock 
solutions are presented below. 
Compound 
(as cited in 
paper) 
Metal  
Molecular 
Weight 
Weight 
(mg) 
Volume 
DMSO 
(µl) 
Stock solution 
(mM) 
Structure 
RML075 (1) 
Ruthenium 
 
525.03 5.4 102.8 100 
 
RML100 (7) 
Ruthenium 
585.93 8.7 148.48 100 
 
RML102 (8) 
Ruthenium 
585.93 9.5 162.14 100 
 
RML368 (9) 
Ruthenium 
632.99 10.2 161.14 100 
 
 
Table 5.1: Ruthenium and Iridium β-ketoiminate compounds structure and stock solution preparation.  
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Table 5.1 (continued): Ruthenium and Iridium β-ketoiminate compounds structure and stock solution 
preparation.  
 
Compound 
(as cited in 
paper) 
Metal  
Molecular 
Weight 
Weight 
(mg) 
Volume 
DMSO 
(µl) 
Stock solution 
(mM) 
Structure 
RML249 (11) 
Ruthenium 
521.06 7.6 145.85 100 
 
RML265 (12) 
Ruthenium 
557.10 8.6 154.37 100 
 
RML113 (13) 
Ruthenium 
561.06 6.7 119.42 100 
 
RML363 (14) 
Ruthenium 
430.94 10.7 248.29 100 
 
RML107 (15) 
Ruthenium 
449.91 12 226.7 100 
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Table 5.1 (continued): Ruthenium and Iridium β-ketoiminate compounds structure and stock solution 
preparation.  
 
5.2.2 - Chemo-Sensitivity Testing 
The response of HT-29 (human colon adenocarcinoma), MCF7 (human breast 
adenocarcinoma), A2780 (human ovarian carcinoma) and A2780cis (cisplatin resistant 
human ovarian carcinoma) was previously completed and published by Lord et al 
(2015) and these details are presented below (table 12.1 in the appendix). In this 
study, the activity of these compounds against the non-cancerous retinal epithelial cell 
line ARPE-19 was determined under aerobic conditions following continuous 96-hour 
exposures using the MTT assay, details of which have been described elsewhere in this 
thesis (see 2.5). 
Compound 
(as cited in 
paper) 
Metal 
Molecular 
Weight 
Weight 
(mg) 
Volume 
DMSO 
(µl) 
Stock solution 
(mM) 
Structure 
RML247 (18) 
Iridium 
542.0 7.6 140.22 100 
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5.3 - Results  
5.3.1 - Chemosensitivity Studies in Aerobic Conditions 
The response of ARPE-19 cell line to various test RML compounds are presented in 
table 5.2.  A broad range of IC50 values were obtained ranging from inactive (IC50 > 100 
µM, RML247), moderately active (IC50 = 51.55 ± 5.14µM, RML107) to active (IC50 = 4.48 
± 0.07µM, RML075). The IC50 values in ARPE-19 cells were compared to those of HT-29 
cells and these are presented in figure 5.2. With regards to potency, all of the novel 
RML compounds are less potent than cisplatin against the HT-29 cell line. In contrast, 
the potency of RML compounds against ARPE-19 cells is broadly similar to that of 
cisplatin with the exception of compounds 14 (RML107) and 15 (RML247) which were 
significantly less active.  With regards to selectivity indices, the results presented in 
figure 5.4 demonstrate that none of the test compounds have selectivity indices that 
are greater than cisplatin. The only possible exception to this is RML247 which is 
inactive against ARPE-19 cells at the highest dose tested. 
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5.3.1.1 - Response of ARPE19 Cells to Ruthenium and Iridium Complexes 
Under Aerobic Conditions 
 
  IC50 value (µM) ± SD 
Compound  Compound number as cited in Lord et al 
(2015) 
ARPE-19 
RML075  1 4.48 ± 0.07 
RML100  7 7.76 ± 0.07 
RML102 8 14.59 ± 0.41 
RML368  9 12.0 ± 1.48 
RML249  11 9.17 ± 2.36 
RML265  12 7.17 ± 0.93 
RML113  13 3.62 ± 0.03 
RML363  14 32.03 ± 9.23 
RML107  15 51.55 ± 5.14 
RML247  18 >100 
Cisplatin - 6.41 ± 0.95 
 
Table 5.2: Response of the non-cancerous retinal epithelial cell line ARPE-19 following continuous 96-
hour exposure to novel RML Ruthenium and Iridium β-ketoiminate based compounds. The results 
presented are the mean IC50 values ± standard deviations for three independent experiments n=3 (each 
individual experiment replicated twice ). The “>” symbol represents the highest dose tested in vitro.  
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5.3.1.2 - Comparison of RML Compounds with Platinum Based Anti-Cancer 
Drugs Chemosensitivity Data In Vitro 
 
Figure 5.3: Comparison of the potency of novel RML Ruthenium and Iridium β-ketoiminate based 
compounds to cisplatin on HT-29 and ARPE-19 cells. The values presented are the mean IC50 values ± 
standard deviation of three independent experiments n=3 (each individual experiment replicated twice). 
RML247 (18) IC50 value on ARPE-19 cell line was displayed as 100µM but as it’s IC50 value is higher than 
the maximum concentration tested (100µM) no SD is available. 
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Compound HT-29  
1 1.28 
7 1.27 
8 1.48 
9 1.02 
11 0.89 
12 0.32 
13 0.57 
14 0.6 
15 2.86 
18 1.08 
Cisplatin 23.88 
 
Figure 5.4: Comparison of the selectivity of novel RML Ruthenium and Iridium β-ketoiminate based 
compounds to cisplatin.  The selectivity index is defined as the mean IC50 for non-cancerous cells divided 
by the IC50 of cancer cells. Values greater than 1 indicate that compounds have selectivity for cancer 
cells as opposed to non-cancer cells. As the mean IC50 values are used to calculate selectivity indices, no 
error bars are included on the graphs. RML247 (18) IC50 value on ARPE-19 cell line was displayed as 1.08 
(IC50 value set at 100µM in ARPE-19 cell line therefore SI= >1.08). 
0.1 1 10
Cisplatin
1
7
8
9
11
12
13
14
15
18
Selectivity index 
   
 
Page | 162  
 
 
 
 
5.4 - Discussion 
Initially, the testing against cancer cells on this class of compounds was conducted 
by the McGowan research group and my study focused on providing additional data 
investigating the response of non-cancerous ARPE-19 retinal epithelial cells to the 
same set of compounds. This nevertheless played a key role in getting the work 
published (R. M. Lord et al., 2015). This discussion essentially focuses on the ARPE-19 
data generated in this thesis in the context of using potency and selectivity indices to 
make decisions about progression of compounds for further testing.  
The response of a panel of four cancer cell lines (i) HT-29 (colon adenocarcinoma), 
(ii) MCF-7(breast ductal carcinoma), (iii) A2780 (ovarian carcinoma) and (iv) A2780cis 
(cisplatin resistant ovarian carcinoma) was determined alongside the response of 
ARPE-19 cells as described above.  With regards to potency, RML075 (compound 1) 
was the most active compound against all four cancer lines and was ̴ 3-fold more 
active towards the cisplatin resistant A2780cis than cisplatin. It also showed evidence 
of selectivity in all cell lines with a selectivity index ranging from 1.28 to 2.35. Although 
this data initially presents compound 1 as a positive lead, it does not have a superior in 
vitro selectivity index compared to cisplatin with the exception of the cisplatin 
resistant A2780cis cell line where the in vitro selectivity index was 0.57.  This data 
suggests compound 1 is likely to be inferior to cisplatin but on the other hand, its 
improved activity and selectivity against the cisplatin resistant cell lines suggests an 
alternative mechanism of action to cisplatin and this therefore warranted further 
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investigation of RML075. Other compounds were selected for further analysis and 
further details can be found in Lord et al (2015) and additional studies included 
analysis of the effect of hypoxia on cytotoxicity, inhibition of thioredoxin reductase and 
DNA damage induction. These studies demonstrated that these compounds have very 
different mechanisms of action than cisplatin and they were therefore of interest as 
potentially interesting form a mechanistic standpoint. In the context of the overall aim 
of this thesis, the key issue is whether or not analysis of potency and the in vitro 
selectivity index provides sufficient evidence to take compounds forward to in vivo 
testing. Whilst mechanistically interesting as described in Lord et al (2015), the 
experimental data suggests that the in vitro selectivity index is not sufficiently better 
than cisplatin to warrant taking these specific compounds forward for in vivo testing. It 
is unlikely that these compounds will have a better therapeutic index in vivo than 
cisplatin and on this basis, they were not selected for in vivo studies. As stated above 
however, they remain of interest from a mechanistic point of view and further studies 
at the University of Leeds are ongoing. 
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Chapter 6 -Iridium Complexes as Anti-Cancer 
Therapies 
6.1 - Introduction 
As previously discussed in chapter 5, iridium complexes in contrast to other 
organometallic complexes have received little interest in terms of their use as 
potential anti-cancer agents. This lack of interest is due to them being considered 
unlikely candidates owing to the kinetic inertness of iridium as a transitional metal 
centre (Geldmacher et al., 2012). Although previously known for their inert nature, an 
investigation by Lord et al. (2015) concluded that iridium complexes with a β-
ketoiminato ligand exerted promising anti-cancer activity toward a number of 
cancerous cell lines. In addition, it was observed that almost all the β-ketoiminato 
complexes were slightly more active than cisplatin towards the cisplatin resistant cell 
line A2780cis. 
Dr Gemma Sweeney of the Innovative Physical Organic Solutions (IPOS) at The 
University of Huddersfield has synthesised a series of iridium complexes and the fact 
that these were 'home grown' compounds that were novel made them worth including 
in this program of work. In addition, it potentially builds on the success of the iridium 
complexes synthesised by Patrick McGowans research group and extends the studies 
on this metal based complex. The aim of this study was therefore to evaluate these 
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against cancer cell lines initially to establish if any of these compounds had cytotoxic 
activity.  
6.2 - Methods 
6.2.1 - Preparation of Drug Stock Solution 
A series of iridium based compounds were obtained from Dr Gemma Sweeny’s 
research group, their chemical structures and the preparation of stock solutions are 
presented below. 
Compound 
name 
MW 
Weight 
(mg) 
Diluent  
Volume 
(µl) 
Concentration 
(mM) 
Structure 
GMSI-1 796.70 4 DMSO 50.21 100 
 
GMSI-3 1162.50 5.1 DMSO 43.90 100 
 
GMSII-1 1000.29 2.4 DMSO 24 100 
 
GMSII-8 
 
1784.22 6.8 DMSO 38.11 100 
 
GMSII-32 492.67 9.7 DMSO 196 79.13 
 
GMSII-33 1276.61 5.7 DMSO 44.65 64.61 
 
Table 6.1: Novel iridium compounds structure and stock solution preparation. 
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6.2.2 - Chemosensitivity Testing 
The response of HT-29 (human colon adenocarcinoma), BE (human colonic 
carcinoma) and ARPE-19 (non-cancerous retinal epithelial) cell lines was determined 
under aerobic conditions following continuous 96-hour exposures to test compounds 
using the MTT assay, details of which have been described elsewhere in this thesis (see 
2.5). 
6.3 - Results 
6.3.1 - Chemosensitivity Studies in Aerobic Conditions 
The response of cell lines to the various GMS compounds are presented in table 
6.2.  The majority of these compounds proved to be inactive against the panel of cell 
lines with only two compounds showing activity below the highest dose tested. The 
lowest IC50 value was 62.51±22.90µM (GMSII-32) against the colorectal 
adenocarcinoma cell line HT-29. In regard to selectivity indices the majority of the 
compounds had IC50 values higher than the maximum concentration tested (100μM) 
except GMSII-1 on the colorectal carcinoma cell line BE (74.63 ± 11.19µM) and the 
aforementioned GMSII-32 on HT-29, which are both inactive against the non-
cancerous retinal epithelial cell line ARPE-19.  
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 IC50 value µM (S.D) 
Compound BE HT-29 ARPE-19 
GMSI-1 >100 >100 >100 
GMSI-3 >100 >100 >100 
GMSII-1 74.63 ± 11.19 >100 >100 
GMSII-8 >100 >100 >100 
GMSII-32 >100 62.51 ± 22.90 >100 
GMSII-33 >100 >100 >100 
Cisplatin  0.66 ±  0.33 0.25 ±  0.11 6.41 ±  0.95 
 
Table 6.2: Response of colorectal adenocarcinoma HT-29, colorectal carcinoma BE and the non-
cancerous retinal epithelial cell line ARPE-19 following continuous 96-hour exposure to novel GMS 
iridium based compounds. The results presented are the mean IC50 values ± standard deviations for 
three independent experiments n=3 (each individual experiment replicated twice). The “>” symbol 
represents the highest dose tested. 
6.4 - Discussion 
From these initial chemo-sensitivity investigations, it is very clear that these 
compounds do not display any cytotoxic activity towards cancerous cells.  The most 
potent compound in this series was 250 times less potent than the gold standard 
cisplatin in the HT29 colorectal cell line.  Only two compounds display potential 
selectivity toward the cancerous cell lines due to their inactivity on the non-cancerous 
cell line ARPE-19 but their poor potency on HT-29 cells and BE cells (IC50 for GMSII-32 = 
62.51 ± 22.90µM and IC50 for GMSII-1 = 74.63 ± 11.19µM) make them unlikely 
candidates for further biological investigation. Whilst these results are disappointing, 
the identification of inactive compounds is still of value in the context of phenotypic 
screening programs. Although there is no on-going research with this research group 
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previous collaborations pave the way for future pre-clinical testing on any additional 
compounds synthesised by IPOS. 
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Chapter 7 – Metal N-Heterocyclic Compounds as 
Anti-Cancer Agents 
7.1 - Introduction 
Transition metal N-heterocyclic carbene (metal-NHC) complexes are 
organometallic compounds consisting of a divalent organic ligand co-ordinated to the 
metal centre (figure 7.1) ( Gasser et al., 2010). Free carbenes are characteristically 
unstable but once joined to a metal centre, they become stabilised and this has seen 
them become the most popular ligands for multiple applications including catalysis 
(Herrmann, 2002). Metal-NHC complexes have gained significant attention as potential 
anti-cancer agents due to their practical suitability for efficient drug design, fast 
optimisation (Liu & Gust, 2013), high degree of stability and their ease of development. 
NHCs bind strongly to transition metals such as gold, silver, platinum and ruthenium 
and several studies have demonstrated that they have anti-microbial and anti-cancer 
properties. Mechanistically all these metals interfere with multiple pathways, several 
of which play key roles in cancer biology (Oehninger, Rubbiani, & Ott, 2013). 
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Figure 7.1: Structure of NHCs and the principles forming the basis of their appealing properties. Taken  
from Mercs and Albrecht (2010). 
 
To exemplify this, a recent study published with collaborators at the University of 
Leeds (Dr Charlotte Willans) demonstrated that a silver NHC complex known as Ag8 
(table 7.1) induced its cytotoxic effects via multiple mechanisms of action that did not 
involve alkylation to DNA. These mechanisms included (i) inhibition of topoisomerases 
I and II leading to single and double strand breaks in DNA (ii) inhibition of thioredoxin 
reductase (iii) inhibition of poly (ADP Ribose) polymerase (PARP) and (iv) inhibition of 
glycolysis (Allison et al., 2017). This study demonstrates that silver NHC complexes 
induce their cytotoxic effects in vitro via multiple mechanisms that are distinct from 
the platinates and they are therefore of considerable interest in the field of anti-cancer 
drug discovery.  
Previous research regarding silver-NHCs has ubiquitously been in the antimicrobial 
field and their incorporation in various applications including wound dressing, creams 
and deodorants. The unparalleled structural diversity of NHCs offers high synthetic 
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flexibility, which alongside their strong σ donor capabilities (strong ability to bind to 
the metal ions) facilitates the modification of release rates making silver a promising 
NHC candidate (Johnson, Southerland, & Youngs, 2017; Mercs & Albrecht, 2010). In 
addition to its already established antimicrobial properties a number of studies have 
investigated silver NHCs as potential anti-cancer complexes (Mohamed, Lake, Laing, 
Phillips, & Willans, 2015). As silver is believed to have relatively low toxicity and is 
ubiquitously used in biomedical fields, it is an attractive choice as a potential anti-
cancer compound.  While silver is one of the most widely studied metals for anti-
infective applications, a relatively small amount of research has been devoted to the 
metal for its anticancer properties (Wagers, Shelton, Panzner, Tessier, & Youngs, 
2014). Its mechanism of action in regard to solid tumours is therefore not fully 
understood. It is therefore of great importance not only cytotoxic studies are 
completed on such complexes, but also comprehensive mechanistic studies would be 
of great importance to the organometallic anti-cancer therapeutic field.  
Although silver NHCs exert promising activity in vitro their activity does not usually 
translate into comparable in vivo activity attributed to their lack of targeting and 
modification in metal species upon entering a biological environment (Allison et al., 
2017). It is therefore of great interest to develop targeted drug delivery systems which 
allow the delivery and release of drug to specific sites.  
In this chapter, a series of metal NHC complexes synthesised by Dr Charlotte 
Willans research group were evaluated in vitro.  As in previous chapters, the aim of this 
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study was to characterise the activity of these compounds with regards to potency and 
selectivity to cancer cells in vitro. Compounds with superior properties than the 
platinates were selected and preliminary mechanistic studies conducted.  
7.2 - Methods 
7.2.1 - Chemical Structures and Preparation of Drug Stock Solution  
All compounds for the exception HA236 (water soluble) were solubilised in DMSO. 
Compounds HA222 and HA223 appeared to initially dissolve in DMSO forming a 
homogenous solution but on recovery from storage at -20°C, precipitation occurred, 
and these compounds were therefore prepared fresh for each experiment. The 
chemical structures and preparation of stock solutions are presented below. 
 
Table 7.1: Metal N-Heterocyclic compound structures, stock solution concentrations. 
 
Compound 
name 
(description) 
Molecular 
Weight 
Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
Structure 
Ag8 
(Silver 
xanthine 
derivative) 
717.89 9.1 126.76 100  
HA150 
(Silver 
hydroxylated 
ligands) 
395.6 7 176.94 100 
 
HA163 
(Silver 
hydroxylated 
ligands) 
609.6 8.3 136.15 100 
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Table 7.1 (continued): Metal N-Heterocyclic compound structures, stock solution concentrations. 
 
Compound 
name 
(description) 
Molecular 
Weight 
Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
Structure 
NL-17 
(Silver 
hydroxylated 
ligands) 
455.7 6 131.66 100 
 
NL-21 
(Silver 
hydroxylated 
ligands) 
501.3 1.9 37.90 100 
 
NL-26 
(Silver 
hydroxylated 
ligands) 
547.8 2 36.51 100 
 
HA240 
(Silver amino 
acid based 
ligand) 
562.1 5 88.95 100 
 
HA222 
(Silver 
polymer 
ligand) 
490.8 7.4 150.77 100 
 
HA223 
(Silver 
polymer 
ligand) 
566.9 6.6 116.42 100 
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Table 7.1 (continued): Metal N-Heterocyclic compound structures, stock solution concentrations. 
  
Compound 
name 
(description) 
Molecular 
Weight 
Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
Structure 
HA221 
(Silver poly-L-
glutamic acid) 
608.5 12.5 205.42 100 
 
NL-37 
(Silver 
hydroxylated 
ligands) 
548.08 2.1 38.32 100 
 
NL-39 
(Silver 
hydroxylated 
ligands) 
556.04 1 18 100 
 
HA241 
(Silver amino 
acid based 
ligand) 
923.07 5.5 59.58 100 
 
HA266 
(Silver 
hydroxylated 
ligands) 
726.15 9.3 124.6 100 
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Table 7.1 (continued): Metal N-Heterocyclic compound structures, stock solution concentrations. 
  
Compound 
name 
(description) 
Molecular 
Weight 
Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
Structure 
HA229 
(copper 
xanthine 
derivative) 
439.98 3.5 79.55 100 
 
HA230 
(copper 
xanthine 
derivative) 
473.96 6.1 128.7 100 
 
HA269 
(Ruthenium 
xanthine 
derivative) 
514.05 2.1 40.85 100 
 
HA270 
(Ruthenium 
xanthine 
derivative) 
556.10 2 35.97 100 
 
HA271 
(Ruthenium 
xanthine 
derivative) 
590.08 2 33.89 100 
 
MD-9 
(Silver, 
clotrimazole 
based ligands) 
467.04 9.7 207.69 100 
 
HB-34 
(Silver 
clotrimazole 
based ligands) 
501 8.7 173.65 100 
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Table 7.1 (continued): Metal N-Heterocyclic compound structures, stock solution concentrations. 
  
Compound 
name 
(description) 
Molecular 
Weight 
Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
Structure 
HB-38 
(Silver 
clotrimazole 
based ligands) 
527.02 10.5 199.23 100 
 
MD-44 
(Silver 
clotrimazole 
based ligands) 
493.06 6.4 129.80 100 
 
HA197 
(Silver 
clotrimazole 
based ligands) 
788.76 6.2 78.60 100 
 
HA201 
(Silver 
clotrimazole 
based ligands) 
732.16 7.7 105.17 100 
 
HB-39 
(Silver 
clotrimazole 
based ligands) 
577.04 5 86.64 100 
 
HA200 
(Silver 
clotrimazole 
based ligands) 
782.18 5 63.92 100 
 
HA202 
(Silver 
clotrimazole 
based ligands) 
642.09 1.1 17.13 100 
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Table 7.1 (continued): Metal N-Heterocyclic compound structures, stock solution concentrations. 
  
Compound 
name 
(description) 
Molecular 
Weight 
Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
Structure 
HB-16 
(Silver 
clotrimazole 
based ligands) 
643.99 7.5 118.11 100 
 
HA327 
(Silver amino 
acid based 
ligands) 
778.2 1.2 15.42 100 
 
HA333 
(Silver amino 
acid based 
ligands) 
514.0 4.1 79.7 100 
 
HB-13 
(Silver 
clotrimazole 
based ligands) 
621.94 2.5 40 100 
 
HB-18 
(Silver 
clotrimazole 
based 
hydroxylated 
ligands) 
913.04 10.9 119.38 100 
 
HA341 
(Silver 
clotrimazole 
based ligands) 
788.76 2 25.34 100 
 
HA345 
(Silver 
clotrimazole 
based ligands) 
732.16 2.3 31.41 100 
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7.2.2 - Chemo-Sensitivity Testing, Analysis of Cell Viability and Cell Cycle 
Parameters 
The response of cell lines following continuous 96-hour exposures to test 
compounds under aerobic conditions and as a drug-polymer system was determined 
using the MTT assay, details of which have been described elsewhere in this thesis (see 
2.5 for aerobic MTT assay and section 7.2.3 for further description of drug-polymer 
systems). Analysis of cell viability and induction of apoptosis was determined using the 
NC3000 cytometer, details of which have been described elsewhere (see 2.6). For 
these experiments, drug exposure concentrations ranged from 2.5µM to 10µM; 
duration of drug exposures was set at 96 hours to replicate the conditions of the MTT 
assays. 
7.3 - Results 
7.3.1 - Chemosensitivity Studies in Aerobic Conditions 
Initially all the compounds provided were tested on the Panc10.05 cells with the 
most potent compounds (with IC50 values below 10µM) tested further on ARPE-19 
cells. A broad spectrum of activity was obtained ranging from inactive at the highest 
dose tested (IC50> 100µM; HA151 for example) to potent activity (IC50 = 1.25 ± 0.50µM; 
HA197). Compounds displaying desirable potency and selectivity in the first round of 
testing were also further investigated on two additional cancerous cell lines MIA-PaCa2 
and BE. The only exceptions to this were HA341/345 which were submitted by the 
Willans group later together with a request to test primarily on the MIA-PaCa2 cell line 
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to serve as a direct comparison to their corresponding one ligand complex (HB18) 
which was more potent in the MIA-PaCa2 cell line the Panc10.05 cell line. The full set of 
chemosensitivity data is displayed in table 7.3 with the response of selected 
compounds presented in figure 7.2 alongside the results for the platinum based 
compounds. The selectivity index data for selected test compounds and platinates is 
presented in figure 7.3. 
Table 7.2: Response of pancreatic adenocarcinoma cell lines Panc10.05 and MIA-PaCa2, colorectal 
carcinoma cell line BE and non-cancerous retinal epithelial cell line ARPE-19, following continuous 96-
hour exposure to novel metal NHC complexes in aerobic conditions. The results presented are the mean 
IC50 values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice). The most promising compounds in terms of potency are highlighted in red.  The “>” 
symbol represents the highest dose tested in vitro. 
 
IC50 µM (SD) 
Compound Panc10.05 MIA-PA-CA2 BE ARPE-19 
Ag8 11.33±0.4 4.09±0.36 5.85±1.59 36.7± 6.36 
HA150 30.57±13.2 - - >100 
HA151 >100 - - - 
HA163 24.0±3.43 - - - 
HA197 1.25±0.50 3.30±1.22 5.75±4.57 21.86±4.41 
HA200 9.59±1.23 - - - 
HA201 5.27±1.66 
 
5.86±1.31 6.13±2.96 27.99±4.19 
HA202 10.14±4.61 - - 16.28±3.15 
HA221 14.35±3.73 - - - 
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Table 7.2 (continued): Response of pancreatic adenocarcinoma cell lines Panc10.05 and MIA-PaCa2, 
colorectal carcinoma cell line BE and non-cancerous retinal epithelial cell line ARPE-19, following 
continuous 96-hour exposure to novel metal NHC complexes in aerobic conditions. The results 
presented are the mean IC50 values ± standard deviations for three independent experiments n=3 (each 
individual experiment replicated twice). The most promising compounds in terms of potency are 
highlighted in red.  The “>” symbol represents the highest dose tested in vitro. 
  
 IC50 µM (SD) 
Compound Panc10.05 MIA-PA-CA2 BE ARPE-19 
HA222 21.06±1.20 - - - 
HA223 9.17±2.27 - - - 
HA225 17.05±6.71 - - - 
HA229 >100 - - - 
HA236 12.27±3.20 - - >100 
HA240 7.51±0.34 4.85±2.56 5.4±3.56 19.01±5.12 
HA241 10.44±1.86 - - - 
HA266 8.27±2.06 6.15±3.57 12.0±3.63 13.65±2.91 
HA269 93.66±5.06 - - - 
HA270 >100 - - - 
HA271 >100 - - - 
HA327 26.34±11.47 - - 68.7±7.16 
HA230 66.93±12.90 - - - 
HA333 >100 - - >100 
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 IC50 µM (SD) 
Compound Panc10.05 MIA-PA-CA2 BE ARPE-19 
HA341 - 3.29±0.93 - 90.75±12.67 
HA345 - 2.73±0.34 - 92.99±7.45 
HB-13 10.04±6.79 5.72±2.30 3.31±1.16 24.21±2.60 
HB-16 3.85±1.95 4.55±3.87 3.59±0.93 8.67±1.48 
HB-18 13.28±8.16 6.89±2.07 1.99±0.31 15.82±2.93 
HB-34 7.10±3.67 11.72±1.56 18.04±4.41 >50 
HB-38 9.38±5.63 6.32±4.8 6.73±1.07 11.49±2.96 
HB-39 5.75±1.41 7.0±1.61 8.44±1.25 10.25±0.76 
MD-9 16.1±0.89 - - 26.65±7.78 
MD-44 16.06±1.96 - - 27.47±7.52 
MD-46 16.80±1.85 - - 13.77±6.54 
NL-17 14.74±3.44 - - - 
NL-21 16.99±4.07 - - - 
NL-26 2.95±0.47 5.68±1.80 6.97±2.64 21.44±2.92 
 
Table 7.2 (continued): Response of pancreatic adenocarcinoma cell lines Panc10.05 and MIA-PaCa2, 
colorectal carcinoma cell line BE and non-cancerous retinal epithelial cell line ARPE-19, following 
continuous 96-hour exposure to novel metal NHC complexes in aerobic conditions. The results 
presented are the mean IC50 values ± standard deviations for three independent experiments n=3 (each 
individual experiment replicated twice). The most promising compounds in terms of potency are 
highlighted in red.  The “>” symbol represents the highest dose tested in vitro. 
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Table 7.2 (continued): Response of pancreatic adenocarcinoma cell lines Panc10.05 and MIA-PaCa2, 
colorectal carcinoma cell line BE and non-cancerous retinal epithelial cell line ARPE-19, following 
continuous 96-hour exposure to novel metal NHC complexes in aerobic conditions. The results 
presented are the mean IC50 values ± standard deviations for three independent experiments n=3 (each 
individual experiment replicated twice). The most promising compounds in terms of potency are 
highlighted in red.  The “>” symbol represents the highest dose tested in vitro. 
7.3.2 - Comparison of “hit” Novel Metal NHC Complexes to Platinum 
Compounds 
The seven “hit” compounds chosen based on their potency and selectivity index 
are displayed in figures 7.2 and 7.3 respectively. Overall the “hit” compounds show 
either improved or comparable potency compared to oxaliplatin and carboplatin on 
Panc10.05, MIAPaCa2 and BE cell lines.  Of the cancer cell lines tested, cisplatin is the 
most active platinum agent making it the gold standard to which compare our novel 
compounds. With regards to the test compounds, only HA197 was more active against 
Panc10.05 and MIA-PaCa2 cell lines compared to cisplatin. The activity of all the 
IC50 µM (SD) 
Compound Panc10.05 MIA-PA-CA2 BE ARPE-19 
NL-37 15.77±1.03 - - - 
NL-39 33.18±3.49 - - - 
Cisplatin 1.71 ± 0.41 3.62 ± 0.74 0.66 ± 0.33 6.41 ± 0.95 
Carboplatin 10.45 ± 3.15 35.59 ± 7.91 32.72 ± 4.64 77.73 ± 10.52 
Oxaliplatin 7.54 ± 3.85 6.44 ± 1.05 8.56 ± 0.48 3.12 ± 0.28 
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selected compounds were nevertheless comparable to the level of activity obtained 
for carboplatin and oxaliplatin (figure 7.2. The selectivity index of the test compounds 
generally demonstrated significant selectivity for cancer cells compared to ARPE-19 
cells with SI values ranging from 0.77 to 17.49 (figure 7.3) ) with only a handful of 
compounds failing to produce a statistically significant reduction in potential toxicity in 
the non-cancerous cell lines opposed to the cancerous cell lines (figure 7.3). Of 
particular note, the largest selectivity index was 17.49 for HA197 against the 
pancreatic adenocarcinoma cell line Panc10.05 and this was significantly greater than 
the highest SI obtained by cisplatin (SI = 3.75), oxalipatin (SI = 7.44) and carboplatin (SI 
= 0.41).  
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Figure 7.2: Comparison of the potency of novel metal NHC complexes to cisplatin, carboplatin and 
oxaliplatin on Panc10.05, MIAPaCa2, BE and ARPE-19 cell lines. The values presented are the mean IC50 
values ± standard deviation of three independent experiments n=3 (each individual experiment 
replicated twice). 
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Compound MIA-PaCa2  p-value BE p-value Panc10.05 p-value 
Ag8 8.97 0.012 6.27 0.0081 3.24 0.018 
HA197 6.62 0.026 3.8 0.090 17.49 0.013 
HA201 4.78 0.018 4.57 0.030 5.31 0.0081 
HA240 3.92 0.035 3.52 0.0049 2.53 0.055 
HB-13 4.23 0.018 7.31 0.0054 2.41 0.043 
HB-16 1.91 0.098 2.42 0.021 2.25 0.047 
HB-18 2.3 0.032 7.95 0.018 1.19 0.53 
Nl-26 3.77 0.011 3.08 0.0016 7.27 0.010 
Cisplatin  1.77 0.10 9.71 0.0043 3.75 0.025 
Carboplatin 2.18 0.031 2.38 0.029 7.44 0.0089 
Oxaliplatin 0.48 0.020 0.36 0.0064 0.41 0.047 
Figure 7.3: Comparison of the selectivity of novel metal NHC compounds cells to cisplatin, carboplatin 
and oxaliplatin.  The selectivity index is defined as the mean IC50 for non-cancerous cells divided by the 
IC50 of cancer cells. Values greater than 1 indicate that compounds have selectivity for cancer cells as 
opposed to non-cancer cells. As the mean IC50 values are used to calculate selectivity indices, no error 
bars are included on the graphs. Ag8 a previous compound synthesised by the Charlotte Willans has also 
been used as a “yardstick” due to a wealth of previous research surrounding the complex. Statistical 
analysis was performed using a student’s t-test where values <0.05 indicates a statistically significant 
difference between IC50 values in cancerous and none cancerous cell lines. 
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7.3.3 - Cell Viability and Apoptosis Induction Investigations  
Based on their potency and selectivity profile, seven “hit” compounds were 
selected for further investigation. The results of cell viability and induction of apoptosis 
using the NC3000 are presented in figures 7.4 to Y. In all cases, cells were treated with 
increasing concentrations of compound and their viability along with any cell cycle 
disruption was determined using the viability and cell cycle assays using the same data 
analysis outlined in section 3.3.5. The results for each of the compounds selected are 
described in the various sub-sections below. 
7.3.3.1 - HA197 
The effect of HA197 on the cell number and viability of MIA PaCa2 is shown in 
figure 7.4. Following a continuous 96-hour exposure to HA197, a dose dependent 
reduction in cell number and percentage viability was obtained. The IC50 obtained 
using the NC3000 (IC50 = 3µM) was comparable to that obtained using the MTT assay 
described above (IC50 = 3.30 ± 1.22µM). These results are also illustrated visually in 
figure 7.5 and they confirm that cell viability decreases in a dose dependent manner. 
The results of apoptosis induction in MIA PaCa2 cells following continuous exposure to 
HA197 are presented in figure 7.6. These results indicate that HA197 induces apoptosis 
and it does so in a dose dependent manner (figure 7.6). 
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Control 2.5µM 5µM 10µM 
Total cells in sample  4.8 x 106 2.7 x 106 2.0 x 106 1.1 x 106 
Percentage cell viability  98.1 91.7 93.3 87.5 
 
Figure 7.4: Effect of increasing doses of HA197 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 2.5µM, 
5µM and 10µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 7.5: Microscope images of MIA-PaCa2 cell line following 96-hour exposures to increasing doses of 
HA197. 
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Figure 7.6: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to HA197. The exposure concentrations 
ranged from 2.5µM - 10µM with “0” denoting the control sample (n=1). 
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7.3.3.2 - HA201 
The effect of HA201 on the cell number and viability of MIA PaCa2 is shown in 
figure 7.7. Following a continuous 96-hour exposure to HA201, a dose dependent 
reduction in cell number and percentage viability was obtained. The IC50 obtained 
using the NC3000 (IC50 = <2.5µM) was much less than the results obtained using the 
MTT assay described above (IC50 = 5.86 ± 1.31µM). Visually however, the images 
obtained at 2.5µM (figure 7.8) suggest that a considerable number of cells are present 
within the cultures. The reason for this discrepancy is unknown. The results of 
apoptosis induction in MIA PaCa2 cells following continuous exposure to HA201 are 
presented in figure 7.9. These results along with visual morphological changes (figure 
7.8) could indicate that HA201 induces apoptosis and it does so in a dose dependent 
manner (figure 7.9). 
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Figure 7.7: Effect of increasing doses of HA201 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 2.5µM, 
5µM and 10µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 7.8: Microscope images of MIA-PaCa2 cell line following 96-hour exposures to increasing doses of 
HA201. 
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Figure 7.9: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to HA201. The exposure concentrations 
ranged from 2.5µM - 10µM with “0” denoting the control sample (n=1). 
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7.3.3.3 - HA240 
The effect of HA240 on the cell number and viability of MIA PaCa2 is shown in 
figure 7.10. Following a continuous 96-hour exposure to HA201, a dose dependent 
reduction in cell number and percentage viability was obtained. The IC50 obtained 
using the NC3000 (IC50 = 5µM approximately) was similar to the results obtained using 
the MTT assay described above (IC50 = 4.85 ± 2.56µM). Visually, these results are 
confirmed under the microscope (figure 7.11) where cell number is vastly reduced and 
cells appear to be floating opposed to functional and attached. The results of apoptosis 
induction in MIA PaCa2 cells following continuous exposure to HA240 are presented in 
figure 7.12. These results are therefore indicative toward HA240 inducing apoptosis 
and in a dose dependent manner (figure 7.12). 
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Figure 7.10: Effect of increasing doses of HA240 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 2.5µM, 
5µM and 10µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 7.11: Microscope images of MIA-PaCa2 cell line following 96-hour exposures to increasing doses 
of HA240. 
 
0
1000000
2000000
3000000
4000000
5000000
6000000
0 2 4 6 8 10 12
C
e
ll 
N
u
m
b
er
  
Concentration (μM) 
 
Control 2.5µM 5µM 10µM 
Total cells in sample  4.8 x 106 3 x 106 2.52 x 106 8.48 x 104 
Percentage cell viability  98.1 82.4 85.1 69.9 
10µM Control 2.5µM 5µM 
   
 
Page | 194  
 
 
 
 
 
  
Figure 7.12: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to HA240. The exposure concentrations 
ranged from 2.5µM - 10µM with “0” denoting the control sample (n=1). 
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7.3.3.4 - HB13 
The effect of HB13 on the cell number and viability of MIA PaCa2 is shown in figure 
7.13. Following a continuous 96-hour exposure to HB13, a dose dependent reduction 
in cell number and percentage viability was obtained. The IC50 obtained using the 
NC3000 (IC50 = 5µM approximately) was similar to the results obtained using the MTT 
assay described above (IC50 = 5.72 ± 2.30µM). Visually, these results are confirmed 
under the microscope with vastly reduced cell number and dramatic alteration in 
cellular morphology where cells appear almost elongated and less clonogenic (figure 
7.14). The results of apoptosis induction in MIA PaCa2 cells following continuous 
exposure to HB13 are presented in figure 7.15. These results therefore suggest that 
HB13 induces apoptosis and it does so in a dose dependent manner (figure 7.15).  
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Figure 7.13: Effect of increasing doses of HB13 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 2.5µM, 
5µM and 10µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 7.14: Microscope images of MIA-PaCa2 cell line following 96-hour exposures to increasing doses 
of HB13. 
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Figure 7.15: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to HB13. The exposure concentrations 
ranged from 2.5µM - 10µM with “0” denoting the control sample (n=1). 
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7.3.3.5 - HB16 
The effect of HB16 on the cell number and viability of MIA-PaCa2 is shown in figure 
7.16. Following a continuous 96-hour exposure to HB16, a dose dependent reduction 
in cell number and percentage viability was obtained. The IC50 obtained using the 
NC3000 (IC50 = > 2.5µM approximately) was similar to the results obtained using the 
MTT assay described above (IC50 = 4.55 ± 3.87µM). Visually, these results are 
confirmed under the microscope with a visual reduction in cell number and interesting 
alteration in cell morphology where cells appear detached from the flask surface 
(figure 7.17). The results of apoptosis induction in MIA-PaCa2 cells following 
continuous exposure to HB16 are presented in figure 7.18. These results clearly 
demonstrate that HB16 induces apoptosis and it does so in a dose dependent manner 
(figure 7.18). 
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Figure 7.16: Effect of increasing doses of HB16 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 2.5µM, 
5µM and 10µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
Figure 7.17: Microscope images of MIA-PaCa2 cell line following 96-hour exposures to increasing doses 
of HB16. 
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Figure 7.18: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to HB16. The exposure concentrations 
ranged from 2.5µM - 10µM with “0” denoting the control sample (n=1). 
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7.3.3.6 - HB18 
The effect of HB18 on the cell number and viability of MIA PaCa2 is shown in figure 
7.19. Following a continuous 96-hour exposure to HB18, a dose dependent reduction 
in cell number and percentage viability was obtained. The IC50 obtained using the 
NC3000 (IC50 = > 2.5µM approximately) was similar to the results obtained using the 
MTT assay described above (IC50 = 6.89 ± 2.07µM). Visually, these results are 
confirmed under the microscope where cell number is greatly reduced and cell seem 
more dispersed with altered morphology (figure 7.20). The results of apoptosis 
induction in MIA-PaCa2 cells following continuous exposure to HB18 are presented in 
figure 7.21. These results clearly demonstrate that HB18 induces apoptosis and it does 
so in a dose dependent manner (figure 7.21). 
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Control 2.5µM 5µM 10µM 
Total cells in sample  4.8 x 106 2.48 x 106 1.70 x 106 2.94 x 105 
Percentage cell viability  98.1 82.6 77.5 65.3 
 
Figure 7.19: Effect of increasing doses of HB18 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 2.5µM, 
5µM and 10µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 7.20: Microscope images of MIA-PaCa2 cell line following 96-hour exposures to increasing doses 
of HB18. 
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Percentage of cell population 
Cell state Control 2.5µM 5µM 10µM 
Healthy 81 50 31 27 
Apoptotic  10 45 60 65 
Late apoptotic 9 5 9 8 
 
Figure 7.21: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to HB18. The exposure concentrations 
ranged from 2.5µM - 1µM with “0” denoting the control sample (n=1). 
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7.3.3.7 - NL26 
The effect of NL26 on the cell number and viability of MIA-PaCa2 is shown in figure 
7.22. Following a continuous 96-hour exposure to NL26, a dose dependent reduction in 
cell number and percentage viability was obtained. The IC50 obtained using the NC3000 
(IC50 = > 10µM approximately) was much lower than the results obtained using the 
MTT assay described above (IC50 = 5.68 ± 1.80µM). Visually, cells appear to be viable at 
5 µM and even at 10µM, a significant number of viable cells are present, the cells do 
however alter in morphology and appear as individual finely dispersed cells which look 
to have detached from the cell culture flasks (figure 7.23). The reasons for the 
discrepancy between the MTT assay and the NC3000 data are not known. The results 
of apoptosis induction in MIA-PaCa2 cells following continuous exposure to NL26 are 
presented in figure 7.24. These results clearly demonstrate that NL26 induces 
apoptosis and it does so in a dose dependent manner (figure 7.24). 
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Figure 7.22: Effect of increasing doses of NL26 on the cell number of pancreatic adenocarcinoma cell 
line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 2.5µM, 
5µM and 10µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 7.23: Microscope images of MIA-PaCa2 cell line following 96-hour exposures to increasing doses 
of NL26. 
 
0
1000000
2000000
3000000
4000000
5000000
6000000
0 2 4 6 8 10 12
C
e
ll 
N
u
m
b
er
  
Concentration (μM) 
 
Control 2.5µM 5µM 10µM 
Total cells in sample  4.8 x 10
6 
3.93 x 10
6 
3.87 x 10
6 
3.41 x 10
6 
Percentage cell viability  98.1 67.8 66.0 56.0 
10µM Control 2.5µM 5µM 
   
 
Page | 206  
 
 
 
 
 
 
Figure 7.24: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to NL26. The exposure concentrations 
ranged from 2.5µM - 10µM with “0” denoting the control sample (n=1). 
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7.4 - Discussion  
The results of this study have identified a number of metal NHC complexes as 
illustrated in table 7.3.  Seven 'hit' compounds were identified based upon equivalent 
or increased potency and selectivity index compared to the platinates. All the lead 
compounds are silver NHCs with the copper and ruthenium complexes displaying poor 
activity towards the Panc10.05 cell line with IC50 values of above 51µM (table 7.3). 
Therefore, despite the promising mechanistic selectivity of ruthenium and its ability to 
act as a pro-drug, the compounds synthesised exerted poor activity on cancer cells. 
This could be due to its in ability to enter the cell and become active in the oxidising 
environment of the cancer cell or it could simply be that it’s anti-proliferative effect is 
poor (structural issue). 
Copper NHC complexes in this study failed to display adequate chemotoxicity with 
the most potent complex being HA230 (IC50 = 66.93 ± 12.90µM against the Panc10.05 
cell line). Although these compounds demonstrate a poor cytotoxic profile, previous 
studies have shown that alternative copper NHC complexes do possess a strong 
cytotoxic profile with its mechanism of action being attributed to substantial DNA 
damage as a result of ROS production (Oehninger et al., 2013), (Gautier & Cisnetti, 
2012). This therefore suggests copper NHC complexes do have appeal as novel 
therapeutic agents but in regard to the complexes investigated in this study, their poor 
activity means that they are not worth pursuing further. 
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From the hit silver NHCs identified as potential lead compounds, five out of the 
seven compounds are silver(I)-N-heterocyclic carbene complexes derived from 
clotrimazole. These are compounds HB-13, HB-18, HA-197, HA-201 and HB-16. From 
the IC50 values alone it is apparent the use of clotrimazole derivatives as a precursor 
for silver-NHCs improves their cytotoxic activity with HA197 displaying IC50 values 
comparable to that of cisplatin in both the Panc10.05 and MIA-PaCa2 cell lines (figure 
7.2). To further understand the nature of silver-clotrimazole NHC complexes as novel 
cytotoxic agents, a number of clotrimazole derivatives were tested using a unique 
sensing device which has been developed by Coldrick, Steenson, Millner, Davies, and 
Nelson (2009). The device mimics the cell membrane and it consists of dioleoyl 
phosphatidyl choline (DOPC) monolayers on which all five of the silver clotrimazole 
derivatives were tested at the University of Leeds by our collaborative group. The 
DOPC monolayer is positioned on a micro fabricated Pt/Hg electrode, which measures 
and displays two peaks of current corresponding to the entry of electrolytes into the 
cell membrane layer and the reorganisation of the layer in initiation of pore formation 
(Coldrick et al., 2009; Mohamadi, Tate, Vakurov, & Nelson, 2014; Nelson & Nolan, 
2013).  
The resulting images produced by the chemical department at Leeds University 
(figure 12.3 in the appendix) demonstrate the compounds ability to interact with the 
cell membrane and this broadly correlates with the chemosensitivity results obtained 
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in this study. Interaction with the membrane is denoted by the deviation of the red 
line signal away from the undisturbed DOPC signal (grey line).  
As with the chemo-sensitivity assays, clotrimazole compounds HA197 and HB-18 
display a larger interaction with the cell membrane. The resulting data displayed in 
12.3 suggest they possess a mechanism of improved cell entry and potentially increase 
irreversible cell membrane damage as the signal does not return to its baseline. To 
investigate the role of the clotrimazole precursor the imidazolium salts plus ligands 
with no silver ion were also tested, which resulted in an initial interruption (indicating 
cell membrane diffusion) the disruption was completely reversed, and the signal 
returned to baseline (figure 12.3). This indicates it is the silver entity initiating the 
irreversible damage observed by the original compounds. Cisplatin was also 
investigated as a negative control (figure 12.3), which as expected showed no 
membrane disruption as cisplatin is widely known to enter the cell via copper influx 
transporters and not via passive diffusion (Holzer, Manorek, & Howell, 2006). These 
assays although completed externally validate the screening methodology we have 
adopted by further confirming the exclusion of inactive compounds and selection of 
active lead compounds.  
It is unclear how clotrimazole exerts its anti-cancer effects either directly or 
whether it possibly enhances the activity of silver itself. The majority of mechanistic 
data currently available are focused on its anti-bacterial and anti-fungal activities but 
little is known about its activity on cancer cells. This makes any mechanistic 
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investigation surrounding these complexes novel and potentially of high impact in the 
field of chemotherapeutic organometallic complexes. The most active and selective 
compound HA197 is believed to be so due to its intermediate lipophilicity owed to it 
having both hydrophilic and lipophilic properties. Its hydrophilic properties owed to 
hydroxylether group increasing the compounds solubility improving its transfer 
through the bloodstream. Its lipophilic properties owed to its triphenyl group typical of 
clotrimazole compounds, improves the compounds ability to pass through the cell 
membrane. 
To gain more insight into the mechanistic profile of these novel lead compounds, a 
mitochondrial potential assay was completed to investigate if these compounds induce 
cancer cell death via apoptosis. All the “hit” compounds tested result in dose 
dependent reductions in cell number and increased rates of apoptotic induction. Each 
compound displays varying degrees of dose dependent cell death with HA240 (figure 
7.10) and HB16 (7.16) resulting in the greatest reduction in cell number and largest 
percentage of cells undergoing apoptosis at concentrations of 10µM. Although these 
compounds do not display the lowest IC50 values in the previous chemo-sensitivity 
assays on the MIA-PaCa2 cell line, the viability and mitochondrial potential assays 
suggest these compounds have a greater attainable response than compounds such as 
HA197 which demonstrates a lower IC50 value.  Further studies are however required 
to (i) evaluate shorter drug exposure conditions (ii) confirm the induction of apoptosis 
using other assays such as Annexin V and (iii) conduct similar experiments on ARPE-19 
   
 
Page | 211  
 
 
 
 
cells to determine if the induction of apoptosis is cancer specific. In addition to further 
mechanistic investigations it is imperative to mention our appreciation of conducting 
additional experiments in order to further support the data already generated. In light 
of this priority investigation will consist of rerunning experiments already conducted in 
order to produce mean values ruling out experimental bias or random error.   
Alongside generating more robust and informative mechanistic data undertaking 
more informative chemo-sensitivity  investigations would shed light on the toxicity 
profile of the compounds in regards to if they induce a cytostatic or cytotoxic response 
in the cancerous cell lines. This can be managed via MTT assays establishing the 
absorbance of the cell seeding densities on the day of treatment in order to determine 
if the reduction in cell number is due to cell death or cytostatic action. This in 
conjunction with the optimisation and implementation of clonogenic assays will give a 
greater insight into the nature of chemosensitivity of the cell lines toward these novel 
complexes.  
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7.5 - Conclusion  
In conclusion, the results of this study have identified seven novel metal NHC 
compounds that are as potent as the platinates (particularly cisplatin). Silver based 
NHC compounds were found to be the most active metal complexes with clotrimazole 
derivatives being the most active. Initial mechanistic studies were performed in the 
form of mitochondrial potential assays and viability cell count assays. Although it 
showed a number of compounds induced apoptosis, the assay has limitations. The 
main being that a reduction in the mitochondrial potential of a cell is not specific to 
apoptosis and can be induced via other external stresses and therefore an additional 
apoptotic assay is required to further validate the results obtained. Several of the 
compounds not only rival the platinum agents in regard to the chemo-sensitivity and 
selectivity data but the indication of alternative mechanistic pathways via cell 
membrane DOPC investigations suggest an application for these complexes in platinum 
resistant tumours. In the context of the overall objectives of the thesis, the phenotypic 
screen based on potency alone compared to platinates identified seven compounds of 
interest. With regards to the selectivity index in vitro, only one compound (HA197) 
showed greater selectivity than all the platinates tested. This demonstrates that the 
selectivity index together with potency data has greater discrimination than potency 
alone and is capable of identifying promising hit compounds.  
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Chapter 8 - Half Sandwich Metal Complexes as Anti-
Cancer Therapies 
8.1 - Introduction 
Due to their versatility, half sandwich organometallic complexes have been 
extensively researched during the past few decades. They have had wide spread 
application and have been especially prominent in the field of catalysis (Gras et al., 
2010). The piano stool, pseudo-tetrahedral complex displayed in figure 8.1 offers great 
flexibility, with the piano seat arene moiety protecting the oxidation state of the 
central metal ion by occupying 3 coordinating sites. The L ligand controls the reactivity 
of the complex while the chelating ligand when dissociated reveals the biomolecule 
targeting active site. The substitution of either arene, chelating ligand or leaving group 
therefore strongly influences the biological activity of these complexes (Adhikari et al., 
2016). Our collaboration with North Eastern Hill, India focused on the investigation of 
half sandwich complexes with varying ligands, counter ions, leaving groups and central 
metal ions. Iridium and ruthenium have been discussed in more detail in chapter 5 and 
their activity is investigated in this chapter as part of a half sandwich system.  
Rhodium a group 9 transition metal, like cobalt and iridium, long thought to be 
inert, has recently sparked interest as part of a half sandwich system with its lability 
thought to be responsible for observed anti-cancer activity. This is thought to induce 
cytostatic activity, cellular uptake and DNA binding via intercalation (Ma et al., 2016).  
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This chapter explores the use of various ligands and metal centres in order to 
manipulate the half sandwich structures and synthesise complexes with both high 
potency and selectivity towards cancerous cells. One of the ligands investigated in this 
chapter are chain diazine Schiff base ligands linked by a single N-N bond, which offer 
flexibility and a variety of coordination complexes. Another ligand in the half sandwich 
system is the oxime ligand and these have been shown to induce pronounced 
cytotoxicity and antimicrobial activity with the potency of some complexes exceeding 
that of cisplatin (Gerasimchuk, Gamian, Glover, & Szponar, 2010; Gerasimchuk et al., 
2007).The appeal of the oxime ligands is thought to be their ability to form an 
ambidentate ligand coordinating with the metal ion thereby stabilising and protecting 
its oxidation state and reducing premature degradation (Adhikari et al., 2016). Like 
oxime ligands, pyrimidine ligands are intermediates for a number of biologically active 
complexes, with metal oxime complexes being poorly understood in comparison to 
pyrimidine which is a core structure in a large number of biologically important 
complexes. Pyrimidine ligands are not only present in both DNA and RNA but are the 
building blocks of a number of antibacterial, anti-HIV, anti-convulsant and ant-
hypertensive agents they also already hold a role in cancer chemotherapy in the form 
of 5-fluorouracil (Dudhe, Sharma, Verma, & Chaudhary, 2011). 
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Figure 8.1: Classic half sandwich “piano stool” adapted  from Gasser et al. (2010) 
 
Over the past few years Dr Mohan Rao and his research group have synthesised 
many half sandwich Ru (II), Ir (III) and Rh (III) complexes with azine, oxime and 
pyrimidine ligands. These compounds were not designed to target specific biochemical 
pathways and therefore the initial aim of this study was to conduct a phenotype based 
approach using potency and selectivity for cancer cells as the primary endpoint for 
selecting lead compounds for subsequent evaluation.  
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8.2 - Methods 
8.2.1 - Preparation of Drug Stock Solution  
 
 
Table 8.1: Concentration of drug solutions and structure of novel iridium and rhodium half sandwich 
compounds containing azine Schiff base ligands. 
Compound 
name (Metal) 
 
MW Weight 
(mg) 
Diluent   Volume  
(µl) 
Concentration 
(mM) 
Ligands 
KMR-SA03 (Rh) 688.84 2.5 DMSO 36.29 100 R1=H, R2 =OH, 
R3=OCH3 
KMR-SA04 (Ir) 778.15 3.2 DMSO 41.12 100 R1=H, R2 =OH, 
R3=OCH3 
KMR-SA05 (Rh) 658.81 2 DMSO 30.36 100 R1=H, R2 =OH, R3=H 
KMR-SA06 (Ir) 748.12 5.4 DMSO 72.18 100 R1=H, R2 =OH, R3=H 
KMR-SA07 (Rh) 672.84 2.8 DMSO 41.61 100 R1= CH3, R2 =OH, R3=H 
KMR-SA08 (Ir) 762.15 3.6 DMSO 47.23 100 R1= CH3, R2 =OH, R3=H 
KMR-SA09 (Rh) 642.81 4.2 DMSO 65.34 100 R1= CH3, R2 =H, R3=H 
KMR-SA10 (Ir) 732.12 2.7 DMSO 36.88 100 R1= CH3, R2 =H, R3=H 
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Table 8.2: Concentration of drug solutions and structure of novel ruthenium, iridium and rhodium 
neutral half sandwich complexes with 2-pyridyl cyanoxime ligands. 
  
Compound 
name (Metal) 
 
MW Weight 
(mg) 
Diluent  Volume 
 (µl) 
Concentration 
(mM) 
Precursor 
KMR-SA01 
(Ru) 
416.87 10.5 DMSO 252 100 
 
 
KMR-SA02 
(Rh) 
417.88 10.7 DMSO 256 100 
 
KMR-SA11 (Ir) 509.02 3.52 DMSO 69.2 100 
 
Precursor  
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Table 8.3: Concentration of drug solutions and structure of novel ruthenium, iridium and rhodium 
cationic half sandwich complexes with 2- pyridyl phenyloxime ligands. 
  
  
Compound 
name 
(Metal) 
 
MW Weight 
(mg) 
Diluent  Volume 
 (µl) 
Concentration 
(mM) 
Precursor 
KMR-SA12 
(Ru) 
613.93 4.25 DMSO 69.2 100 
 
KMR-SA13 
(Rh) 
616.77 3.23 DMSO 52.4 100 
 
KMR-SA14 
(Ir) 
706.08 1.70 DMSO 24 100 
 
Precursor  
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Table 8.4: Concentration of drug solutions and structure of novel ruthenium, iridium and rhodium 
cationic half sandwich complexes with 2-thiazolyl methyloxime ligands. 
  
Compound 
name 
(Metal) 
 
MW Weight 
(mg) 
Diluent Volume  
(µl) 
Concentration 
(mM) 
Precursor  
KMR-SA15 
(Ru) 
557.88 8.96 DMSO 160.6 100 
 
KMR-SA16 
(Rh) 
559.73 6.46 DMSO 115.4 100 
 
KMR-SA17 
(Ir) 
650.04 6.40 DMSO 98.5 100 
 
Precursor  
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Table 8.5: Concentration of drug solutions and structure of novel ruthenium half sandwich complexes 
with ketoxime ligands. 
  
Compound 
name  
(M=Ru) 
MW Weight 
(mg) 
Diluent Volume  
(µl) 
Concentration 
(mM) 
Precursor  
KMR-NR 1  495.75 4.6 DMSO 92.79 100 benzene 
KMR-NR 3  551.86 6.9 DMSO 125.09 100 p-cymene 
R group = 
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Table 8.6: Concentration of drug solutions and structure of novel rhodium and iridium CP*half sandwich 
complexes with aldoxime, ketoxime, amioloxime ligands. 
 
 
 
 
Compound 
name 
(Metal) 
MW Weight 
(mg) 
Diluent Volume  
(µl) 
Concentration 
(mM) 
R group 
KMR-NR 2 
(Ir) 
629.99 9.2 DMSO 146.03 100  
KMR-NR 4 
(Rh) 
540.68 5.5 DMSO 101.72 100  
KMR-NR 5 
(Rh) 
572.72 7.1 DMSO 123.97 100  
KMR-NR 7 
(Rh) 
1001.8
7 
2.8 DMSO 27.95 100  
KMR-NR 8 
(Ir) 
1180.4
5 
7.9 DMSO 66.92 100  
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Table 8.7: Concentration of drug solutions and structure of novel binuclear rhodium and iridium half 
sandwich complexes with aminopyrimidine ligands. 
 
 
 
Table 8.8: Concentration of drug solutions and structure of novel mononuclear rhodium and iridium half 
sandwich complexes with 2-mercaptopyrimidine ligands. 
 
 
Compound 
name  
MW Weight 
(mg) 
Diluent Volume  
(µl) 
Concentration 
(mM) 
Metal  
KMR-SA 9 713.17 6.2 DMSO 86.94 100 Rh 
KMR-SA 10 891.75 8.9 DMSO 99.80 100 Ir 
Compound 
name  
 
MW Weight 
(mg) 
Diluent Volume  
(µl) 
Concentration 
(mM) 
Metal 
KMR-SA 13 460.42 11.1 DMSO 241.08 100 Rh 
KMR-SA 14 549.71 9.4 DMSO 170.10 100 Ir 
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Table 8.9: Concentration of drug solutions and structure of novel mononuclear ruthenium half sandwich 
complex with 2-mercaptopyrimidine ligand. 
 
Once dissolved the compounds were aliquoted into single-use batches to prevent 
freeze thawing, each aliquot was given a 3-month expiry. 
8.2.2 - Chemo-Sensitivity, Viability and Mitochondrial Potential Assays 
The response of cell lines following continuous 96-hour exposures to test 
compounds under aerobic and hypoxic conditions was determined using the MTT 
assay, details of which have been described elsewhere in this thesis (see 2.5). Analysis 
of cell viability and cell cycle parameters was determined using the NC3000 cytometer, 
details of which have been described elsewhere (see 2.6). For these experiments, drug 
exposure concentrations ranged from 5µM to 20µM; duration of drug exposures was 
set at 96 hours to replicate the conditions used in the MTT assays.   
  
Compound 
name  
 
MW Weight 
(mg) 
Diluent Volume 
 (µl) 
Concentration 
(mM) 
Metal 
KMR-NR 11 539.57 10.7 DMSO 198.31 100 Ru 
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8.3 - Results 
8.3.1 - Response of MIA-PaCa2, HT-29 and ARPE-19 Cells to Test Compounds 
Under Aerobic Conditions 
 
 
Table 8.10: Response of pancreatic carcinoma cell line MIA-PaCa2, colorectal adenocarcinoma cell line 
HT-29 and the non-cancerous retinal epithelial cell line ARPE-19 following continuous 96-hour exposure 
to novel iridium and rhodium half sandwich compounds containing azine Schiff base ligands. The results 
presented are the mean IC50 values ± standard deviations for three independent experiments n=3 (each 
individual experiment replicated twice). The “>” symbol represents the highest dose tested in vitro. 
  
IC50 value (μM) ± SD 
Compound MIA-PaCa2 HT-29 ARPE-19 
KMR-SA 3 (Rh) 93.68±8.94 56.95±11.76 85.31±14.86 
KMR-SA 4 (Ir) 98.50±2.28 89.42±18.33 93.45±11.34 
KMR-SA 5 (Rh) >100 82.32±15.55 83.03±14.76 
KMR-SA 6 (Ir) 98.39±2.89 96.93±5.31 >100 
KMR-SA 7 (Rh) 95.26±6.70 46.17±12.78 97.39±4.53 
KMR-SA 8 (Ir) >100 83.74±28.17 >100 
KMR-SA 9 (Rh) >100 93.16±11.84 >100 
KMR-SA 10 (Ir) >100 88.09±20.63 >100 
Cisplatin 3.62±0.38 0.25±0.11 6.41±0.95 
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Table 8.11: Response of pancreatic carcinoma cell line MIA-PaCa2, colorectal adenocarcinoma cell line 
HT-29 and the non-cancerous retinal epithelial cell line ARPE-19 following continuous 96-hour exposure 
to novel half sandwich ruthenium, iridium and rhodium compounds with oxime and oximato ligands. 
The results presented are the mean IC50 values ± standard deviations for three independent experiments 
n=3 (each individual experiment replicated twice). The most promising results in terms of potency are 
highlighted in red. The “>” symbol represents the highest dose tested in vitro. 
  
IC50 value (μM) ± SD 
Complex (metal) Be HT-29 MIA-Pa-Ca2 ARPE-19 
KMR-SA 1 (Ru) >100 >100 >100 >100 
KMR-SA 2 (Rh) 23.74±4.25 22.25±5.29 9.16±2.89 24.95±8.36 
KMR-SA 11 (Ir) - 5.82±2.41 2.87±0.26 8.12±2.30 
KMR-SA 12 (Ru) - 68.83±27.0 26.42±0.67 71.63±8.10 
KMR-SA 13 (Rh) - 42.32±10.69 67.18±3.16 70.53±8.73 
KMR-SA 14 (Ir) - 7.92±1.00 8.35±0.29 17.92±7.76 
KMR-SA 15 (Ru) - 12.56±4.45 8.28±0.42 18.95±1.51 
KMR-SA 16 (Rh) - >100 >100 >100 
KMR-SA 17 (Ir) - 10.54±4.73 9.65±1.68 11.50±2.12 
KMR-NR 1 (Ru) >100 >100 - - 
KMR-NR 2 (Ir) 6.32±0.06 10.00±2.77 5.46±3.41 12.76±5.4 
KMR-NR 3 (Ru) 6.91±0.50 13.24±6.47 5.31±1.95 28.92±6.05 
KMR-NR 4 (Rh) >100 >100 - - 
KMR-NR 5 (Rh) >100 >100 - - 
KMR-NR 7 (Rh) >100 >100 - - 
KMR-NR 8 (Ir) >100 >100 - - 
Cisplatin  0.66±0.33 0.25±0.11 3.62±0.38 6.41±0.95 
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Table 8.12: Response of pancreatic carcinoma cell line MIA-PaCa2, colorectal adenocarcinoma cell line 
HT-29 and the non-cancerous retinal epithelial cell line ARPE-19 following continuous 96-hour exposure 
to novel half sandwich complexes with pyridine derivative ligands. The results presented are the mean 
IC50 values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice). The “>” symbol represents the highest dose tested in vitro. 
8.3.2 - Comparison of “hit” Novel Metal NHC Complexes to Platinum 
Compounds 
The four “hit” compounds chosen based on their potency and selectivity index are 
displayed in figures 8.2 and 8.3 respectively. In the cancer cell lines tested, cisplatin 
presented as the most active platinum agent toward the pancreatic adenocarcinoma 
MIA-PaCa2 cell line and the only agent with complete colorectal adenocarcinoma HT-29 
data making it the gold standard to which compare our novel compounds.  Overall the 
“hit” compounds show either improved or comparable potency compared to cisplatin 
on the MIAPaCa2 cell line with KMR-SA 11 demonstrating improved potency (2.87 ± 
0.26µM). On the HT-29 cell line however cisplatin displays far superior potency than 
any of the hit compounds tested. The selectivity index of the test compounds generally 
demonstrated intermediate selectivity for cancer cells compared to ARPE-19 cells with 
SI values up to 5.45 displayed by KMR-NR 3 on MIA-PaCa2 cells (figure 8.3) which was 
IC50 value (μM) ± SD 
Complex Be HT-29 MIA-Pa-Ca2 ARPE-19 
KMR-NR 9 >100 >100 >100 >100 
KMR-NR 10 23.13±3.83 >100 >100 >100 
KMR-NR 11 >100 >100 - - 
KMR-NR 12 >100 >100 - - 
KMR-NR 13 14.25±2.14 24.32±2.80 20.43±4.59 47.22±4.88 
KMR-NR 14 42.09±8.68 57.46±2.97 19.86±4.58 69.25±1.75 
Cisplatin  0.66±0.33 0.25±0.11 3.62±0.38 6.41±0.95 
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the only novel compounds to display a statistically significant reduction in toxicity 
toward the none cancerous cell line opposed to the cancerous lines. Of particular note, 
all the novel complexes displayed superior selectivity toward the MIA-PaCa2 cell line 
(Cisplatin = 1.71) yet cisplatin was over 10-fold more selective than the most selective 
novel compounds on HT-29 cells (Cisplatin =25.64). 
 
Figure 8.2: Comparison of the potency of lead novel half sandwich ruthenium and iridium compounds 
with oxime and oximato ligands to cisplatin on MIA-PaCa2, HT-29 and ARPE-19 cells. The values 
presented are the mean IC50 values ± standard deviation of three independent experiments n=3 (each 
individual experiment replicated twice). 
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Compound MIA-PaCa2  p-value HT-29 p-value 
KMR-NR 2 2.34 0.19 1.28 0.46 
KNR-NR 3 5.45 0.010 2.18 0.063 
KMR-SA 11 2.83 0.054 1.39 0.41 
KMR-SA 14 2.15 0.17 2.26 0.16 
Cisplatin  1.77 0.10 25.64 0.0028 
 
Figure 8.3: Comparison of the selectivity of novel half sandwich ruthenium and iridium compounds with 
oxime and oximato ligands to cisplatin on cancerous cell lines MIA-PaCa2 and HT-29 in comparison to 
non-cancerous cell line ARPE-19. The selectivity index is defined as the mean IC50 for non-cancerous cells 
divided by the IC50 of cancer cells. Values greater than 1 indicate that compounds have selectivity for 
cancer cells as opposed to non-cancer cells. As the mean IC50 values are used to calculate selectivity 
indices, no error bars are included on the graphs. Statistical analysis was performed using a student’s t-
test where values <0.05 indicates a statistically significant difference between IC50 values in cancerous 
and none cancerous cell lines. 
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8.3.3 - Cell Viability and Apoptosis Induction Investigations 
Based on their potency and selectivity profile, four “hit” compounds were selected 
for further investigation. The results of cell viability and induction of apoptosis using 
the NC3000 are presented in figures 8.4 to 8.15. In all cases, cells were treated with 
increasing concentrations of compound and their viability along with any cell cycle 
disruption was determined using the viability and mitochondrial potential assays using 
the same data analysis outlined in sections 3.3.5.1 and 3.3.5.3. The results for each of 
the compounds selected are described in the various sub-sections below.  
8.3.3.1 - KMR-SA 11 
The effect of KMR-SA 11 on the cell number and viability of MIA-PaCa2 is shown in 
figure 8.4. Following a continuous 96-hour exposure to KMR-SA 11, a dose dependent 
reduction in cell number and percentage viability was obtained. The IC50 obtained 
using the NC3000 (IC50 = 10µM approximately) was significantly higher than that 
obtained using the MTT assay described above (IC50 = 2.87 ± 0.26µM) yet the cell 
response at 10µM and above are dramatic. These results are also illustrated visually in 
figure 8.5 and they confirm that cell viability decreases in a dose dependent manner  
with dramatic changes to cell morphology with increasing drug concentration. The 
results of apoptosis induction in MIA-PaCa2 cells following continuous exposure to 
KMR-SA 11 are presented in figure 8.6. These results clearly demonstrate that KMR-SA 
11 induces apoptosis and it does so in a dose dependent manner (figure 8.6). 
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Control 5µM 10µM 20µM 
Total cells in sample  4.8 x 10
6 
3.5 x 10
6 
2.34 x 10
6 
6.72 x 10
4 
Percentage cell viability  98.1 91.5 94.9 61.7 
 
Figure 8.4: Effect of increasing doses of KMR-SA 11 on the cell number of pancreatic adenocarcinoma 
cell line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 5µM, 
10µM and 20µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
 
Figure 8.5: Microscope images of pancreatic adenocarcinoma cell line MIA-PaCa2 cell line exposed to 
increasing doses of KMR-SA 11 over a 96-hour exposure time.  
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Percentage of cell population 
Cell state Control 5µM 10µM 20µM 
Healthy 81 55 55 17 
Apoptotic  10 29 28 75 
Late apoptotic 9 16 17 8 
 
Figure 8.6: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to KMR SA-11. The exposure concentrations 
ranged from 5µM - 20µM with “0” denoting the control sample (n=1). 
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8.3.3.2 - KMR-SA 14 
The effect of KMR-SA 14 on the cell number and viability of MIA-PaCa2 is shown in 
figure 8.7. Following a continuous 96-hour exposure to KMR-SA 14, a dose dependent 
reduction in cell number and percentage viability was obtained. The IC50 obtained 
using the NC3000 (IC50 = between 5µM and 10µM) was comparable to that obtained 
using the MTT assay described above (IC50 = 8.35 ± 0.29µM). These results are also 
illustrated visually in figure 8.8 and they confirm that cell viability decreases in a dose 
dependent manner again displaying morphological changes in the cells with increasing 
drug concentration with remaining cells appearing detached and potentially 
undergoing apoptosis. The results of apoptosis induction in MIA-PaCa2 cells following 
continuous exposure to KMR-SA 14 are presented in figure 8.9. These results clearly 
demonstrate that KMR-SA 14 induces apoptosis and it does so in a dose dependent 
manner (figure 8.9). 
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Control 5µM 10µM 20µM 
Total cells in sample  4.8 x 106 2.46 x 106 2.45 x 105 1.5 x 105 
Percentage cell viability  98.1 79.0 69.2 71.3 
 
Figure 8.7: Effect of increasing doses of KMR-SA 14 on the cell number of pancreatic adenocarcinoma 
cell line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 5µM, 
10µM and 20µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
Figure 8.8: Microscope images of pancreatic adenocarcinoma cell line MIA-PaCa2 cell line exposed to 
increasing doses of KMR-SA 14 over a 96-hour exposure time.  
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Percentage of cell population 
Cell state Control 5µM 10µM 20µM 
Healthy 81 52 46 33 
Apoptotic  10 32 40 56 
Late apoptotic 9 16 15 11 
 
Figure 8.9: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to KMR SA-14. The exposure 
concentrations ranged from 5µM - 20µM with “0” denoting the control sample (n=1). 
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8.3.3.3 - KMR-NR 2 
The effect of KMR-NR 2 on the cell number and viability of MIA-PaCa2 is shown in 
figure 8.10. Following a continuous 96-hour exposure to KMR-SR 2, a dose dependent 
reduction in cell number and percentage viability was obtained. The IC50 obtained 
using the NC3000 (IC50 = between 5µM and 10µM) was comparable to that obtained 
using the MTT assay described above (IC50 = 5.46 ± 3.41µM). These results are also 
illustrated visually in figure 8.11 and they confirm that cell viability decreases and 
alterations to cell morphology occur in a dose dependent manner. The results of 
apoptosis induction in MIA-PaCa2 cells following continuous exposure to KMR-SR 2 are 
presented in figure 8.12. These results therefore suggest that KMR-SR 2 induces 
apoptosis and it does so in a dose dependent manner (figure 8.12). 
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Control 5µM 10µM 20µM 
Total cells in sample  4.8 x 106 3 x 106 9 x 105 1.5 x 105 
Percentage cell viability  98.1 76.5 81.8 72.5 
 
Figure 8.10: Effect of increasing doses of KMR-NR 2 on the cell number of pancreatic adenocarcinoma 
cell line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 5µM, 
10µM and 20µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 8.11: Microscope images of pancreatic adenocarcinoma cell line MIA-PaCa2 cell line exposed to 
increasing doses of KMR-NR 2 over a 96-hour exposure time. 
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Percentage of cell population 
Cell state Control 5µM 10µM 20µM 
Healthy 81 39 44 16 
Apoptotic  10 46 43 56 
Late apoptotic 9 14 13 27 
 
Figure 8.12: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to KMR –NR 2. The exposure concentrations 
ranged from 5µM - 20µM with “0” denoting the control sample (n=1). 
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8.3.3.4 - KMR-SR 3 
The effect of KMR-NR 3 on the cell number and viability of MIA-PaCa2 is shown in 
figure 8.13. Following a continuous 96-hour exposure to KMR-NR 3, a dose dependent 
reduction in cell number and percentage viability was obtained. The IC50 obtained 
using the NC3000 (IC50 = >10µM) was higher to that obtained using the MTT assay 
described above (IC50 = 5.31 ± 1.95µM). These results are also illustrated visually in 
figure 8.14 and they confirm that cell viability decreases in a dose dependent manner, 
which like the MTT assays sees a cell response from 5µM.  Figure 8.14 also 
demonstrates that the novel compound KMR-SR 3 induces morphological changes in 
the MIA-PaCa2 cell line with very little in the form of functional living cells remaining at 
higher concentrations. The results of apoptosis induction in MIA-PaCa2 cells following 
continuous exposure to KMR-SR 3 are presented in figure 8.15. These results are 
indicative that KMR-SR 3 induces apoptosis and it does so in a dose dependent manner 
(figure 8.15). 
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Control 5µM 10µM 20µM 
Total cells in sample  4.8 x 10
6 
3.93 x 10
6 
3.87 x 10
6 
3.41 x 10
5 
Percentage cell viability  98.1 67.8 66.0 56.0 
 
Figure 8.13: Effect of increasing doses of KMR-NR 3 on the cell number of pancreatic adenocarcinoma 
cell line MIA-PaCa2 after 96-hour exposure. “0” denotes the control sample with concentrations of 5µM, 
10µM and 20µM being tested. Cell viability is expressed as a percentage based on acridine Orange 
staining the entire population and DAPI which stains non-viable cells (n=1). 
 
 
Figure 8.14: Microscope images of pancreatic adenocarcinoma cell line MIA-PaCa2 cell line exposed to 
increasing doses of KMR-NR 3 over a 96-hour exposure time. 
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 Percentage of cell population 
Cell state Control 5µM 10µM 20µM 
Healthy 81 24 28 32 
Apoptotic  10 66 63 59 
Late apoptotic 9 10 9 9 
 
Figure 8.15: Mitochondrial potential assay identifying induction of apoptosis in the pancreatic 
adenocarcinoma cell line MIA-PaCa2 after 96-hour exposure to KMR –NR 3. The exposure concentrations 
ranged from 5µM - 20µM with “0” denoting the control sample (n=1). 
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8.4 - Discussion  
A number of varying ruthenium, iridium and rhodium half sandwich complexes 
were investigated with novel ruthenium and iridium oxime and oximato ligand 
compounds being the most promising (table 8.11).  These “hit” compounds were 
identified based upon equivalent or increased potency and selectivity in comparison to 
cisplatin the platinate gold standard. Despite the novel potential of rhodium as an 
alternative to existing platinum and ruthenium metallodrugs (Leung, Zhong, Chan, & 
Ma, 2013) in this investigation the rhodium complexes synthesised fail to exert 
sufficient cytotoxic activity.  
From the four lead compounds selected in this investigation KMR-SA 11 is the 
most potent displaying superior potency to cisplatin on the pancreatic 
adenocarcinoma cell line MIA-PaCa2 (IC50=2.87 ± 0.26μM table 8.2) with the potency of 
the other three lead compounds displaying IC50 values of between 5μM and 8μM 
(cisplatin=3.62 ± 0.74μM).  Although the potency of the majority of these compounds 
is less than that of cisplatin the selectivity profile of these novel compounds is very 
promising with all the compounds displaying superior selectivity to cisplatin on the 
pancreatic adenocarcinoma cancer cell line MIA-PaCa2 relative to the non-cancerous 
retinal epithelial cell line ARPE-19 (table 8.3). KMR-NR 2 displays the highest selectivity 
index at 5.45 the compound is 3-fold more selective than the gold standard cisplatin 
(SI=1.77) on this particular cell line. The extreme potency and selectivity displayed by 
cisplatin on the HT-29 colorectal adenocarcinoma cell line does result in neither of the 
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novel compounds displaying comparable potency or selectivity in this particular cell 
line. Another observation throughout the exposure of the cancerous cell lines to the 
lead novel compounds is that the morphology of cells is dramatically altered with 
increasing concentration. Observations from the microscope images show cells 
become more circular, appearing less functional (floating opposed to attached) and 
unable to form colonies as they become dispersed.  
As discussed in chapter 7 additional investigations such as alternative apoptotic 
assays will give greater insight and further prove/disprove the initiation of apoptosis 
following exposure to the novel compounds. Greater clarification of the activity of the 
compounds to determine whether the compounds are cytotoxic or cytostatic will also 
increase our understanding of the mechanistic profile of these compounds. Alongside 
additional assays reruns of assays already completed will allow for more robust data, 
as previously discussed running an assay once does not allow for potential error.  
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8.5 - Conclusion  
In conclusion, the results of this study have identified four novel ruthenium and 
iridium oxime and oximato ligand compounds that are as potent as cisplatin in the 
pancreatic adenocarcinoma cell line MIA-PaCa2. Ruthenium and iridium based 
compounds were found to be the most active metal complexes and rhodium being the 
most inactive. Initial mechanistic studies were performed in the form of mitochondrial 
potential assays and viability cell count assays. Although it showed all the compounds 
resulted in dose dependent apoptosis, the assay has limitations. The main being that a 
reduction in the mitochondrial potential of a cell is not specific to apoptosis and can be 
induced via other external stresses and therefore an additional apoptotic assay is 
required to further validate the results obtained. These investigations would also 
benefit from further studies to (i) evaluate shorter drug exposure conditions (ii) 
confirm the induction of apoptosis using other assays such as Annexin V and (iii) 
conduct similar  
In the context of the overall objectives of the thesis, the phenotypic screen based 
on potency alone compared to platinates identified four compounds of interest from 
thirty-one previously unscreened compounds. With regards to the selectivity index in 
vitro, all four of the four identified lead compounds showed greater selectivity than 
cisplatin with one of the compounds KMR-SA 11 also displaying superior potency to 
cisplatin on the MIA-PaCa2 cell lines. 
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Chapter 9 - Evaluation of Metallohelices as Anti-
Cancer Therapies 
9.1 - Introduction  
In the field of anti-cancer drug development, there are certain rules or guidelines 
that steer the development of novel compounds (Lipinski, Lombardo, Dominy, & 
Feeney, 2001). These are called the Lipinski rules and for a molecule to be active 
following oral administration, specific conditions should be met; (i) the total number of 
oxygen-hydrogen and nitrogen-hydrogen bonds (collectively called hydrogen bond 
donors) should be no more than 5 (ii) Hydrogen bond acceptors (all nitrogen or oxygen 
atoms) should number no more than 10 (iii) the molecular mass should be less than 
500 Daltons (iv) the log P value (octanol/water partition coefficient) should not be 
greater than 5. In this chapter, the evaluation of a series of large molecular weight 
metallohelices are described, none of which comply the Lipinski these rules described.  
There are many exceptions to the Lipinski rules and the work described in this 
chapter exemplifies this. The molecules examined are a series of metallohelicies 
developed by Professor Peter Scott at the University of Warwick. They were initially 
developed not only because of their interesting chemistry but also because their 
helical shape and structure suggested that they may act as pepdidomimetics. There is 
considerable interest in the development of peptides and peptidomimetics as direct 
acting anti-cancer drugs and as immunomodulatory agents (Junaid et al., 2015). One of 
the major limitations of peptide based drugs is their pharmacological instability in 
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biological systems and peptidomimetics are widely viewed as an important way 
forward to tackling this problem (Cunningham, Qvit, & Mochly-Rosen, 2017). This was 
the primary reason for selecting these compounds for evaluation in this thesis. It is 
important to stress that the compounds tested were not developed to target a specific 
pathway and therefore a phenotype based approach was the strategy adopted.   
Metallohelices are assemblies of rigid organic ligands around a metal ion core, 
resembling α-helices in terms of their diameter and charge (shown in figure 9.1) (Kaner 
& Scott, 2015; Lehn et al., 1987). These are complex, large molecular weight 
compounds and in order to be potential anti-cancer drugs, a number of issues should 
be addressed. These include optical purity, stability, solubility, availability on a 
practical scale and synthetic diversity. Therefore the key has been to develop simple 
self-assembling, optically pure, monometallic complexes utilising amino acids as the 
source of chirality and not rigid ligands (Howson et al., 2009). This was achieved by 
preparing thermodynamically stable, single enantiomers of monometallic units 
connected together by organic linkers resulting in self-assembling, water stable, 
helicate-like compounds with high stereo-chemical purity. These compounds are 
referred to as flexicates, with one such being an iron (II) “flexicate” system exhibiting 
promising antimicrobial activity (Howson et al., 2012). The general structures of these 
compounds together with specific examples of ligands and compounds is presented in 
figure 9.2. The compounds described in this chapter exhibit structural diversity and the 
details will be described in each sub-section. The overall aim of the studies conducted 
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here was to assess (i) potency and (ii) selectivity against cancer and non-cancer cells in 
vitro with the aim of selecting potential lead compounds for mechanistic studies. 
Selected compounds were also evaluated in vivo against human tumour xenografts 
and this work was conducted under the direction of Dr Steve Shnyder at the University 
of Bradford. These results are reported here to illustrate the effectiveness of the 
screening procedures and acknowledgment to those who performed the studies is 
given at the appropriate place. 
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Figure 9.1: Chemical structures of metallohelicates. Schematic representation (upper) of one 
enantiomer, which comprises of three relatively rigid ditopic ligands, in this example the N-N system 
(middle), wrapped in a helical array around two metal ions. Taken from(Brabec et al., 2013). The 
compound in the lower panel represents the full helicate structure of one of the complexes under 
investigation in this thesis. 
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9.2 - Methods   
9.2.1 - Chemosensitivity Studies  
The response of tumour and non-cancer cell lines to the novel metallohelices were 
determined using the MTT assays as described in sections 2.5.3. As with previous 
chapters the aim of the initial chemosensitivity was to identify “hit” compounds with 
regards to (i) potency and (ii) selectivity. The potency of the compounds was tested on 
colonic adenocarcinoma HCT116 p53+/+ cell lines and the relative selectivity measured 
by testing the said compounds on the retinal epithelial non-cancerous cell line ARPE-
19. As with previous MTT investigations, the results represent the mean ± standard 
deviation of three independent experiments. The selectivity index is defined as the 
mean IC50 of non-cancer cells divided by the IC50 for tumour cells; values >1 indicate 
selectivity for tumour cells in vitro.  
9.2.1.1 - Chemical Structures and Preparation of Drug Stock Solution 
A series of compounds were obtained from Professor Peter Scott’s research group 
and these were organised into Classes 1 and 3 each with class 1 compounds split into 2 
sets (1a and 1b) and class 3 split into five subsets sets based on structural criteria. The 
chemical structures and preparation of stock solutions are presented below. A number 
of compounds were initially dissolved in methanol and in these cases, the final 
concentration of methanol in all cell culture experiments was 0.1% (v/v) which is not 
toxic to cells.  
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Class 1a 
 
 
Compound Compound type Fe Diluent MW Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
AKK015 (m)Xylene-H Λ Methanol 1911.54 3.55 18.57 100 
AKK022 (m)Xylene-H Δ Methanol 1911.54 4.80 25.11 100 
SEH531 (P)Xylene-H Λ Methanol 2043.7 3.14 15.36 100 
SEH532 (P)Xylene-H Δ Methanol 2043.7 7.08 34.64 100 
DHS41 DBFuran-H Λ Methanol 2187.82 1.96 8.95 100 
DHS42 DBFuran-H Δ Methanol 2187.82 4.79 21.89 100 
DHS74 Biphen-H Λ Methanol 2145.87 1.92 8.95 100 
DHS115 Biphen-H Δ Methanol 2145.87 3.15 14.68 100 
DHS101 PhSPh-H Λ Methanol 2242.05 1.83 8.17 100 
DHS103 PhSPh-H Δ Methanol 2242.05 6.20 27.65 100 
DHS124 PhOPh-H Λ Methanol 2193.86 3.25 14.81 100 
DHS105 PhOPh-H Δ Methanol 2193.86 2.62 11.94 100 
DHS128 PhCH2Ph-H Δ Methanol 2187.95 3.64 16.64 100 
DHS130 PhCH2Ph-H Λ Methanol 2187.95 4.43 20.25 100 
DHS132 Bibenzyl-H Δ Methanol 2230.03 2.39 10.72 100 
DHS134 Bibenzyl-H Λ Methanol 2230.03 4.14 18.56 100 
KLB016 (m)Xylene-OProp  Λ Methanol 2386 3.91 16.39 100 
KLB007 (m)Xylene-OProp Δ Methanol 2386 2.44 10.23 100 
 
Table 9.1: Class 1a flexicate metallohelix complexes structure and stock solution preparation. 
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Class 1b 
 
 
 
 
Table9.2: Class 1b flexicate metallohelix complexes structure and stock solution preparation. 
  
Compound Compound 
type 
Fe Diluent MW Weight 
(mg) 
Volume 
(µl) 
Concentration 
(mM) 
RAK373 F-ALKE-H Δ Methanol 1767.37 3.45 19.52 100 
HS183 F-HS-Alkyne Λ Methanol 2340.71 4.48 19.14 100 
HS186 F-HS-Alkyne Δ Methanol 2322.70 6.63 28.54 100 
   
 
Page | 251  
 
 
 
 
Class 3a 
 
 
 
Table 9.3: Class 3a triplex metallohelixes complex structure and stock solution preparation. 
  
Compound Compound 
type 
Fe Diluent MW Weight 
(mg) 
Volume  
(ml) 
Concentration 
(µM) 
ADF495 T-ADF-H Δ Medium 1599.05 4.38 27.39 100 
HS138 T-HS-Alkyne Λ Medium 1920.46 1.70 8.85 100 
HS139 T-HS-Alkyne Δ Medium  1920.46 7.01 36.50 100 
T-ADF-H T-HS-ALKYNE 
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Class 3a click 
 
 
Table 9.4: Class 3a triplex metallohelix complexes with sugar and arene clicked R groups structure and 
stock solution preparation. Representative of R groups Glucose (A) and benzyl (B) displayed above. 
 
Compound Compound type Fe Diluent MW Weight 
(mg) 
Volume  Concentration  
HS130 T-HS-FluorBenzene Λ Methanol 2355.66 3.86 16.4µl 100Mm 
HS103 T-HS-FluorBenzene Δ Methanol 2391.68 9.52 39.8µl 100Mm 
HS093 T-HS-
Methoxybenzene 
Λ Methanol 2463.76 12.55 50.9µl 100Mm 
HS085 T-HS-
Methoxybenzene 
Δ Methanol 2481.77 1.88 7.6µl 100Mm 
HS094 T-HS-benzonitrile Λ Methanol 2430.7 3.93 16.2µl 100Mm 
HS095 T-HS-benzonitrile Δ Methanol 2376.67 4.10 17.3µl 100Mm 
HS100 T-HS-Benzoic acid Λ Methanol 2415.65 3.15 13.0µl 100Mm 
HS104 T-HS-Benzoic acid Δ Methanol 2433.66 5.98 24.6µl 100Mm 
HS089 T-HS-peracetylated-
Glucose 
Λ Methanol 3165.92 7.75 24.5µl 100Mm 
HS090 T-HS-peracetylated-
Glucose 
Δ Methanol 3183.93 2.50 7.9µl 100Mm 
HS120 T-HS-Glucose Λ Medium 2517.7 1.20 4.8ml 100µM 
HS121 T-HS-Glucose Δ Medium 2553.73 1.65 6.5ml 100µM 
HS136 T-HS-Deoxy-glucose Λ Medium 2463.67 1.33 5.4ml 100µM 
HS137 T-HS-Deoxy-glucose Δ Medium 2463.67 1.30 5.3ml 100µM 
HS111 T-HS-peracetylated-
Galactose 
Λ Methanol 3147.91 11.01 35µl 100Mm 
HS112 T-HS-peracetylated-
Galactose 
Δ Methanol 3183.93 6.68 21µl 100Mm 
HS118 T-HS-Galactose Λ Medium 2589.75 3.07 11.9ml 100µM 
HS119 T-HS-Galactose Δ Medium 2553.73 1.49 5.8ml 100µM 
B) 
A) 
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Table 9.4 (continued): Class 3a triplex metallohelix complexes with sugar and arene clicked R groups 
structure and stock solution preparation. Representative of R groups Glucose (A) and benzyl (B) 
displayed above. 
  
Compound Compound type Fe Diluent MW Weight 
(mg) 
Volume  Concentration  
HS097 T-HS-
Aceylgalactosamine 
Λ Medium 2676.81 3.02 11.3ml 100µM 
HS098 T-HS-
Aceylgalactosamine 
Δ Medium 2640.78 1.25 4.7ml 100µM 
HS131 T-HS-peracetylated-
Mannose 
Λ Methanol 3057.85 4.01 13.1µl 100Mm 
HS132 T-HS-peracetylated-
Mannose 
Δ Methanol 3057.85 6.84 22.4µl 100Mm 
HS134 T-HS-Mannose Λ Medium 2481.68 4.03 16.2ml 100µM 
HS135 T-HS-Mannose Δ Medium 2463.67 1.25 5.1ml 100Mm 
HS141 T-HS-Benzyl Λ Methanol 2337.71 7.05 30.16µl 100Mm 
HS142 T-HS-Benzyl Δ Methanol 2391.74 2.71 11.3µl 100Mm 
HS145 T-HS-
Aceylglucosamine 
Δ Medium 2640.78 1.45 5.5µl 100mM 
HS146 T-HS-
Aceylglucosamine 
Λ Medium 2658.79 1.15 4.3µl 100mM 
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Class 3a Partially Clicked Alkynes 
 
 
Compound Compound 
type 
Fe Diluent MW Weight 
(mg) 
Volume  Concentration  
HS252 Partially clicked 
arenes based 
on HS142 
Λ Methanol 2154.74 2.60 12.07µl 100mM 
HS253 Partially clicked 
arenes based 
on HS142 
Δ Methanol 2154.74 5.18 24.04µl 100mM 
HS255 Partially clicked 
sugars based 
on HS121 
Λ Medium 2165.71 10.20 47.10ml 100µM 
HS256 Partially clicked 
sugars based 
on HS121 
Δ Medium 2165.71 2.09 9.65ml 100µM 
 
Table 9.5: Class 3a triplex metallohelix complexes with partially clicked alkyne R groups structure and 
stock solution preparation 
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Class 3b 
 
 
 
Table 9.6: Class 3b triplex metallohelix complexes structure and stock solution preparation. 
  
Compound Compound type Fe Diluent MW Weight 
(mg) 
Volume  
(ml) 
Concentration 
(µM)  
RAK435 T-RAK-ALKY Λ Medium 1599.05 1.92 12.01 100 
RAK434 T-RAK-ALKY Δ Medium 1599.05 4.79 29.96 100 
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Class 3C 
 
Compound Compound type Fe Diluent MW Weight 
(mg) 
Volume  Concentration  
HS220 T-HS-Benzyl-
triazol-aldehyde 
Λ Medium 1926.54 3.24 16.82ml  100µM 
HS224 T-HS-Benzyl-
triazol-aldehyde 
Δ Medium 1926.54 3.8 19.72ml 100µM 
HS232 T-HS-
Benzonitrile-
triazol-aldehyde 
Λ Medium 1965.51 6.34 32.26ml  100µM 
HS233 T-HS-
Benzonitrile-
triazol-aldehyde 
Δ Medium 1947.50 5.10 26.19ml  100µM 
HS238 T-HS-
methoxybenzyl-
triazol-aldehyde 
Λ Medium 2016.58 4.34 21.52ml  100µM 
HS239 T-HS-
methoxybenzyl-
triazol-aldehyde 
Δ Medium 2016.58 3.44 17.06ml  100µM 
HS240 T-HS-
fluorobenzyl-
triazol-aldehyde 
Λ Medium 1962.50 3.60 18.34ml  100µM 
HS241 T-HS-
fluorobenzyl-
triazol-aldehyde 
Δ Medium 1962.50 4.79 24.41ml  100µM 
HS244 T-HS-benzoic 
acid-triazol-
aldehyde 
Λ Methanol 2076.52 3.33 16.04µl 100mM 
HS245 T-HS-benzoic 
acid-triazol-
aldehyde 
Δ Methanol 2094.53 2.78 13.27µl 100mM 
 
Table 9.7: Class 3c triplex metallohelix complexes structure and stock solution preparation. Class 3b with 
triazole aldehyde in the place of pyridine. 
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9.2.2 - Analysis of Cell Viability, Apoptotic Induction and Cell Cycle 
Parameters  
Cell lines were exposed to “hit” compounds for 2, 8 and 24 hours and analysis of 
cell viability, induction of apoptosis and effects on cell cycle parameters were 
determined using the NC3000 cytometer, details of which have been described 
elsewhere (see 2.6 seeded as per 2.6.2). For these experiments, drug exposure 
concentrations were dependent upon the dose response curve of the complexes on 
both HCT116 and ARPE-19 cell lines; a single concentration which exert maximal toxic 
effect on the cancerous cell line but did not prove toxic to non-cancerous cells were 
chosen for each 'hit' compound. 
9.2.3 - Drug Localisation Assay  
HCT116 p53+/+ and ARPE-19 cells were seeded at 10,000 cells per well into each of 
the eight chambers of The Falcon™ Chambered Cell Culture Slides (Cat# 10162861). 
These were then incubated for 24 hours (37°C 5% CO2). After 24 hours, the cells were 
exposed to 10µM and 100µM concentrations of compounds containing alkyne groups 
suitable for click conjugation reactions (compounds summarised in table 9.5). 
Corresponding control wells were also treated with media alone or media plus 0.1% 
methanol dependent on the diluent used to dissolve the compound To conduct the 
click reaction, the following reagents were prepared: 
1. Click IT reaction buffer (10 x Tris-buffered saline): 4ml Tris 10x buffer and 36ml 
of ultra-pure distilled water which can be stored at 2-6°C for up to 6 months. 
   
 
Page | 258  
 
 
 
 
2. Alexa Fluor 555 Azide: 200µl of high quality cell culture grade methanol was 
added to 0.5mg MW powder to give a final concentration of 5µM). This can be 
stored at -20°C for up to 12 months.   
3. Click IT reaction additive (sodium ascorbate): A 100mM solution of sodium 
ascorbate in ultra-pure water was freshly prepared on the day of the 
experiment and protected from light as it is prone oxidisation (presenting as a 
light brown liquid). 
After 1-hour drug exposure, the medium was carefully removed, and cells were 
carefully washed with PBS and fixed with 4% paraformaldehyde in PBS for 15 minutes. 
The paraformaldehyde was removed, and cells given one wash in PBS. The cells were 
then permeabilised with 0.1% Triton-X100 in PBS for 5mins and washed once again in 
PBS. To block any unspecific binding, the cells were then washed in 2% BSA in PBS and 
500µl of freshly prepared Click-IT reaction cocktail was then added to each well. The 
Click-IT cocktail consisted of; 3.82ml reaction buffer (1), 100µl (2.5mM) reaction 
additive (3), 6.8µl 555 Alexafluor azide and 80µl CoSO4 100mM aqueous solution. The 
chamber with the Click-IT cocktail are then incubated at room temperature in the 
absence of light for 30 mins. After 30 minutes the cocktail was removed and DAPI 
(1µM) in PBS was added for a further 5 minutes at room temperature and protected 
from light. After 5 minutes the cells were then washed with 2% BSA in PBS followed by 
a further wash in PBS to reduce the BSA causing smear marks on images. Immediately 
after washing, the slides are then mounted with Mounting Medium and coverslips 
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carefully placed on the slides using tweezers to avoid causing air bubbles. The samples 
were processed on the Leica SP5 X laser scanning confocal microscope located at The 
University of Warwick, where the drug localisation investigations were completed. 
Compound  MW Diluent  Classification  
HS138 2340.71 Medium Class 1b alkynes based on 
RAK373 HS139 2322.70 Medium 
HS183 1920.46 Medium Class 3a alkynes based ADF495 
HS186 1920.46 Medium 
HS255 2165.71 Medium Partially clicked sugars based on 
HS121 HS256 2165.71 Medium 
HS252 2154.74 Methanol Partially clicked arenes based on 
HS142 HS253 2154.74 Methanol 
RAK434 1599.05 Medium Class 3b alkyne  
RAK435 1599.05 Medium 
KLB007 2386.00 Methanol Class 1a alkyne based on AKK022 
KLB013 2386.00 Methanol 
 
Table 9.8: Alkyne click compounds used for drug localisation investigation. These compounds were used 
due to their available “click” alkyne ligands to which Alexa Fluor 555 attaches. Concentrations used were 
either 100µM or 10µM as specified in the results section. 
9.2.4 - Autophagy Inhibition Via the Use of 3-Methyladenine (3-MA) 
Because a small number of compounds (ADF495, RAK373, HS220 and HS121) 
induced clearly visible vacuole formation in the cytoplasm, their ability to induce 
autophagy was investigated. These compounds were tested in the absence and 
presence of 3 methyladenine (3-MA) which is an autophagy inhibitor. If autophagy is 
being induced by these compounds leading to cell death, the addition of 3-MA should 
reduce the sensitivity of cells to test compounds in vitro. 96 well plates were seeded as 
per optimum density from the seeding density assay (2.5.2), plated as per section 2.5.3 
and left overnight in the incubator at 37°C 5% CO2 for cells to adhere to the plates. 
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After 24 hours the medium is removed, washed with PBS and replaced with fresh 3-
MA (5mM) supplemented media containing drug solutions covering a range of 
concentration. Control lanes were also treated with 3-MA (5mM). Following a 96-hour 
drug exposure under aerobic conditions, cell survival was determined using the MTT 
assay as described above.  Each experiment was repeated in triplicate and the results 
presented are the mean ± standard deviation n=3 (each individual experiment 
replicated twice). 
9.3 - Results 
9.3.1 - Chemo-Sensitivity Assays 
68 compounds were initially synthesised and evaluated. The results in terms of 
their potency and in vitro selectivity index are presented below. Out of the 68 
compounds tested, only 5 failed to show potency below 10µM. These compounds are 
therefore potent cytotoxic agents with IC50 values that are comparable to the 
platinates. In many cases, sub-micromolar IC50 values were obtained which represents 
a significant increase in potency relative to cisplatin, oxaliplatin and carboplatin in 
particular. Selection of compounds for further analysis based on potency criteria alone 
would have led to a large number of compounds being identified as potential 'hit' 
compounds. From the 68 compounds, several compounds from each class were 
selected based on potency and their in vitro selectivity index. A total of 11 'hit' 
compounds were identified, all of which underwent further investigation. Description 
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of said “hit” compounds and their selection are described in more detail  in the 
corresponding sections. 
9.3.1.1 - Chemosensitivity Studies: Class 1a Compounds 
Within this class of compounds, there are a number of very potent compounds 
displaying IC50 values in the nM range. The most active compound was DHS74 with an 
IC50 of 40 nM (figure 9.2). All compounds tested had IC50 values under 10µM deeming 
them all potent against the colonic adenocarcinoma HCT116 p53+/+ cell line. In 
contrast, the response of ARPE-19 cells was much less with IC50 values ranging from 
23.10µM (KLB016) to 170 nM (DHS74). These results demonstrate that several 
compounds have a good selectivity index in vitro which exceeds that of cisplatin and 
this will be described in more detail once the chemosensitivity data for all the 
compounds tested has been reported. 
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Figure 9.2: Response of HCT116 p53+/+ and ARPE-19 cells following continuous 96-hour exposure to 
novel Class 1a flexicate metallohelix complexes under aerobic conditions. The results are presented in 
both graphical and tabular forms and in both cases, the mean IC50 values ± standard deviations for three 
independent experiments are presented n=3 (each individual experiment replicated twice ). 
IC50 value (µM) ± SD 
Compound HCT116 p53+/+ ARPE-19 
AKK015 0.69 ± 0.08 22.44 ± 2.56 
AKK022 0.17 ± 0.05 6.39 ± 2.36 
SEH531 0.61 ± 0.31 18.69 ± 2.09 
SEH532 1.66 ± 1.05 13.90 ± 1.14 
DHS41 0.50 ± 0.32 1.98 ± 0.45 
DHS42 2.31 ± 1.71 1.94 ± 0.56 
DHS74 0.04 ± 0.001 0.17 ± 0.07 
DHS115 0.12 ± 0.02 0.29 ± 0.10 
DHS101 0.12 ± 0.005 0.29 ± 0.12 
DHS103 0.36 ± 0.02 1.14 ± 0.31 
DHS124 0.33 ± 0.03 0.89 ± 0.46 
DHS105 0.63 ± 0.23 2.37 ± 0.46 
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Figure 9.2 (continued): Response of HCT116 p53+/+ and ARPE-19 cells following continuous 96-hour 
exposure to novel Class 1a flexicate metallohelix complexes under aerobic conditions. The results are 
presented in both graphical and tabular forms and in both cases, the mean IC50 values ± standard 
deviations for three independent experiments are presented n=3 (each individual experiment replicated 
twice). 
9.3.1.2 - Chemosensitivity Studies: Class 1b Compounds. 
This class as with class 1a comprises of 3 potent candidates but with a clear lead 
compound (RAK373) which is at least 5 times more potent than HS183 and HS186. The 
sensitivity of ARPE-19 cells is also significantly less than HCT116 cells, particularly so in 
the case of RAK373 where a very high selectivity index exists (described in greater  
detail later in this chapter). 
 
 IC50 value (µM) ± SD 
DHS128 0.38 ± 0.02 1.07 ± 0.32 
DHS130 0.14 ± 0.004 0.67 ± 0.25 
DHS132 1.03 ± 0.04 6.84 ± 1.57 
DHS134 0.36 ± 0.02 2.26 ± 1.07 
KLB016 3.78 ± 1.07 23.10 ±0.72 
KLB007 8.61 ± 0.38 17.59 ±1.55 
Cisplatin 3.26 ± 0.38 6.41 ± 0.95 
Carboplatin 32.37 ± 11.14 77.73 ± 10.52 
Oxaliplatin 0.93 ± 0.11 3.12 ± 0.28 
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Figure 9.3: Response HCT116 p53+/+ and ARPE-1 cells following continuous 96-hour exposure to novel 
Class 1b flexicate metallohelix complexes in aerobic conditions. The results presented are the mean IC50 
values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice). 
9.3.1.3 - Chemosensitivity Studies: Class 3a Compounds 
Of the three compounds in this class, HS138 proved to exhibit comparatively low 
potency with an IC50 against HCT116 cells of 19.35 ± 1.55µM. ADF495 and HS139 were 
active with IC50 values below 10µM and both compounds showed reduced potency 
against ARPE-19 cells indicating a degree of selectivity for HCT116 cells. 
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 IC50 value (µM) ± SD 
Compound HCT116 p53+/+ ARPE-19 
RAK373 0.36 ± 0.05 33.42 ± 8.25 
HS183 3.96 ± 1.60 32.62 ± 8.49 
HS186 2.06 ± 0.15 25.32 ± 2.52 
Cisplatin 3.26 ± 0.38 6.41 ± 0.95 
Carboplatin 32.37 ± 11.14 77.73 ± 10.52 
Oxaliplatin 0.93 ± 0.11 3.12 ± 0.28 
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Figure 9.4: Response of HCT116 p53+/+ and ARPE-19 cells following continuous 96-hour exposure to 
novel Class 3a triplex metallohelix complexes in aerobic conditions. The results presented are the mean 
IC50 values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice ). 
 
 
 
 
 
 IC50 value (µM) ± SD 
Compound HCT116 p53
+/+
 ARPE-19 
ADF495 0.41 ± 0.01 10.0 ± 1.77 
HS138 19.35 ± 1.55 73.81 ± 13.05 
HS139 2.41 ± 0.60 100.44 ± 4.67 
Cisplatin 3.26 ± 0.38 6.41 ± 0.95 
Carboplatin 32.37 ± 11.14 77.73 ± 10.52 
Oxaliplatin 0.93 ± 0.11 3.12 ± 0.28 
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9.3.1.4 - Chemosensitivity Studies: Class 3a Click Compounds 
This class is not only of interest due to the nature of the compounds which are 
tethered to various ligands including various sugar tethered complexes, but it also 
offers a large number of potent compounds. Out of the 28 investigated, only 4 
compounds have IC50 values above 10µM and these, with the exception for HS098, can 
be excluded based on their potency alone. The rationale of not initially excluding 
HS098 is due to the importance of its structure and very low potency against ARPE-19. 
In discussion with Professor Peter Scott's group in Warwick University, the sugar 
tethered complexes were considered priority compounds and HS098 was not rejected 
after the initial round of testing. In cases where IC50 values of > 100µM were recorded 
in the first round of testing against ARPE19 cells, concentrations of compound were 
increased in order to obtain an IC50 value and therefore obtain an accurate selectivity 
index in vitro. 
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Figure 9.5: Response of HCT116 p53+/+ and ARPE-19, following continuous 96-hour exposure to novel 
Class 3a sugar and arene clicked triplex metallohelix complexes. The results presented are the mean IC50 
values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice ). 
 IC50 value (µM) ± SD 
Compound HCT116 p53+/+ ARPE-19 
HS130 1.00 ± 0.19 6.88 ± 1.2 
HS103 1.94 ± 0.84 25.37 ± 1.94 
HS093 2.12 ± 2.17 2.94 ± 0.31 
HS085 3.13 ± 0.47 59.60 ± 5.60 
HS094 0.73 ± 0.30 3.08 ± 0.15 
HS095 2.25 ± 0.96 76.14 ± 3.66 
HS100 1.63 ± 1.13 8.75 ± 0.63 
HS104 10.15 ± 2.12 72.23 ± 10.52 
HS089 3.53 ± 0.18 5.44 ± 3.01 
HS090 9.52 ± 0.10 63.17 ± 8.08 
HS120 1.05 ± 0.51 11.64 ± 1.98 
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 IC50 value (µM) ± SD 
Compound HCT116 p53+/+ ARPE-19 
HS121 2.69 ± 1.71 115.55 ± 19.28 
HS136 0.74 ± 0.08 10.18 ± 1.21 
HS137 4.54 ± 0.31 101.12 ± 12.91 
HS111 3.6 ± 0.23 11.04 ± 3.25 
HS112 10.7 ± 0.74 65.45 ± 1.44 
HS118 0.63 ± 0.02 2.96 ± 0.19 
HS119 1.68 ± 0.04 59.68 ± 5.44 
HS097 12.16 ± 0.74 79.64 ± 10.67 
HS098 10.62 ± 5.42 315.35 ± 29.78 
HS131 3.28 ± 0.28 13.35 ± 5.85 
HS132 9.93 ± 0.92 57.9 ± 6.31 
HS134 0.72 ± 0.08 8.22 ± 0.19 
HS135 5.42 ± 1.16 89.31 ± 2.43 
HS141 0.91 ± 0.28 8.82 ± 1.04 
HS142 2.16 ± 0.97 65.58 ± 6.82 
HS145 2.08 ± 0.08 77.73 ± 5.28 
HS146 1.56 ± 0.23 16.56 ± 5.76 
Cisplatin 3.26 ± 0.38 6.41 ± 0.95 
Carboplatin 32.37 ± 11.14 77.73 ± 10.52 
Oxaliplatin 0.93 ± 0.11 3.12 ± 0.28 
 
Figure 9.5 (continued): Response of HCT116 p53+/+ and ARPE-19, following continuous 96-hour 
exposure to novel Class 3a sugar and arene clicked triplex metallohelix complexes. The results presented 
are the mean IC50 values ± standard deviations for three independent experiments n=3 (each individual 
experiment replicated twice ). 
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9.3.1.5 - Chemosensitivity Studies: Class 3a Partially Clicked Alkyne 
Compounds 
These compounds were initially synthesised for the use in the drug localisation 
assay (section 6.2.3) as they have an alkyne click to which the fluorescent dye attaches 
to. They do however display favourable potency. 
 
Figure 9.6: Response of HCT116 p53+/+ and ARPE-19 cells following continuous 96-hour exposure to 
novel Class 3a partially alkyne clicked triplex metallohelix complexes in aerobic conditions. The results 
presented are the mean IC50 values ± standard deviations for three independent experiments n=3 (each 
individual experiment replicated twice). 
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HCT116 p53+/+ ARPE-19
 IC50 value (µM) ± SD 
Compound HCT116 p53+/+ ARPE-19 
HS252 2.51 ± 0.29 11.42 ± 4.51 
HS253 2.29 ± 0.68 11.82 ± 3.93 
HS255 1.56 ± 0.91 9.22 ± 3.26 
HS256 1.22 ± 0.94 9.12 ± 1.19 
Cisplatin 3.26 ± 0.38 6.41 ± 0.95 
Carboplatin 32.37 ± 11.14 77.73 ± 10.52 
Oxaliplatin 0.93 ± 0.11 3.12 ± 0.28 
   
 
Page | 270  
 
 
 
 
9.3.1.6 - Chemosensitivity Studies:  Class 3b Partially Clicked Alkyne 
Compounds 
This group has less potent compounds than the previous groups with one 
compound (RAK434) displaying an IC50 value above 10µM.  The values on the 
cancerous and non-cancerous cell lines are also very close demonstrating that the 
selectivity of these compounds is poor. 
 
 IC50 value (µM) ± SD 
Compound HCT116 p53+/+ ARPE-19 
RAK435 5.28 ± 0.49 10.75 ± 3.14 
RAK434 10.02 ± 3.32 13.35 ± 4.95 
Cisplatin 3.26 ± 0.38 6.41 ± 0.95 
Carboplatin 32.37 ± 11.14 77.73 ± 10.52 
Oxaliplatin 0.93 ± 0.11 3.12 ± 0.28 
 
Figure 9.7: Response of HCT116 p53+/+ and ARPE-19 cells following continuous 96-hour exposure to 
novel Class 3b triplex metallohelix complexes in aerobic conditions. The results presented are the mean 
IC50 values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice). 
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9.3.1.7 - Chemosensitivity Studies: Class 3C Compounds 
This class hosts extremely potent compounds against HCT116 p53+/+ cells with only 
one compound displaying an IC50 value above 0.5µM (HS245). In general, potency 
against ARPE19 cells was less with IC50 values generally being in the µM range. 
 
 IC50 value (µM) ± SD 
Compound HCT116 p53+/+ ARPE-19 
HS220 0.19 ± 0.01 0.97 ± 0.25 
HS224 0.32 ± 0.14 6.31 ± 0.78 
HS232 0.20 ± 0.02 1.83 ± 0.80 
HS233 0.35 ± 0.20 9.88 ± 3.82 
HS238 0.20 ± 0.01 2.22 ± 0.58 
HS239 0.23 ± 0.02 7.97 ± 1.18 
HS240 0.20 ± 0.01 1.92 ± 0.43 
HS241 0.41 ± 0.30 6.89 ± 1.94 
HS244 0.30 ± 0.10 0.72 ± 0.11 
HS245 1.72 ± 0.07 3.05 ± 1.29 
Cisplatin 3.26 ± 0.38 6.41 ± 0.95 
Carboplatin 32.37 ± 11.14 77.73 ± 10.52 
Oxaliplatin 0.93 ± 0.11 3.12 ± 0.28 
Figure 9.8: Response of HCT116 p53+/+ and ARPE-19 cells following continuous 96-hour exposure to 
novel Class 3c triplex metallohelix complexes in aerobic conditions. The results presented are the mean 
IC50 values ± standard deviations for three independent experiments n=3 (each individual experiment 
replicated twice). 
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9.3.1.8 - Selectivity Indices In Vitro: Class 1a Compounds 
Using the IC50 values presented above, the selectivity index for all the class 1a 
compounds tested was determined. Of all the compounds tested, only one compound 
(DHS42) displays a selectivity index below 1 highlighting how selective these 
compounds are. AKK022 displays the greatest selectivity and potency of these 
compounds and is over four times more potent than AKK015 an SEH531. 
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Figure 9.9: Selectivity of novel Class 1a flexicate metallohelix complexes. The selectivity index is defined 
as the mean IC50 ARPE-19 cells divided by the IC50 for HCT116 p53
+/+ cells. Values greater than 1 indicate 
that compounds have selectivity for cancer cells as opposed to non-cancer cells. As the mean IC50 values 
are used to calculate selectivity indices, no error bars are included on the graphs. This legend applies to 
all the figures reporting selectivity indices below. 
Compound Selectivity Index 
AKK015 32.52 
AKK022 37.59 
SEH531 30.64 
SEH532 8.37 
DHS41 3.96 
DHS42 0.84 
DHS74 4.25 
DHS115 2.42 
DHS101 2.42 
DHS103 3.17 
DHS124 2.70 
DHS105 3.76 
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Figure 9.9 (continued): Selectivity of novel Class 1a flexicate metallohelix complexes. The selectivity 
index is defined as the mean IC50 ARPE-19 cells divided by the IC50 for HCT116 p53
+/+
 cells. Values greater 
than 1 indicate that compounds have selectivity for cancer cells as opposed to non-cancer cells. As the 
mean IC50 values are used to calculate selectivity indices, no error bars are included on the graphs. This 
legend applies to all the figures reporting selectivity indices below. 
 
 
 
 
 
 
 
 
 
Compound Selectivity Index 
DHS128 2.82 
DHS130 4.79 
DHS132 6.64 
DHS134 6.28 
KLB016 6.11 
KLB007 2.04 
Cisplatin 1.97 
Carboplatin 2.40 
Oxaliplatin 3.35 
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9.3.1.9 - Selectivity Indices In Vitro: Class 1b 
As with the potency profile RAK373 is far superior and displays the highest 
selectivity index of all the compounds of 92.83. 
 
 
 
 
 
 
 
Figure 9.10: Selectivity of novel Class 1b flexicate metallohelix complexes. 
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9.3.1.10 - Selectivity Indices In Vitro: Class 3a 
ADF495 and HS139 display superior selectivity and their role as unclicked 3a 
compounds can give real insight to the effects of tethering the complexes. 
 
 
 
 
 
 
 
Figure 9.11: Selectivity of novel Class 3a triplex metallohelix complexes. 
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9.3.1.11 - Selectivity Indices In Vitro: Class 3a Click 
This class of compounds displayed mixed selectivity profiles with HS145, HS142, 
HS098, HS119, HS121 and HS095 displaying the highest selectivity values.  
 
Figure 9.12: Selectivity of novel Class 3a sugar and arene clicked triplex metallohelix complexes. 
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Figure 9.12 (continued): Selectivity of novel Class 3a sugar and arene clicked triplex metallohelix 
complexes. 
 
 
Compound Selectivity Index 
HS103 6.88 
HS093 13.08 
HS085 1.39 
HS094 19.04 
HS095 4.22 
HS100 33.84 
HS104 5.37 
HS089 7.12 
HS090 1.54 
HS120 6.64 
HS121 11.09 
HS136 42.96 
HS137 13.76 
HS111 22.27 
HS112 3.07 
HS118 6.12 
HS119 4.70 
HS097 35.52 
HS098 6.55 
HS131 29.69 
HS132 4.07 
HS134 5.83 
HS135 11.42 
HS141 16.48 
HS142 9.69 
HS145 30.36 
HS146 37.37 
Cisplatin 1.97 
Carboplatin 2.40 
Oxaliplatin 3.35 
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9.3.1.12 - Selectivity Indices In Vitro: Class 3a Partially Clicked Alkynes 
These compounds were synthesized as alkyne click compounds for drug 
localization assays, they show selectivity index values of between 4-8, which in 
comparison to other leads fairs poorly. 
 
 
 
 
 
 
 
Figure 9.13: Selectivity of novel Class 3a partially alkyne clicked triplex metallohelix complexes. 
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9.3.1.13 - Selectivity Indices In Vitro: Class 3b 
This class of compounds displays low selectivity and potency and are therefore 
undesirable complexes for further chemo-toxicity investigation. 
 
 
 
 
 
 
 
Figure 9.14: Selectivity of novel Class 3b triplex metallohelix complexes. 
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9.3.1.14 - Selectivity Indices In Vitro: Class 3c  
This class of compounds shows a varied selectivity with HS239 displaying the 
highest selectivity. 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.15: Selectivity of novel Class 3c triplex metallohelix complexes. 
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9.3.2 - Comparison of “hit” Novel Metal NHC Complexes to Platinum Standard 
Complex 
9.3.2.1 - Chemosensitivity Data In Vitro: Comparison to Platinates  
The IC50 values of the selected leads are displayed in figure 9.16 with the IC50 values 
of the platinum standards as a comparative platform. All the “hit” compounds display 
greater potency than carboplatin and only two compounds HS098 and HS135 
displaying reduced potency compared to cisplatin. Oxaliplatin is considered a highly 
potent standard yet four of the eleven “hit compounds” display greater potency. 
 
Figure 9.16: Comparison of the potency of novel metallohelix complexes to cisplatin, carboplatin and 
oxaliplatin in cancerous HCT116 p53
+/+
 and non-cancerous ARPE-19 cell lines. The values presented are 
the mean IC50 values ± standard deviation of three independent experiments n=3 (each individual 
experiment replicated twice). 
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9.3.2.2 - Selectivity Indices In Vitro: Comparison to Platinates 
 
Figure 9.17: Comparison of the selectivity of novel metal NHC compounds cells to cisplatin, carboplatin 
and oxaliplatin.  The selectivity index is defined as the mean IC50 for ARPE-19 cells divided by the IC50 of 
HCT116 p53+/+. Values greater than 1 indicate that compounds have selectivity for cancer cells as 
opposed to non-cancer cells. As the mean IC50 values are used to calculate selectivity indices, no error 
bars are included on the graphs. 
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9.3.3 - Response of HCT116 Cells to Cisplatin, Carboplatin and Oxaliplatin: 
P53 Dependency 
The HCT116 p53+/+ and HCT116 p53-/- cells are isogenic colorectal carcinoma cells 
that differ only with regards to their p53 status. The relationship between p53 status 
and the response of cells to the “hit” metallohelix complexes is presented in table 9.9 
and illustrated graphically in figure 9.18. With all the lead compounds the loss of p53 
causes a significant reduction in potency with the exception of HS142 which is 
equitoxic to both cell lines. The degree of resistance to test compounds in the HCT116 
p53-/- cell line is greater than that observed with the platinum compounds.  
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IC50 (µM) 
Compound HCT116 p53+/+ HCT116 p53-/- p-value 
ADF495 0.41 ± 0.01 4.7 ± 0.43 0.42 
HS121 2.69 ± 1.71 11.46 ± 2.15 0.0083 
HS139 2.41 ± 0.6 3.36 ± 0.15 0.12 
HS119 1.68 ± 0.04 7.25 ± 0.57 0.0033 
HS135 5.42 ± 1.16 26.89 ± 4.82 0.014 
HS098 10.62 ± 5.42 >100 0.00030 
HS145 2.08 ± 0.08 29.99 ± 4.88 0.010 
RAK373 0.36 ± 0.05 12.74 ± 3.32 0.089 
HS142 2.16 ± 0.97 3.31 ± 0.28 0.0082 
HS239 0.23 ± 0.02 1.46 ± 0.56 0.069 
AKK022 0.17 ± 0.05 2.07 ± 0.17 0.30 
Cisplatin 3.26 ± 0.38 7.52 ± 0.65 0.0035 
Carboplatin 32.37 ± 11.14 35.7 ± 9.06 0.25 
Oxaliplatin 0.93 ± 0.11 6.44 ± 1.05 0.086 
Table 9.9: Comparison of IC50 values ± SD of “hit” metallohelix and platinate compounds towards p53
+/+ 
and p53
−/− 
isogenic clones of HCT116 human colorectal epithelial cancer cells. Data generated by 
triplicated MTT assays completed on consecutive days n=3 (each individual experiment replicated 
twice). Statistical analysis was performed using a student’s t-test where values <0.05 indicates a 
statistically significant difference between IC50 values HCT116 p53
+/+ and HCT116 p53-/-cell lines. 
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Figure 9.18: Comparison of IC50 values ± SD of “hit” metallohelix compounds and platinum compounds 
towards p53+/+ and p53−/− isogenic clones of HCT116 cancer cells. Data generated by triplicated MTT 
assays completed on consecutive days n=3 (each individual experiment replicated twice). The data for 
HS098 is not included in this figure with the IC50 on the HCT116 p53
-/- cell line being over the maximum 
concentration tested (100µM). 
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9.3.4 - Response of Cancer Cells Following Continuous Exposure to Novel 
Metallohelices Under Pseudo-Hypoxic Conditions 
The response of HCT116 p53+/+ cells to potent and selective sugar tethered triplex 
metallohelix complexes under aerobic and pseudo-hypoxic conditions is presented in 
figures 9.18 - 9.25. HS139 which is the parent compound to HS121 minus the glucose 
tether acts as a comparison to the sugar tethered compounds to investigate if the 
addition of various sugars effects the chemosensitivity of compounds under varying 
conditions. These pseudo-hypoxic investigations are the beginning of investigations 
into the role of the sugar moiety in these potent and selective compounds. The results 
demonstrate that pseudo-hypoxic conditions result in increased resistance to the 
metallohelix compounds. The non-sugar tethered complexes HS139 is less active under 
pseudo-hypoxic conditions but it display a lesser shift in potency compared to the 
sugar tethered complexes.  
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IC50 (µM) 
Compound HCT116 p53+/+ 
Aerobic 
HCT116 p53+/+ 
Pseudo-hypoxic 
p-value 
HS139 2.41 ± 0.6 87.99 ± 16.16 0.011 
HS121 2.69 ± 1.71 53.15 ± 7.09 0.013 
HS119 1.68 ± 0.04 58.34 ± 15.14 0.023 
HS135 5.42 ± 1.16 58.44 ± 14.44 0.024 
HS098 10.62 ± 5.42 >100 0.00025 
HS145 2.08 ± 0.08 56.28 ± 12.45 0.017 
HS142 2.16 ± 0.97 21.59 ± 2.32 0.0052 
Cisplatin 3.26 ± 0.38 6.83 ± 2.12 0.095 
Carboplatin 32.37 ± 11.14 >100 0.0089 
Oxaliplatin 0.93 ± 0.11 1.53 ± 0.52 0.14 
Table 9.18b: Comparison of IC50 values ± SD of “hit” metallohelix and platinate compounds towards 
p53+/+ human colorectal epithelial cancer cells in aerobic and pseudo-hypoxic condtions. Data generated 
by triplicated MTT assays completed on consecutive days n=3 (each individual experiment replicated 
twice). Statistical analysis was performed using a student’s t-test where values <0.05 indicates a 
statistically significant difference between IC50 values HCT116 p53
+/+ in aerobic and pseudo-hypoxic 
conditions. 
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Figure 9.19: Dose response curves of HS139 class 3a triplex towards HCT116
+/+
 cell lines in both pseudo-
hypoxic and aerobic conditions. Data from three independent MTT assays and are represented by the 
mean ± SE n=3 (each individual experiment replicated twice). The percentage cell survival values are 
expressed as a percentage of viable cells compared with untreated controls. 
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Figure 9.20: Dose response curves of HS121 class 3a glucose click triplex towards HCT116+/+ cell lines in 
both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays and are 
represented by the mean ± SE n=3 (each individual experiment replicated twice). The percentage cell 
survival values are expressed as a percentage of viable cells compared with untreated controls. 
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Figure 9.21: Dose response curves of HS119 class 3a galactose click triplex towards HCT116
+/+
 cell lines 
in both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays and are 
represented by the mean ± SE n=3 (each individual experiment replicated twice). The percentage cell 
survival values are expressed as a percentage of viable cells compared with untreated controls. 
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Figure 9.22: Dose response curves of HS135 class 3a mannose click triplex towards HCT116+/+ cell lines in 
both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays and are 
represented by the mean ± SE n=3 (each individual experiment replicated twice). The percentage cell 
survival values are expressed as a percentage of viable cells compared with untreated controls. 
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Figure 9.23: Dose response curves of HS098 class 3a acetyl-galactosamine click triplex towards 
HCT116+/+ cell lines in both pseudo-hypoxic and aerobic conditions. Data from three independent MTT 
assays and are represented by the mean ± SE n=3 (each individual experiment replicated twice). The 
percentage cell survival values are expressed as a percentage of viable cells compared with untreated 
controls. 
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Figure 9.24: Dose response curves of HS145 class 3a acetyl-glucosamine click triplex towards HCT116+/+ 
cell lines in both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays and 
are represented by the mean ± SE n=3 (each individual experiment replicated twice). The percentage 
cell survival values are expressed as a percentage of viable cells compared with untreated controls. 
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Figure 9.25: Dose response curves of HS142 class 3a benzyl click triplex towards HCT116
+/+
 cell lines in 
both pseudo-hypoxic and aerobic conditions. Data from three independent MTT assays and are 
represented by the mean ± SE n=3 (each individual experiment replicated twice). The percentage cell 
survival values are expressed as a percentage of viable cells compared with untreated controls. 
9.3.5 - Analysis of Induced Apoptosis, Reduction in Cell Viability and Cell 
Cycle Arrest 
To gain further insight into the mechanism in which these novel “hit” compounds 
exert their activity, their effect on (i) cell viability, (ii) the induction of apoptosis and 
(iii) cell cycle parameters was investigated using the NC3000 cytometer. Description of 
the assays and the interpretation of the resulting data is explained in chapter 3. The 
measurements were taken after 24-hour exposures which was informed by previous 
cisplatin investigations deeming this an appropriate time interval to a) have optimal 
cell numbers for the experimental procedures b) measure initiation of apoptosis (if 
present) and c) observe cell cycle disruption (if initiated).  The working concentrations 
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for the novel “hit” compounds were determined from the dose response curve for 
both HCT116 p53+/+ and ARPE-19. The concentration at which maximal effect on 
HCT116 p53+/+ cells but had minimal effect on ARPE-19 cells was determined and 
identified as the working concentration (figure 9.26, summary of all concentrations 
displayed in table 9.10). A number of these working concentrations were similar to the 
compounds IC50 value but some compounds such as HS119 display a marked difference 
in drug response therefore higher concentrations were selected. Throughout this 
section, the compounds are split by their diluent as some were dissolved in methanol 
and in medium resulting in the requirement of separate control samples. 
 
Figure 9.26: Drug response of both HCT116 p53+/+ cells ARPE-19 cells to HS119. The optimum working 
concentration selected for NC3000 investigations is illustrated by the arrows which show the dose 
where major cell kill occurs in HCT116 cells, but minimal effects are present in the ARPE-19 cells. 
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Table 9.10: Working concentrations identified for each “hit” compound based on dose response curves 
as explained in figure 9.26.  
9.3.5.1 - Viability Assay and Microscope Images 
The effect of 24-hour drug exposure with the selected “hit” compounds was 
investigated using a viability assay which not only provides an accurate cell count but 
also measures the viability of the cell population measured. This was completed on 
both HCT116 p53+/+ cells and ARPE-19 cells. The cell viability (tables 9.11, 9.13, 9.12 
and 9.14 respectively) overall remains consistent and does not drop below 80% 
viability. Relatively small variations on cell number were observed across the panel of 
compounds tested with the largest reduction in cell number being seen in HS119 
treated cultures (figures 9.27 and 9.28). Figures 9.29 and 9.30 demonstrate the visual 
effects of the novel compounds after 24-hour exposure. The main observations being 
the presence of potential autophagic vacuoles in HCT116 p53+/+ samples treated with 
Compound HCT116 p53
+/+ 
IC50 (µM)
 
Working concentration (µM)
 
ADF495 0.41 ± 0.01 0.4 
HS121 2.69 ± 1.71 3 
HS139 2.41 ± 0.6 20 
HS119 1.68 ± 0.04 10 
HS135 5.42 ± 1.16 20 
HS098 10.62 ± 5.42 11 
HS145 2.08 ± 0.08 20 
RAK373 0.36 ± 0.05 0.4 
HS142 2.16 ± 0.97 10 
HS239 0.23 ± 0.02 0.3 
AKK022 0.17 ± 0.05 0.4 
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ADF495, HS139 and AKK022. Furthermore, cells treated with HS098 had a very 
different morphology compared to controls (figure 9.29). 
Sample Total cells in sample Percentage cell viability 
Control 3.80 x 106 89.3 
HS139 2.48 x 106 90.6 
ADF495 3.64 x 10
6
 87.3 
HS121 3.12 x 106 88.5 
HS119 1.56 x 10
6
 80.8 
HS135 1.89 x 106 88.1 
HS098 2.96 x 106 87.7 
HS145 3.04 x 106 87.6 
HS239 2.27 x 106 90.6 
 
Table 9.11: Viability assay data of   water soluble metallohelices on HCT116 p53
+/+ 
cells after 24 hours 
exposure. The viability is presented as a percentage and an accurate cell count calculated based on the 
entire population which is stained with Acridine Orange and non-viable cells stained by 4',6-diamidino-2-
phenylindole (DAPI) (n=1). 
Sample Total cells in sample Percentage cell viability 
Control 1.31 x 106 94.0 
HS139 6.2 x 105 94.8 
ADF495 1.08 x 106 93.9 
HS121 1.19 x 106 95.5 
HS119 5.02 x 105 92.2 
HS135 9.84 x 10
5
 94.2 
HS098 1.11 x 106 95.4 
HS145 1.15 x 106 95.9 
HS239 1.22 x 10
6
 92.2 
 
Table 9.12: Viability assay data of   water soluble metallohelices on non-cancerous ARPE-19 cells after 
24 hours exposure. The viability is presented as a percentage and an accurate cell count calculated 
based on the entire population which is stained with Acridine Orange and non-viable cells stained by 
4',6-diamidino-2-phenylindole (DAPI) (n=1). 
 
   
 
Page | 299  
 
 
 
 
 
Figure 9.27: The influence of water soluble metallohelices on the cell number of both cancerous HCT116 
p53+/+ cells and non-cancerous ARPE-19 cells after 24-hour exposure (n=1). 
 
Table 9.13: Viability assay data of methanol soluble metallohelices on HCT116 p53+/+ cells after 24 hours 
exposure. The viability is presented as a percentage and an accurate cell count calculated based on the 
entire population which is stained with Acridine Orange and non-viable cells stained by 4',6-diamidino-2-
phenylindole (DAPI) (n=1). 
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Table 9.14: Viability assay data of   methanol soluble metallohelices on non-cancerous ARPE-19 cells 
after 24 hours exposure. The viability is presented as a percentage and an accurate cell count calculated 
based on the entire population which is stained with Acridine Orange and non-viable cells stained by 
4',6-diamidino-2-phenylindole (DAPI) (n=1). 
 
 
Figure 9.28: The influence of methanol soluble metallohelices on the cell number of both HCT116 p53
+/+ 
cells and ARPE-19 cells after 24-hour exposure (n=1). 
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Figure 9.29: Microscope images of colorectal adenocarcinoma HCT116 p53+/+ cells after 24-hour 
exposure to a number of novel metallohelix compounds.  
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Figure 9.30: Microscope images of colorectal adenocarcinoma non-cancerous retinal epithelial ARPE-19 
cells after 24-hour exposure to a number of novel metallohelix compounds. 
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9.3.5.2 - Annexin V Assay 
As previously discussed in section 2.6.5 this assay detects the induction of 
apoptosis via the expression of annexin V an apoptotic marker protein. Displayed in 
figures 9.31 – 9.38 it can be observed there is no significant induction of apoptosis in 
either HCT116 p53+/+ and ARPE-19 cells across the panel of compounds tested. There is 
a slight increase in the non-viable cells for compounds 
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Figure 9.31: Summary of annexin V assay on HCT116 p53
+/+
 cells after exposure to media soluble 
metallohelix compounds after 24-hour exposure (n=1). 
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Figure 9.32: Summary of annexin V assay on non-cancerous ARPE-19 cells after exposure to media 
soluble metallohelix compounds after 24-hour exposure (n=1). 
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Control RAK373 HS142 AKK022 
Healthy 97 96 97 94 
Apoptotic 1 1 1 2 
Late apoptotic/ 
necrotic 
1 1 1 1 
None viable  1 2 1 3 
 
Figure 9.33: Summary of annexin V assay on HCT116 p53
+/+
 cells after exposure to Methanol soluble 
metallohelix compounds after 24-hour exposure (n=1). 
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Figure 9.34: Summary of annexin V assay on non-cancerous r ARPE-19 cells after exposure to Methanol 
soluble metallohelix compounds after 24-hour exposure (n=1). 
9.3.5.3 - Mitochondrial Potential Assay 
The use of an additional apoptotic assay is always recommended due to the lack of 
specificity of most apoptotic assays to apoptosis alone. The loss of mitochondrial 
membrane potential is known to precede apoptosis and will further validate the 
previous apoptotic investigations.  Overall the healthy portion of the cells remains 
consisted with only slight increases in apoptotic and necrotic cell populations 
observed.  
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Figure 9.35: measurement of mitochondrial potential on HCT116 p53+/+ cells following 24-hour exposure 
to water soluble novel metallohelices to investigate the presence of apoptotic induction (n=1). 
 
0
10
20
30
40
50
60
70
80
90
100
Control ADF495 HS121 HS139 HS119 HS135 HS098 HS145 HS239
%
 c
el
l p
o
p
u
al
ti
o
n
  
Necrotic Apoptotic Healthy
Control ADF 
495 
HS 
121 
HS 
139 
HS 
119 
HS 
135 
HS 
098 
HS 
145 
HS 
239 
Healthy  91 93 83 94 94 91 96 93 95 
Apoptotic 7 2 14 3 2 2 1 2 2 
Necrotic  2 5 3 3 4 7 3 5 3 
   
 
Page | 308  
 
 
 
 
 
 
Figure 9.36: Measurement of mitochondrial potential on non-cancerous retinal epithelial ARPE-19 cells 
following 24-hour exposure to water soluble novel metallohelices to investigate the presence of 
apoptotic induction (n=1). 
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Control RAK373 HS142 AKK022 
Healthy  86 89 82 82 
Apoptotic 8 4 16 4 
Necrotic  5 7 2 14 
 
Figure 9.37: measurement of mitochondrial potential on HCT116 p53+/+ cells following 24-hour exposure 
to Methanol soluble novel metallohelices to investigate the presence of apoptotic induction (n=1). 
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Figure 9.38: measurement of mitochondrial potential on non-cancerous ARPE-19 cells following 24-hour 
exposure to water soluble novel metallohelices to investigate the presence of apoptotic induction (n=1). 
9.3.5.4 - Cell Cycle Assay 
To investigate if these novel metallohelices induce a cell cycle arrest, cells were 
treated with test compound (at previously determined working concentrations, table 
9.10) for 24 hours and the cell cycle was performed as described in section 2.6.6.   The 
cell cycle assay was completed by quantifying DNA, allowing identification of specific 
cell cycle phases.  Overall slight variations are observed across the compounds with the 
only marked differences seen with HS135 which increases the cell population within 
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the S phase on HCT116 p53+/+ cells but not in ARPE-19 cells. HS139 also causes a small 
increase in the S phase in the ARPE-19 but not the HCT116 p53+/+ cells. 
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Figure 9.39: Effects of exposure to novel water soluble metallohelices on HCT116 p53+/+ cell cycle 
distribution after 24-hour exposure. Determination of cell cycle phase based on DNA intensity of DAPI 
stained cells (n=1). 
 
0
10
20
30
40
50
60
70
80
90
100
Control ADF495 HS121 HS139 HS119 HS135 HS098 HS145 HS239
%
 c
el
l p
o
p
u
al
ti
o
n
  
G2/M S phase G0/G1 Sub G0 /apoptotic
   
 
Page | 312  
 
 
 
 
 
 
Figure 9.40: Effects of exposure to novel water soluble metallohelices on non-cancerous ARPE-19 cell 
cycle distribution after 24-hour exposure. Determination of cell cycle phase based on DNA intensity of 
DAPI stained cells (n=1). 
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Figure 9.41: Effects of exposure to novel methanol soluble metallohelices on HCT116 p53+/+ cell cycle 
distribution after 24-hour exposure. Determination of cell cycle phase based on DNA intensity of DAPI 
stained cells (n=1). 
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Figure 9.42: Effects of exposure to novel methanol soluble metallohelices on non-cancerous retinal 
epithelial ARPE-19 cell cycle distribution after 24-hour exposure. Determination of cell cycle phase 
based on DNA intensity of DAPI stained cells (n=1). 
 
9.3.6 - Autophagy Inhibition Via the Use of 3-Methyladenine (3-MA) 
From visual observations (figure 9.29) made mainly during NC3000 cytometer 
studies, potential autophagic vacuoles were seen thereby prompting studies to 
investigate the potential role of autophagy in the cytotoxic activity exerted by the 
compounds. Selected compounds were tested in the presence an absence of the 
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autophagy inhibitor 3-MA to determine if IC50 values are reduced. The results in figure 
9.43 demonstrate that potency is reduced in the presence of 3-MA suggesting that 
autophagy plays a role in the mechanism of action of these compounds.  
 
Average IC50 (µM) ± SD  
Compound Drug alone +3-MA 5mM Fold reduction  
ADF495 0.41±0.01 2.61±0.8 6-fold 
RAK373 0.36±0.05 7.46±1.11 20-fold 
HS121 2.69±1.71 6.61±1.28 2.4-fold 
 
Figure 9.43: Comparison of IC50 values ± SD of “hit” metallohelix compounds towards HCT116 p53+/+ ± 
3-MA. Data generated by triplicated MTT assays completed on consecutive days n=3 (each individual 
experiment replicated twice). 
 
9.3.7 - Drug Localisation Determination by Confocal Laser Microscopy 
To gain insight into the mechanism of these novel compounds a number of 
compounds which possess an alkyne click region were tagged with a complimentary 
fluorescent dye (Alexafluor 555) which helps visualise where the compounds localise in 
0.1
1
10
ADF495 RAK373 HS121
IC
5
0
 v
al
u
e 
(µ
M
) 
drug alone
5mM 3-MA
   
 
Page | 316  
 
 
 
 
the cells. Specific localisation within organelles would help guide future studies 
designed to explore mechanism(s) of action. To validate the assay and to discount any 
unspecific binding, control samples were processed for both the media soluble and 
methanol soluble compounds (displayed in 9.3.7.1). Only the DAPI stained nucleus are 
present with no visible red light which attach to the drug.  
A sample of the confocal images are displayed in figures 9.44 to 9.48 which clearly 
demonstrate that the compounds are able to enter the cell within a one-hour drug 
exposure. The compounds do not seem to localise into specific sites within the cell but 
appear to be present throughout the cytoplasm and the nucleus. There are variations 
to this general statement and these are described in each specific case presented 
below. 
9.3.7.1 - Control  
Cells were stained with DAPI (blue) and Alexafluor 555 (red) and only the nuclei of 
cells appear blue with no red staining apparent. This is the same for both media and 
methanol controls. 
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A) Media alone 
 
B) 0.1% (v/v) methanol 
 
 
Figure 9.44: Untreated media and methanol control HCT116 p53+/+ and ARPE-19 cells stained with 4',6-
Diamidino-2-Phenylindole, Dihydrochloride (DAPI) and Alexafluor reactive dye. 
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9.3.7.2 - HS138 
In general terms, positive staining is observed in both the nucleus and cytoplasm of 
cells indicating that HS138 is able to penetrate into cells. There does not appear to be 
a significant difference in the staining pattern between HCT116 and ARPE-19 cells 
although there is some evidence of punctate staining in ARPE-19 cells suggesting some 
localisation to regions of unknown identity.   
 
 
Figure 9.45: Confocal scanning microscope images of HCT116 p53
+/+
 and ARPE-19 cells treated with 
100μm HS138 for 1 hour. Samples stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) 
staining the nucleus blue and Alexafluor reactive dye (red). 
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9.3.7.3 - RAK434 
Strong positive staining is observed in both the cytoplasm of cells but less staining 
in the nucleus. These results demonstrate that RAK434 is able to penetrate into cells. 
There does not appear to be a significant difference in the staining pattern between 
HCT116 and ARPE-19 cells. There is however clear evidence of the formation of 
vacuoles in the cytoplasm of both cells following treatment with RAK434.    
 
 
Figure 9.46: Confocal scanning microscope images of HCT116 p53
+/+
 and ARPE-19 cells treated with 
100μM RAK434 for 1 hour. Samples stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) 
staining the nucleus blue and Alexafluor reactive dye (red). 
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9.3.7.4 - HS255 
Positive staining is observed in both the nucleus and cytoplasm of cells indicating 
that HS255 is able to penetrate into cells. The intensity of red staining in ARPE-19 cells 
is less than that in HCT116 p53+/+ cells suggesting that selective uptake may be 
occurring. 
 
 
Figure 9.47: Confocal scanning microscope images of HCT116 p53+/+ and ARPE-19 cells treated with 
100μM HS255 for 1 hour. Samples stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) 
staining the nucleus blue and Alexafluor reactive dye (red). 
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9.3.7.5 - HS252 
In general, positive staining is observed in both the nucleus and cytoplasm of cells 
indicating that HS138 is able to penetrate into cells. There does not appear to be a 
significant difference in the staining pattern between HCT116 p53+/+ and ARPE-19 cells.   
 
 
Figure 9.48: Confocal scanning microscope images of HCT116 p53+/+ and ARPE-19 cells treated with 
100μM HS252 for 1 hour. Samples stained with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) 
staining the nucleus blue and Alexafluor reactive dye (red). 
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9.3.8 - In Vivo Investigation of “hit” Compounds 
Based on their potency and selectivity in vitro, ADF495, HS121 and RAK373 were 
selected for evaluation against human tumour xenografts in vivo.  These studies were 
conducted by Dr. Steve Shnyder at the University of Bradford and are reported here to 
demonstrate that the compounds emerging from the phenotypic screen have activity 
against tumours in vivo. Initial studies focused on establishing the dose that can be 
safely administered to animals and the results are presented in figure 12.3 in the 
appendix. All compounds were administered intravenously and acute (behavioral 
changes, obvious signs of distress etc. immediately after administration) and chronic 
(weight loss over several days) toxicities were determined. The maximum doses that 
could be administered to non-tumour bearing animals were 0.3 mg/Kg, 1.75 mg/Kg 
and 2.75 mg/Kg for ADF495, HS121 and RAK373 mg/Kg respectively. Whilst this is less 
than the maximum tolerated doses for cisplatin (6 mg/Kg), the test compounds did not 
cause any loss of weight whereas cisplatin caused a small drop in body weight which 
reached a maximum at 2 days after drug administration before recovering.  
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The response of HCT116 p53-/- human tumour xenografts to test compounds and 
cisplatin administered intravenously on day 0 of the experiment are presented in 
figure 12.4 in the appendix.  The mean relative tumour volumes (RTV) were recorded 
and the growth delay (time taken for the tumours to reach RTV2 in treated compared 
to control populations) determined. As illustrated in figure 12.4, cisplatin and the test 
compounds induce a modest but statistically significant growth delay with RAK373 
being as active as cisplatin in this experimental model. These results demonstrate that 
compounds selected for in vivo evaluation using the criteria of potency and selectivity 
have activity in vivo at a level that is comparable to cisplatin but at doses that cause 
less toxicity to animals in terms of body weight loss. 
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9.4 - Discussion  
9.4.1 Chemosensitivity Investigations  
From this investigation, it is very clear these compounds are very promising 
candidates for further investigation demonstrating superior potency and selectivity in 
vitro compared to the platinum standards cisplatin, carboplatin and oxaliplatin. One of 
the hit compounds identified (RAK373) not only displays significant potency toward the 
colonic adenocarcinoma HCT116 p53+/+ cell line (IC50 values for RAK373 were 
0.36±0.05µM compared to oxaliplatin which was 0.93±0.11µM) but the compound also 
demonstrates a selectivity index of 93. This is nearly 28 times more selective than the 
most selective platinum based drug (oxaliplatin) under comparative experimental 
conditions. This finding alone demonstrates the potential of this class of compound 
albeit at a very early stage in the drug discovery process. The initial part of this 
discussion focuses on specific compounds that emerge from the screen before moving 
on to discuss the mechanistic studies conducted aimed at characterising certain 
pharmacological properties of selected compounds.  
The class 1a flexicate complexes coded AKK/SHE in figure 77 have been evaluated 
by our group before with regards to potency only (Brabec et al., 2013) whereas the 
compounds coded DHS  have not been evaluated previously. After initial 
chemosensitivity testing and comparison to previous hit compounds in this class, 
whilst the DHS compounds were very potent compounds, they were generally poor in 
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terms of their low selectivity indices. Only one compound (AKK022) was selected based 
on its potency (0.17±0.05µM) and selectivity (37.6).  
The novel class 3a flexicates coded HS showed high activity in the HCT116 p53+/+ 
with ADF495 demonstrating an IC50 value of 0.41±0.01µM and a selectivity of 24.4. 
HS139 although displaying a poorer degree of potency (2.41±0.6µM) its selectivity 
index is one of the highest (41.7). Class 3a click flexicates were the most promising 
class resulting in seven “hit” compounds selected based heavily on their selectivity 
index. The majority of these compounds displayed good potency and if this was the 
only criteria used to select compounds for further evaluation, the majority of these 
compounds would have been selected. The use of the in vitro selectivity index 
significantly reduced the number of 'hit' compounds and is therefore more 
discriminatory than just potency alone. Pharmacologically, these compounds were of 
significant interest as the tethered sugar could offer increased potency and selectivity 
to cancer cells that are metabolically reprogrammed to favour aerobic glycolysis over 
oxidative phosphorylation. On the whole, all of the class 3a click compounds fail to 
exert the same potent cytotoxic potency as ADF495 but selectivity indexes are 
improved suggesting that the attachment of various sugars to the molecule improves 
the selectivity index considerably. This is further exemplified by the addition of glucose 
to “sugar naked” compounds HS255 and HS256 to give the glucose 3a click compound 
HS121. HS255 and HS256 display potent cytotoxic potential (1.56±0.91µM and 
1.22±0.94µM respectively), which is reduced with the addition of glucose 
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(HS121=2.69±1.71µM). Although the potency is reduced as observed with ADF495 
(parent 3a compound) the result of adding a glucose alone increases the selectivity of 
HS255 and HS255 (SI=5.91 and 7.48 respectively) up to 7 fold (HS121, SI = 42.95).  
To gain further insight into the role of sugars on these molecules, the hypoxia-
mimetic cobalt chloride which stabilises the HIF-1α protein and promotes HIF1 
transcriptional activity against important metabolic processes such as glucose uptake 
(Pourpirali et al., 2015). HIF1 is known to up-regulate glucose transporters and it was 
proposed that if sugar clicked compounds were interacting with glucose transporters, 
enhanced activity of click 3a sugar compounds may be observed in the presence of 
cobalt chloride. As illustrated in figures 9.19-9.25, the response of HCT116 p53+/+ cells 
to class 3a sugar click compounds decreases significantly in all cases. The reasons for 
this observation are not known but it is possible that by up-regulating glucose 
transporters, more free glucose is being taken and this is out competing and nullifying 
the effects of class 3a sugar click compounds on biochemical pathways such as 
glycolysis. Further studies are required to verify this hypothesis, but the results clearly 
demonstrate that conditioning of cells with cobalt chloride significantly decreases the 
activity of these compounds. 
To investigate the potential role of these “hit” compounds in more chemo-resistant 
cell lines the potency of the 11 lead compounds were tested on the HCT116 p53-/- cell 
line which is typically more resistant to the platinates than the HCT116 p53+/+ isogenic 
clone (table 9.9 and figure 9.18). Although the potency is decreased with the reduction 
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of p53 expression, the IC50 values of AKK022, HS239, HS142, HS119 and HS139 show 
superior potency toward HCT116 p53-/- cells compared to all three platinate 
compounds (table 9.9 and figure 9.18) which suggests these compounds could be 
successful chemotherapuetic agents in more p53 deficient cell lines.  
9.4.2 - Investigation of Cell Viability, Induction of Apoptosis and Disruption of 
Cell Cycle Parameter Via NC3000 Cytometry  
On selection of lead compounds, initial mechanistic studies using the NC3000 were 
conducted following a 24-hour drug exposure to test compounds. These conditions 
were based on the results obtained with platinates which demonstrated that major 
effects on cell viability, apoptosis and cell cycle occurred within this time scale (section 
3.3.5). Two apoptosis induction assays were completed but unlike with the positive 
control (cisplatin), no substantial induction of apoptosis was observed (sections 9.3.5.2 
– 9.3.5.3). There was a slight increase in apoptotic cell population after exposure to 
HS121 (figures 9.31, 9.32, 9.35 and 9.36) but overall, it can be concluded that these 
compounds are not inducing apoptotic cell death. Cell cycle analysis on the lead 
compounds also failed to demonstrate any significant effects post drug exposure 
(section 9.3.5.4). Some effect on the cell cycle by HS135 was observed with an increase 
in S phase population of over 20% suggesting it could possibly be causing an S phase 
arrest. Overall however, the analysis of cell cycle disruption does not offer any 
significant clues as to the compounds mechanism of action. Finally, viability assays 
were completed to not only measure cell number in each sample but to demonstrate 
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the effects of the novel flexicates on cell viability. The viability of the cell population 
remains consistent for both HCT116 p53+/+ and ARPE-19 cell lines with cell number 
reducing slightly after 24-hour exposure. This is a counter intuitive observation as the 
compounds clearly have cytotoxic activity as demonstrated by the MTT assay but it 
could be explained on the basis that cell death could have occurred rapidly (within the 
24 hour drug exposure period) and those cells that remained would appear viable. 
Further studies are required to refine these experimental procedures to address this 
possible explanation but for now, the results of the viability experiments need to be 
interpreted with caution. As discussed in chapter 7 one single experiment is not robust 
enough and does not remove any potential bias or error it is therefore paramount 
these assays are also rerun to produce mean data. In addition to rerunning assays new 
assays will need to be developed to firstly confirm the potential absence of apoptosis 
via  additional apoptosis assays such a caspase assays.  
In conclusion, the results from NC3000 investigations suggest the compounds do 
not induce apoptosis and therefore cell death is induced via alternative mechanisms. 
Further investigation to determine the mechanism of cell death are required and this 
includes the induction of autophagy described below.   
9.4.3 - Drug Localisation Assay  
These compounds exert dramatic cytotoxic effects on both isogenic clones HCT116 
cells whilst demonstrating a high selectivity in comparison to non-cancerous ARPE-19 
cell lines. To try and identify possible reasons for this selectivity, cell localisation 
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studies to determine key differences in the cellular distribution of drugs between 
cancer and non-cancer cell lines may provide clues as to potential mechanism(s) of 
action. The inclusion of alkyne groups on molecules provides the opportunity to attach 
fluorophores post drug exposure using click chemistry reactions. This allows the drug 
to distribute naturally in cells and following fixation, the presence of the drug can be 
detected by the addition of a fluorophore. The results of these studies demonstrate a 
number of things, the most obvious being that these large molecular weight 
compounds are able to rapidly penetrate and distribute throughout the cell. This is not 
a trivial observation in view of their molecular weight and demonstrates that they can 
penetrate and cross several barriers including the plasma and other membranous 
systems in the cell (e.g. nuclear membrane). With regards to localisation within the 
cell, it is apparent that the drugs distribute to both the cytoplasm and the nucleus and 
in many cases, there is little difference in staining between the nucleus and the 
cytoplasm. Metallohelicates have been shown to bind to DNA previously (Brabec et al., 
2013) and therefore their effects could be mediated through DNA damage although 
the lack of induction of apoptosis in this study suggests otherwise. Furthermore, no 
major differences in drug distribution between HCT116p53+/+ cells and ARPE19 cells 
were observed and the same applies to the lack of specific loci or fluorescent 'hot 
spots' in cells. There were some exceptions to this (HS225 and HS138 for example) but 
overall, distribution of drug within the cell was largely uninformative in the current 
experimental design. It is possible that any specific localisation is masked by too much 
'unbound' drug within the cell and if this is the case, removing the drug after a one-
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hour exposure and incubating cells in drug free media for defined periods of time to 
allow any unbound drug to efflux may reveal the location of bound drug. Further 
studies are therefore required before any firm conclusions can be made.  
9.4.4 - Autophagic Induction of Complexes 
Visual observations made during and following drug exposure (figure 9.44) 
demonstrate the appearance of vacuoles within the cytoplasm of cells. In the absence 
of apoptosis induction, this suggested that cells may be undergoing autophagic cell 
death and this possibility was explored further in this study. The results demonstrate 
that the addition of the autophagy inhibitor 3-MA significantly reduced the cytotoxic 
potency of compounds tested (figure 9.43). This suggests that the compounds are 
inducing autophagy and further studies are required to confirm this potential 
mechanism of action. Autophagy defined as a self-degradative process is important for 
balancing energy levels in specific developmental stages and in response to external 
stress factors. In addition to ensuring adequate energy levels for basal cell function 
autophagy plays a housekeeping role in degrading “faulty” cellular components such as 
misfolded, aggregated proteins, damaged organelles and internal pathogens. 
Autophagy is therefore primarily a survival mechanism sustaining cell survival yet if 
executed until completion is a means of achieving cell death (Glick, Barth, & Macleod, 
2010; Jin & White, 2007). Autophagy is a complex process which can be viewed as a 
cell death or a survival pathway (Kondo, Kanzawa, Sawaya, & Kondo, 2005) but in this 
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case, the results suggest that the compounds are inducing autophagy leading to cell 
death. 
The use of additional autophagy inhibitors such as bafilomycin A1 and western blot 
analysis to detect autophagic markers would further support this hypothesis but due 
to time constraints, these studies were not conducted in this thesis.   
9.4.5 - In Vivo Anti-Tumour Activity of Selected Compounds 
Studies conducted by the University of Bradford demonstrated that the most 
promising “hit” compounds (RAK373, ADF495, HS121) have anti-tumour activity in 
vivo. These studies were completed alongside a control and a cisplatin treated positive 
control (figures 12.3 and 12.4 in the appendix). The parameters measured were the 
mean relative tumour volume, growth delay and percentage body weight loss which is 
an indicator of host health post administration. The cell line investigated were HCT116 
p53-/- for which only ADF495 was more potent but the selectivity indexes (especially in 
HS121) combined with competitive potency made this tumour model a good choice. 
The data generated are very promising and it demonstrates that anti-tumour activity 
that is comparable to cisplatin occurs and furthermore, this level of activity occurs at 
doses of compounds that do not induce significant weight loss (unlike cisplatin).  
9.5 - Conclusion  
In the context of the main question being addressed in this thesis, these results 
demonstrate that the use of a phenotypic approach to drug evaluation based upon 
potency and selectivity combined with the use of clinically approved platinates to 
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serve as a 'yardstick' to measure the relative merits of test compounds has identified 
novel compounds that have anti-cancer activity in vivo. This approach led to the 
selection of 3 compounds out of a total of 68 compounds with potent cytotoxic activity 
in vitro, the majority of which were more potent than the platinates. If potency alone 
was used to select compounds, this would not have been sufficiently discriminatory to 
select limited number of compounds for further development. This demonstrates that 
the screen has increased discriminatory powers to enable the rationale selection of 
compounds for further studies including mechanistic and in vivo studies.  No screening 
process is ever going to be 100% efficient and both false positive and false negative 
predictions will occur, but this approach represents a potential way forward for 
rationalising the selection of compounds based upon a phenotypic approach to drug 
discovery. 
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Chapter 10 - General Conclusion 
In the field of anti-cancer drug discovery, a number of preclinical strategies are 
employed to identify potential therapeutic agents. These can be broadly segregated 
into two main areas;  target orientated drug discovery and random or phenotypic 
based drug discovery (Moffat, Rudolph, & Bailey, 2014). Target based drug discovery is 
based on the premise that understanding the biology of cancer will lead to the 
development of drugs that target key pathways and considerable investment in this 
area has been made. Whilst a number of novel therapeutic agents have been 
developed, it is now recognized that the investment made has not been reciprocated 
in the discovery of new molecular entities. Random screening or phenotype based 
drug discovery programs have the potential to discover new chemical entities and it is 
estimated that 33% of new small molecule molecular entities discovered between 
1998 and 2008 emerged from phenotypic based drug discovery programs whereas 
only 17% came from target based discovery (Swinney & Anthony, 2011). It is therefore 
clear to see why a renaissance in phenotypic drug discovery is occurring. 
The process of phenotype based drug discovery is a difficult and time consuming 
one with high rates of attrition. Large scale operations such as the NCI60 screen have 
successfully identified novel therapeutic agents but the process is expensive and time 
consuming. These screens rely heavily on characterising the response of cancer cells to 
novel compounds and they do not take into account the response of normal or non-
cancer cell lines. In this thesis, a phenotype based screen has been employed to 
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evaluate a range of different organometallic complexes with the aim of selecting 
compounds based upon (i) potency (ii) an in vitro selectivity index and (iii) comparable 
or improved performance in these screens compared to three clinically used anti-
cancer drugs. Over the course of this research, compounds from 6 different 
collaborative groups were entered into the screen. A total of 210 useable compounds 
were evaluated with many more discounted due to solubility issues. Of these 210 
compounds 24 were deemed comparable with 5 determined “hit” compounds based 
on their meeting the 3 phenotypic profiles outlined above. If the compounds were 
selected based on potency alone, a total of 91 compounds would have been selected 
making evaluation unmanageable in subsequent mechanistic studies. The 
incorporation of an in vitro selectivity index into the decision-making process makes 
this a more discriminatory tool and provides a good rationale for taking compounds 
forward to in vivo testing. It should be stressed that no selectivity index determined in 
vitro is going to faithfully translate into a good selectivity index in vivo but by 
comparing the selectivity indices of test compounds to clinically approved drugs in the 
same experimental system, taking compounds forward for further evaluation can be 
done with greater confidence.   
In this thesis, a wide range of selectivity indices were obtained with several 
compounds showing values below 1. The majority of compounds had selectivity indices 
which were broadly comparable to the platinates but the most promising results were 
obtained with the series of metallohelicate compounds obtained from the University 
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of Warwick. In this case, several compounds with selectivity indices much higher than 
the platinates were discovered and all of these were novel chemical entities that did 
not fit the convention with respect to Lipinski rules. Three compounds were taken 
forward for in vivo testing and whilst the results were not dramatic, growth delays 
were observed, and these were comparable to those obtained with cisplatin in the 
same xenograft model. Anti-tumour activity in vivo was observed at doses that did not 
induce any weight loss or any other signs of toxicity. With regards to the mechanisms 
of action of these lead compounds, studies demonstrated that cell death was not by 
the induction of apoptosis but preliminary data suggest that these compounds work by 
inducing autophagy. Further studies are required to confirm this but due to time 
constraints, these studies were not performed in this thesis.    
In conclusion, this study has developed a robust and reliable phenotype based 
screen where the inclusion of an in vitro selectivity index into the decision-making 
process provides greater discriminatory powers to select novel compounds for further 
testing. Of all the compounds evaluated, the large molecular weight metallohelicates 
developed by Prof Peter Scott and his team are the most interesting with in vitro 
selectivity indices that were significantly higher than clinically used platinum based 
anti-cancer drugs. The inclusion of an in vitro selectivity index into phenotype based 
drug discovery programs has not been done before (to the best of our knowledge) and 
this thesis provides evidence to support the development of this concept further.    
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Chapter 12 - Appendix  
12. 1 – Ruthenium and iridium Compounds as Anti-Cancer Agents 
 
IC50 value (µM) ± SD (selectivity index) 
 HT-29 MCF-7 A2780 A2780cis 
Cisplatin 0.25 ± 0.11 1.09 ± 0.08 0.94 ± 0.04 10.50 ± 0.20 
1 3.50 ± 0.30 1.90 ± 0.10 2.60 ± 0.08 3.13 ± 0.09 
7 6.10 ± 0.30 3.55 ± 0.09 2.5 ± 0.2 3.69 ± 0.09 
8 10.30 ± 0.6 6.20 ± 0.20 2.3 ± 0.2 7.00 ± 0.04 
9 11.80 ± 0.80 - - - 
11 10.21 ± 0.09 2.9 0 ± 0.10 2.87 ± 0.05 9.1 ± 0.1 
12 22.00 ± 2.00 13.00 ± 0.20 - - 
13 6.30 ± 0.30 7.20 ± 0.20 1.90 ± 0.10 3.80 ± 0.09 
14 53.00 ± 1.00 - 56.00 ± 2.00 - 
15 18.00 ± 2.00 18.40 ± 0.80 19.40 ± 0.80 24.30 ± 0.50 
18 93.00 ± 7.00 51.00 ± 4.00 35.00 ± 1.00 51.00 ± 1.00 
 
Table 12.1: Response of colonic adneocarcinoma HT2-29, metastatic epithelial mammary gland, parent 
ovarian carcinoma A2780 and cisplatin resistant form A2780cis cell lines continuous 96-hour exposure 
to novel RML Ruthenium and Iridium β-ketoiminate based compounds. The results presented are the 
mean IC50 values ± standard deviations for three independent experiments. The “>” symbol represents 
the highest dose tested in vitro. Data collected by Rhianne Lord et al. externally. 
  
   
 
Page | 345  
 
 
 
 
12. 2 - N-Heterocyclic Compounds as Anti-Cancer Agents 
 
 
 
Figure 12.2: SRB analysis of five novel Silver-NHC complexes synthesised by Charlotte Wilans’ research 
groups (chapter 7). 
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Figure 12.3: RCVs recorded at 40 V s
-1
 of a DOPC coated Pt/Hg electrode (grey), overlaid with either one 
of six silver(I)-NHC complexes at 50µM or 2mM of cisplatin (red). Synthesised by Charlotte Wilans’ 
research groups (chapter 7). 
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12. 3 - Metallohelices as Anti-Cancer Agents 
 
 
Figure 12.4: Body weight of non-tumour bearing animals treated with ADF495, HS121, RAK373 and 
cisplatin, all of which were administered intravenously at the doses indicated (single injection given at 
day 0).  Group sizes for each experiment were 3 animals and the results presented represent the mean 
weight ± the standard deviation for 3 animals (chapter 9).  
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Figure 12.5: Anti-tumour activity data of three “hit” novel metallohelices and cisplatin against HCT116 
p53-/- tumours in vivo. Related to chapter 9. 
 
Group 
number 
Median time 
RTV2 (days) 
Growth 
delay 
Significance Maximum % 
weight loss 
Control 4.2 - - 2.0 (day 6) 
ADF495 6.8 2.6 P<0.05 0 
HS121 8.5 4.3 P<0.01 0 
RAK373 9.0 4.8 P<0.01 2.0 (day 6) 
Cisplatin 8.9 4.7 P<0.01 6.0 (day 2) 
